

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT / SE 2005 / 0 0 0 0 9 7

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.




(71) Sökande Medivir AB, Huddinge SE
Applicant (s)

(21) Patentansökningsnummer 0400199-6
Patent application number

(86) Ingivningsdatum 2004-01-30
Date of filing

Stockholm, 2005-04-20

För Patent- och registreringsverket
For the Patent- and Registration Office


Görel Gustafsson

Avgift
Fee

BEST AVAILABLE COPY

Ink. t. Patent- och reg.verket

2004 -01- 3 0

Huvudfaxen Kåssan

M183

1

HCV NS-3 Serine Protease InhibitorsTechnical Field


This invention relates to novel inhibitors of the NS3 serine protease of the flavivirus HCV and to methods for their use in the treatment or prophylaxis of HCV.

Background Art

The NS3 serine protease of HCV is a multifunctional protein which contains a serine protease domain and a RNA helicase domain. The protease cofactor NS4A, which is a relatively small protein, is absolutely required for enhanced serine protease activity. The NS3 serine protease is essential in the viral lifecycle. From analysis of the substrate binding site as revealed by X-ray crystal structure, it has been shown that the binding site of the NS3 protease is remarkably shallow and solvent exposed making small molecule inhibitor design a challenge.

Brief description of the invention

In accordance with a first aspect of the invention, there are provided compounds of the formula I:



wherein

A is COOR¹, CONHSO₂R², CONHR³, or CR⁴R^{4'} wherein;

R¹ is hydrogen, C₁-C₆alkyl, C₀-C₃alkylcarbocyclyl, C₀-C₃alkylheterocyclyl;

R² is C₁-C₆alkyl, C₀-C₃alkylcarbocyclyl, C₀-C₃alkylheterocyclyl;

Ink. t. Patent- och reg.verket

2004-01-30

M183

2

Huvudfaxen Kassa

R^3 is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, $-OC_1$ - C_6 alkyl, $-OC_0$ - C_3 alkylcarbocyclyl, $-OC_0$ - C_3 alkylheterocyclyl;

R^4 is =O, halo, amino, or OH;

$R^{4'}$ is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl; wherein

5 R^2 , R^3 , and $R^{4'}$ are each optionally substituted with from 1 to 3 times with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-C(=O)NRaRb$, $Y-NRaC(=O)Rb$, $Y-NHSO_pRb$, $Y-S(=O)_pRb$, $Y-S(=O)_pNRaRb$, $Y-C(=O)ORb$, $Y-NRaC(=O)ORb$;

10 where Y is a bond or C_1 - C_3 alkyl;

Ra is H or C_1 - C_3 alkyl;

Rb is H or C_1 - C_6 alkyl;

p is 1 or 2;

15 R^7 is C_1 - C_6 alkyl, C_1 - C_3 alkyl C_3 - C_7 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with 1-3 halo atoms, amino or $-SH$;

$R^{7'}$ is H or taken together with R^7 to form a C_3 - C_6 cycloalkyl ring optionally substituted with $R^{7'a}$ wherein;

$R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, C_2 - C_6 alkenyl or J; any of which may be optionally substituted with halo;

20 q is 0 to 3 and k is 0 to 3; where $q+k \geq 1$;

W is $-CH_2-$, $-O-$, $-OC(=O)NH-$, $-OC(=O)-$, $-S-$, $-NH-$, $-NR^{8'}$, $-NHSO_2-$ or $-NHC(=O)-$;

R^8 is a ring system containing 1 or 2 saturated or unsaturated rings each of which has 4-7 ring atoms and 0 to 2 hetero atoms selected from S, O and N, the ring system being optionally spaced from W by a C_1 - C_3 alkyl group; or R^8 is C_1 - C_6 alkyl, any of which R^8 groups can be optionally mono, di, or tri substituted with R^9 , wherein

25 R^9 is independently halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-C(=O)NRaRb$, $Y-NRaC(=O)Rb$, $Y-NHSO_pRb$, $Y-S(=O)_pRb$, $Y-S(=O)_pNRaRb$, $Y-C(=O)ORb$, $Y-NRaC(=O)ORb$; wherein the carbocyclyl or heterocyclyl is optionally substituted with R^{10} ; wherein

30

Ink. t Patent- och reg.verket

2004-01-30

Huvudtaxen Kassan

M183

3

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di- substituted with C_1 - C_6 -alkyl, sulfonyl, (C_1 - C_3 alkyl)sulfonyl, NO_2 , OH, SH, halo, haloalkyl, carboxyl, amide, (C_1 - C_3 alkyl)amide, or heteroaryl optionally substituted with C_1 - C_6 alkyl;

5 R^b is H, C_1 - C_3 alkyl;

E is $-C(=O)-$, $-C(=S)-$, $-S(=O)_2-$, $-S=O-$, $-C=N-R_f$;

R_f is H, $-CN$, $-C(=O)NR_aR_b$; $-C(=O)C_1-C_3^R$ alkyl

X is $-NR_x-$ where R_x is H, or C_1 - C_6 alkyl; or in the case where where E is $-(C=O)-$ X can also be $-O-$;

10 R^{11} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NR_aR_b$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NR_aR_b$, $Y-NR_aC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNR_aR_b$, $Y-C(=O)OR_b$, $Y-NR_aC(=O)OR_b$;

15 when R^7 taken together with R^7 forms a C_3 - C_6 cycloalkyl, then one of R_x or R^{11} can also be J;

J is a 3 to 10-membered saturated or unsaturated alkylene chain extending from the R^7/R^7 cycloalkyl to R_x or R^{11} to form a macrocycle, which chain is optionally interrupted by one to three heteroatoms independently selected from: $-O-$, $-S-$ or $-$

20 NR^{12} - wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14} ; wherein;

R^{12} is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or COR^{13} ;

R^{13} is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl;

R^{14} is independently selected from H, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, hydroxy, halo, amino, oxo, thio, or C_1 - C_6 thioalkyl;

25 Ru and Rz are independently H or C_1 - C_3 alkyl;

m is 0 or 1; n is 0 or 1;

U is $=O$ or is absent;

30 R^{15} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 -alkylaryl, C_0 - C_3 alkylheteroaryl, C_0 - C_3 alkylcyclo C_3 - C_6 alkyl, NH_2CO- , $Y-NR_aR_b$, $Y-O-R_b$, $Y-$

Ink. t. Patent- och reg.verket

2004-01-30

Huvudlaxen Kåsson

M183

4

$C(=O)R_b$, $Y-(C=O)NR_aR_b$, $Y-NR_aC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNR_aR_b$, $Y-C(=O)OR_b$, $Y-NR_aC(=O)OR_b$;


G is $-O-$, $-NR_y-$ or $-NHNH-$ where R_y is H or C_1-C_3 alkyl;

R^{16} is H; or C_1-C_6 alkyl, C_0-C_3 alkylcarbocyclyl, C_0-C_3 alkylheterocyclyl, any of which
 5 can be substituted with halo, oxo, nitrile, azido, nitro, C_1-C_6 alkyl, C_0-C_3 alkylcarbocyclyl, C_0-C_3 alkylheterocyclyl, NH_2CO- , $Y-NR_aR_b$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NR_aR_b$, $Y-NR_aC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNR_aR_b$, $Y-C(=O)OR_b$, $Y-NR_aC(=O)OR_b$;

or a pharmaceutically acceptable salt or prodrug thereof.

10

A second aspect of the invention provides compounds of the formula VI:



wherein

15 R^7 , $R^{7'}$, R^8 , R^{11} , R^{15} , R^{16} , R_x , R_u , A , G , k , m , n , U are as defined above;
 q' is 0 or 1;

R_z is H, or together with the asterisked carbon forms an olefinic bond;

R_q is H or C_1-C_4 -alkyl;

T is $-CHR^{11}-$ or $-NR_d-$, where R_d is H or C_1-C_3 alkyl;

20 in the case where R^7 taken together with $R^{7'}$ forms a C_3-C_6 cycloalkyl, one of R_x , R_d or R^{11} can be J;

Ink. t. Patent- och reg.verket

2004-01-30

M183

5

Huvudföretag Kesson

J is a 5 to 10 membered saturated or unsaturated alkylene chain extending from the R^7/R^7' cycloalkyl to Rx, Rd or R^{11} to form a macrocycle, which chain is otherwise as defined above;

and pharmaceutically acceptable salts and prodrugs thereof.

5

Without in any way wishing to be bound by theory, or the ascription of tentative binding modes for specific variables, P1, P2, P3 and P4 as used herein are provided for convenience only and have their conventional meanings and denote those portions of the inhibitor believed to fill the S1, S2, S3 and S4 subsites respectively of the enzyme, where S1 is adjacent the cleavage site and S4 remote from the cleavage site.

The compounds of the present invention, as embodied in formula I and VI can be briefly represented as R^{16} -G-P4-P3-link-P2-P1, wherein P3 and/or P4 may be absent, and P1, P3 and P4 each represents a building block constituted of a derivative of a natural or unnatural amino acid, P2 is a cyclic residue and G and R^{16} are as defined for formula I and VI. The link is a carbonyl or other function as defined for E. The P1 and P2 building blocks and the P3 and P4 building blocks are thus linked together by amide bonds whereas the P2 and P3 building blocks are linked through the above described link. The amide bonds are thereby reversed relative to each other on each side of the link in the compounds according to formula (I) and (VI).

Additional aspects of the invention include a pharmaceutical composition comprising a compound of Formula I or VI as defined above and a pharmaceutically acceptable carrier or diluent therefore.


The compounds and compositions of the invention have utility in methods of medical treatment or prophylaxis of HCV infections in humans. Accordingly, a further aspect of the invention is the use of a compound as defined above in the manufacture of a

M183

6

medicament for the prophylaxis or treatment of flavivirus infections in humans or animals. Exemplary flavivirus include BVDV, dengue and especially HCV.


- Preferred values for q and k in Formula I include 1:2, 2:1, 2:3, 3:2, 3:3, more preferably 2:2; and most preferably 1:1, in which case preferred compounds have the partial structure:



where e is 1 or 2.

- It is currently preferred that E is $-C(=O)-$ or $-C=N-R_f$, for example where R_f is $-CN$ or $-C(=O)NH_2$

Preferred values for q' and k in formula VI include 0:2, 1:1, 1:3, 2:2, 2:3, more preferably 1:2; and most preferably 0:1, in which case preferred compounds have one of the partial structures:



especially where R_z is H or R_q is H or methyl.

- Compounds of formula I and VI may comprise both a P3 and a P4 function, viz m and n are each 1. These embodiments of the invention thus have the formulae IIIId-IIIIfa for formula I, and VIIdc and VIId for formula VI


Ink. t. Patent- och reg.verket

2004-01-30


Huvudföret: Kassar

M183


7




IIIId




IIIe




IIIIf



IIIIfa



VIIfc



VIIfd

- 5 Alternative configurations of Formula I and VI comprise a P3, but no P4 function, viz m is 1 and n is zero. Preferred embodiments with this configuration include Formulae IIa- IIc within Formula I and Formulae VIIa and VIIb in Formula VI.


Ink. t. Patent- och reg.verket

2004-01-30


Huvudtaxen Kesson

M183


8




IIa




IIb




IIc



IIaa



VIIa



VIIb

Still further alternative configurations of the compounds of Formulae I and VI include those where m and n are zero and thus groups R¹⁶-G abut P2. Embodiments within

Ink. t. Patent- och reg.verket






2004-01-30

Huvudförfaren Kassen

M183

9

this alternative include Formulae IIIa-IIIc within Formula I and Formula VIII within Formula VI:



5

The compounds of the invention may comprise linear molecules, as depicted above. Alternatively, in embodiments wherein R^7 and $R^{7'}$ together define a spiro cycloalkyl group, such as spiro-cyclopropyl, the compounds of the invention may be configured as macrocycles, wherein a linking group J extends between R_x or R^{11} of formula I or R_x , R_d or R^{11} of Formula VI.

10

Embodiments of such macrocyclic structures within formula I with various permutations of P3 and P4 include Formulae XIIa-XIIc, XIIg-XIli and XIIIa and XIIIb.







ink. t. Patent- och reg.verket

7.5.4 - 31-30

Huvudfrågorna Kvar

M183

10




Ink. t. Patent- och reg.verket

S. 1-3 0

Huvudskrivaren Kassan

M183

11



Embodiments of such macrocyclic structures within formula VI with various permutations of P3 and P4 include Formulae XIVa-XIVf:




Ink. t. Patent- och reg.verke

S. 1-30

Huvudföreläsningen

M183

12






M183

13

Ink. t. Patent- och reg.verke

7000-01-30

Huvudföreskriften



In general linker J, where present, is a 3 to 10 chain atom, preferably 5 to 8 atom, such as 6 or 7 atom, saturated or unsaturated alkylene chain. The length of the chain will, of course, depend on whether J extends from Rd, Rx, or R¹¹. Suitable chains are described in detail in WO 00/59929.

Conveniently, the J chain contains one or two heteroatoms selected from: O, S, NH, NC₁-C₆ alkyl or N-C(=O)C₁-C₆alkyl. More preferably, the J chain optionally contains one heteroatom selected from: NH, or N-C(=O)C₁-C₆alkyl, most preferably N(Ac). Most preferably, the chain containing a nitrogen atom is saturated. Alternatively, J contains one heteroatom selected from: O, or S. Preferably, this chain is substituted

M183

14

with R^{14} , such H or methyl. Even more preferably, J is saturated.

Alternatively, J contains a double bond, typically spaced one carbon from the cycloalkyl R^7 function. The double bond may be cis or trans.

- 5 Representative examples of J thus include pentanyl, hexanyl, heptanyl, any of which are substituted with C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, hydroxyl, halo, amino, oxo, thio or C_1 - C_6 thioalkyl; penten:3:yl, hexen:4:yl, hepten:5:yl, where 3, 4 or 5 refers to a double bond between 3 carbon atoms 3 and 4, 4 and 5 etc.

- 10 Convenient R^7 and $R^{7'}$ groups include those wherein $R^{7'}$ is H and R^7 is n-ethyl, n-propyl, cyclopropylmethyl, cyclobutylmethyl, 2,2-difluoroethyl, or mercaptomethyl. Preferred embodiments include those wherein R^7 is n-propyl or 2,2-difluoroethyl.

- 15 Alternatively, R^7 and $R^{7'}$ together define a spiro-cycloalkyl function, such as a spiro-cyclobutyl ring, and more preferably a spiro-cyclopropyl ring. The ring is substituted or unsubstituted. Preferred substituents include mono or di-substitutions with $R^{7'a}$ wherein $R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with halo. Alternatively the substituent may be a J linker as described above.

20

Particularly preferred substituents include $R^{7'a}$ as ethyl, vinyl, cyclopropyl, 1- or 2-bromoethyl, 1- or 2-fluoroethyl, 2-bromovinyl or 2-fluorethyl. Currently preferred stereochemistries for a spiro-cyclopropyl ring are defined below.

25

A favoured configuration for A is $-CR^4R^4$ as illustrated in detail in PCT/EP03/10595, the contents of which are incorporated by reference.

30

Convenient R^4 groups thus include C_1 - C_6 alkyl, such as methyl, ethyl, propyl, ethenyl and $-\text{CHCHCH}_3$. Alternative preferred R^4 groups include aryl or heteroaryl such as optionally substituted phenyl, pyridyl, thiazolyl or benzimidazolyl or C_1 - C_3 alkylaryl or C_1 - C_3 alkylheteroaryl, where the alkyl moiety is methyl, ethyl, propyl, ethenyl and -

M183

15

CHCHCH₃. Preferred aryl moieties include optionally substituted phenyl, benzothiazole and benzimidazole.

5 Favoured R^{4'} groups include -NH₂, fluoro or chloro. Alternative preferred R^{4'} groups include -OH and especially =O.

10 An alternative favoured configuration for A is CONHR³, where R³ is optionally substituted C₀-C₃alkylaryl, C₀-C₃alkylheteroaryl, OC₀-C₃alkylaryl or OC₀-C₃alkylheteroaryl.

15 An alternative favoured configuration for A is CONHSO₂R², especially where R² is optionally substituted C₁-C₆ alkyl, preferably methyl, or optionally substituted C₃-C₇cycloalkyl, preferably cyclopropyl, or optionally substituted C₀-C₆alkylaryl, preferably optionally substituted phenyl.

A particularly preferred configuration for A is COOR¹, especially where R¹ is C₁-C₆ alkyl, such as methyl, ethyl, or tert-butyl and most preferably hydrogen.

20 Substituent -W-R₈ to the cyclic P₂ group can employ any of the proline substituents which are extensively described in WO 00/59929, WO 00/09543, WO 00/09558, WO 99/07734, WO 99/07733, WO 02/60926, WO 03/53349, WO03064416, WO03064455, WO03064456, WO03/99274, WO03/99316 and the like,

25 Preferred W functions include W is -OC(=O)NH-, -OC(=O)-, -NH-, -NR^B-, -NHS(O)₂- or -NHC(=O)-, especially -OC(=O)NH- or -NH-. Favoured R^B groups for such W functions include optionally substituted C₀-C₃-alkylcarbocyclyl or C₀-C₃-alkylheterocyclyl, including those described in WO0009543, WO0009558 and WO 00/174768. For example ester substituents include those disclosed in WO 01/74768 such as C₁-C₆ alkyl, C₀-C₃aryloyl, particularly (optionally substituted) benzoyl or C₀-C₃ het-oyl, especially

30


Ink t. Patent- och reg.verk

2004-01-30

Huvudkontor Kassar

M183

16



This publication also describes alternative $-W-R^8$ possibilities such as C_1-C_6 alkyl, such as ethyl, isopropyl, C_0-C_3 -cycloalkyl such as cyclohexyl, 2,2-difluoroethyl, $-C(=O)NR_c$, where R_c is C_1-C_6 alkyl, C_0-C_3 -cyclopropyl, C_0-C_3 -aryl or C_0-C_3 -heterocyclyl.

Currently preferred W functions include $-S-$ and especially $-O-$. Convenient values for R^8 in such embodiments include C_0-C_3 alkylaryl, or C_0-C_3 alkylheteroaryl either of which is optionally mono, di, or tri substituted with R^9 , wherein;

R^9 is C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2 , OH, halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1-C_6 alkyl, C_0-C_3 alkylaryl, C_0-C_3 alkylheteroaryl, carboxyl, aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, amino optionally mono- or di-substituted with C_1-C_6 alkyl, C_1-C_3 alkyl amide), sulfonyl C_1-C_3 alkyl, NO_2 , OH, halo, trifluoromethyl, carboxyl, or heteroaryl.

Preferred R^9 is C_1-C_6 alkyl, C_1-C_6 alkoxy, amino, di- $(C_1-C_3$ alkyl)amino, C_1-C_3 alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, amino, mono- or di- C_1-C_3 alkylamino, amido, C_1-C_3 alkylamide, halo, trifluoromethyl, or heteroaryl.

Preferred R^{10} include C_1-C_6 alkyl, C_1-C_6 alkoxy, amino optionally mono- or di substituted with C_1-C_3 alkyl, amido, C_1-C_3 -alkylamide, halo, or heteroaryl.

Ink. t. Patent- och reg.verket

: ... -01- 3 0

Huvudtvärs Kassa


M183

17

Particularly preferred R^{10} include methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1 - C_3 alkyl, amido, C_1 - C_3 alkylamide, or C_1 - C_3 alkyl thiazole.

- 5 Especially preferred R^8 include 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-naphthyl, or quinolinyll unsubstituted, mono, or disubstituted with R^9 as defined, in particular 1-naphthylmethyl, or quinolinyll unsubstituted, mono, or disubstituted with R^9 as defined.

- 10 A currently preferred R^8 is:






- 15 wherein R^{9a} is C_1 - C_6 alkyl; C_1 - C_6 alkoxy; thio C_1 - C_3 alkyl; amino optionally substituted with C_1 - C_6 alkyl; C_0 - C_3 alkylaryl; or C_0 - C_3 alkylheteroaryl, C_0 - C_3 alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, C_1 - C_3 alkyl amide, heteroaryl or heterocyclyl; and

- 20 R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl) amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

Convenient R^{9a} include aryl or heteroaryl, all optionally substituted with R^{10} as defined, especially where R^{9a} is selected from the group consisted of :

25



Ink. t. Patent- och reg.verket

2003-01-30


Huvudföreläsning

M183

18


wherein R^{10} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl.

5 R^{9a} is conveniently phenyl and thus R^8 is:



10 wherein R^{10a} is H, C_1 - C_6 alkyl; C_1 - C_6 alkoxy; or halo; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

An alternative preferred R^8 is:



15


20 wherein R^{10a} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.

In the immediately above described embodiments R^{9b} is conveniently C_1 - C_6 alkoxy, preferably methoxy.

M183

19

A further ether substituent R^8 has the formula



- 5 where W is N or CH, r is 0 or 1, Ra is H, C_1 - C_6 alkyl, C_0 - C_3 cycloalkyl, C_1 - C_6 alkyloxy, hydroxy or amine and Rb is H, halo, C_1 - C_6 alkyl, C_0 - C_3 cycloalkyl, C_1 - C_6 alkyloxy, C_1 - C_6 thioalkyl, cycloalkyl- C_0 - C_3 alkyloxy, C_1 - C_3 alkyloxy- C_1 - C_3 alkyl, C_0 - C_3 aryl or C_0 - C_3 heterocyclyl. A particularly preferred ether substituent is 7-methoxy-2-phenyl-quinolin-4-yl oxy.

10

Preferred P3 groups include aliphatic amino acids, such as L-valyl, L-leucyl, L-isoleucyl or L-t-leucyl. Further preferred P3 groups, as shown in WO 02/01898 include C_0 - C_3 cycloalkyl, especially cyclohexylalanine, optionally substituted with CO_2R_g , where R_g is H, is C_1 - C_6 alkyl, C_0 - C_3 -alkylaryl, C_0 - C_3 alkylhet, C_0 -

- 15 C_3 alkylcycloalkyl or amine; or N-acetyl piperidine or tetrahydropyran. Preferred R^{11} groups thus include C_1 - C_6 alkyl, C_0 - C_3 alkyl- C_3 - C_7 cycloalkyl, C_0 - C_3 alkylaryl or C_0 - C_3 alkylheteroaryl, any of which is optionally substituted with hydroxy, halo, amino, C_1 - C_6 alkoxy, C_1 - C_6 thioalkyl, $COOR^{14}$, carboxyl, $(C_1$ - C_6 alkoxy)carbonyl, aryl, heteroaryl or heterocyclyl, especially where the substituent is hydroxy or $COOR^{14}$.

20

Particularly preferred R^{11} include tert-butyl, iso-butyl, cyclohexyl, phenylethyl, 2,2-dimethyl-propyl, cyclohexylmethyl, phenylmethyl, 2-pyridylmethyl, 4-hydroxy-phenylmethyl, or carboxylpropyl. The most preferred R^{11} values are currently tert-butyl, iso-butyl, or cyclohexyl.

25

Representative embodiments of P3 groups which lack a carboxy function (ie variable T is absent) include:


Ink. t. Patent- och reg. verket

2004-01-30

Högskolebibliotek

M183

20



where Ar is carbocyclyl or heterocyclyl, and the corresponding variants of formula VI.

R^{16} is preferably optionally substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl or C_0 - C_3 alkyl/ C_3 - C_7 cycloalkyl. Preferred P4 groups are typically aliphatic amino acids such as L-valyl, L-leucyl, L-isoleucyl, L-f-leucyl or L-cyclohexylalanine and thus favoured R^{16} groups include cyclohexyl, cyclohexylmethyl, tert-butyl, iso-propyl, or iso-butyl.

Preferred G values include $-NR_y$, especially wherein R_y is methyl or preferably H, or hydrazine.

A further preferred G value is O thereby defining an ester with the carbonyl of P4 (if present) or the carbonyl of P3 (if present) or an ether in the case of variants wherein group U is absent. Conventional pharmaceutically acceptable ethers or esters capping groups for R^{16} include C_1 - C_6 alkyl (especially methyl or t-butyl), C_0 - C_3 alkyl/heterocyclyl (especially pyridyl, benzimidazolyl, piperidyl, morpholinyl, piperazinyl) or C_0 - C_3 alkylcarbocyclyl (especially phenyl, benzyl, indanyl) any of which is optionally substituted with hydroxy, halo, amino, or C_1 - C_6 alkoxy.

Favoured R^{16} groups thus include 2-indanol, indanyl, 2-hydroxy-1-phenyl-ethyl, 2-thiophenemethyl, cyclohexylmethyl, 2,3-methylenedioxybenzyl, cyclohexyl, phenyl, benzyl, 2-pyridylmethyl, cyclobutyl, iso-butyl, n-propyl, or 4-methoxyphenylethyl.

Currently preferred R^{16} groups include 2-indanol, indan, 2-hydroxy-1-phenyl-ethyl, 2-thiophenemethyl, 2,3-methylenedioxybenzyl, or cyclohexylmethyl.

M183

21

Unnatural amino acids include L-amino acids wherein the side chain is not one of the 20 naturally occurring amino acids. Examples of non-natural amino acids include L-beta-methylsulfonylmethylalanine, L-cyclohexylalanine, L-tertiary-leucine, L-norleucine, L-norvaline, L-ornithine, L-sarcosine, L-citulline, L-homophenylalanine, L-homoserine, L-beta-(1-naphthyl)alanine, L-beta-(2-naphthyl)alanine etc. Non natural amino acids also include the D-amino acids corresponding to the 20 natural amino acids and D-amino acids bearing other side chains, such as those listed above.

'C₁-C₆-alkyl' as applied herein is meant to include straight and branched chain aliphatic carbon chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl and any simple isomers thereof. The alkyl group may have an unsaturated bond. Additionally, any C₁-C₆-alkyl may optionally be substituted by one or two halogens and/or a heteroatom S, O, NH. If the heteroatom is located at a chain terminus then it is appropriately substituted with one or two hydrogen atoms.

'C₁-C₃-alkyl' as applied herein includes methyl, ethyl, propyl, isopropyl, cyclopropyl, any of which may be optionally substituted as described in the paragraph above or in the case of C₂ or C₃, bear an unsaturated bond such as CH₂=CH.

'Amine' includes NH₂, NHC₁-C₃-alkyl or N(C₁-C₃-alkyl)₂.

'Halo' as applied herein is meant to include F, Cl, Br, I, particularly chloro and preferably fluoro.

'C₀-C₃-aryl' as applied herein is meant to include a phenyl, naphthyl or phenyl fused to C₃-C₇ cyclopropyl such as indanyl, which aryl is directly bonded (ie C₀) or through an intermediate methyl, ethyl, propyl, or isopropyl group. Unless otherwise indicated the aryl group is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl,

M183

22

amino, azido, oxo, mercapto, nitro C₀-C₃carbocyclyl, C₀-C₃-heterocyclyl. "Aryl" has the corresponding meaning.

5 'C₀-C₃-carbocyclyl' as applied herein is meant to include 'C₀-C₃-aryl' and C₃-C₇ cycloalkyl. Unless otherwise indicated the aryl group is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl, amino, azido, oxo, mercapto, nitro C₀-C₃carbocyclyl, C₀-C₃-heterocyclyl. "Carbocyclyl" has the corresponding meaning.

10 'C₀-C₃-heterocyclyl' as applied herein is meant to include a monocyclic, saturated or unsaturated, heteroatom-containing ring such as piperidinyl, morpholinyl, piperazinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazinyl, isothiazinyl, thiazolyl, oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, furanyl, thienyl, pyridyl, pyrimidyl, pyridazinyl, pyrazolyl, or any of such groups fused to a phenyl ring, such
15 as quinolinyl, benzimidazolyl etc, which ring is bonded directly e le (C₀) or through an intermediate methyl, ethyl, propyl, or isopropyl group. Unless otherwise indicated the hetero ring is substituted with 1-3 substituents selected from halo, hydroxy, nitro, cyano, carboxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, C₁-C₆ alkanoyl, amino, azido, oxo, mercapto, nitro, C₀-C₃ carbocyclyl, C₀-C₃-heterocyclyl.
20 "Heterocyclyl" and "Heteroaryl" has the corresponding meaning.

Typically heterocyclyl and carbocyclyl groups are thus a monocyclic ring with 5 or especially 6 ring atoms, or a bicyclic ring structure comprising a 6 membered ring fused to a 4, 5 or 6 membered ring.

25

Typical such groups include C₃₋₈ cycloalkyl, phenyl, benzyl, tetrahydronaphthyl, indenyl, indanyl, heterocyclyl such as from azepanyl, azocanyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, indolyl, pyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiopyranyl, furanyl, tetrahydrofuranly,
30 thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, tetrazolyl, pyrazolyl, indolyl, benzofuranly, benzothenyl,

Ink. t. Patent- och registerverket

2004-01-30

Husudförsamlingen

M183

23

benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, tetrahydroquinazolinyl and quinoxalinyl, any of which may be substituted as defined herein.

5

The saturated heterocycle thus includes radicals such as pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, azetidyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranlyl, hexahydropyrimidinyl, hexahydropyridazinyl, 1,4,5,6-

10 tetrahydropyrimidinylamine, dihydro-oxazolyl, 1,2-thiazinanyl-1,1-dioxide, 1,2,6-thiadiazinanyl-1,1-dioxide, isothiazolidinyl-1,1-dioxide and imidazolidinyl-2,4-dione, whereas the unsaturated heterocycle include radicals with an aromatic character such as furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, 15 pyrimidinyl, pyrazinyl, indoliziny, indolyl, isoindolyl. In each case the heterocycle may be condensed with a phenyl ring to form a bicyclic ring system.

In general preferred monocyclic rings include substituted pyridyl, substituted pyrimidyl, substituted phenyl, particularly phenyl substituted with a cyclic group such as 20 pyrrolidine-1-yl, piperidine-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 2-morpholin-4-yl-ethylamino, and piperazin-1-yl, piperid-4-yl or N-piperazinyl, N-substituted with Ra or piperidin-1-yl which is 4-substituted with -NRaRb.

25 Synthesis of the compounds of the present invention can be performed by different chemical strategies in solution or solid phase or a combination of both. The suitably protected individual building blocks can first be prepared and subsequently coupled together i.e. $P2+P1 \rightarrow P2-P1$. Alternatively, precursors of the building blocks can be coupled together and modified at a later stage of the synthesis of the inhibitor sequence. Further building blocks, precursors of building blocks or prefabricated 30 bigger fragments of the desired structure, can then be coupled to the growing chain,

Ink. t. Patent- och reg.verket

2004-01-30

Huvudkontor: Köpenhamn

M183

24

e.g. $R^{16}\text{-G-P3} + \text{E-P2-P1} \rightarrow R^{16}\text{-G-P3-P2-P1}$ or $R^{16}\text{-G-P4-P3} + \text{E-P2-P1} \rightarrow R^{16}\text{-G-P4-P3-E-P2-P1}$.

- Coupling between two amino acids, an amino acid and a peptide, or two peptide fragments can be carried out using standard coupling procedures such as the azide method, mixed carbonic-carboxylic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimide) method, active ester (p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K-method, carbonyldiimidazole method, phosphorus reagents or oxidation-reduction methods. Some of these methods (especially the carbodiimide method) can be enhanced by adding 1-hydroxybenzotriazole or 4-DMAP. These coupling reactions can be performed in either solution (liquid phase) or solid phase.
- More explicitly, the coupling step involves the dehydrative coupling of a free carboxyl of one reactant with the free amino group of the other reactant in the presence of a coupling agent to form a linking amide bond. Descriptions of such coupling agents are found in general textbooks on peptide chemistry, for example, M. Bodanszky, "Peptide Chemistry", 2nd rev ed., Springer-Verlag, Berlin, Germany, (1993) hereafter simply referred to as Bodanszky, the contents of which are hereby incorporated by reference. Examples of suitable coupling agents are N,N'-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole in the presence of N,N'-dicyclohexylcarbodiimide or N-ethyl-N'-[(3-dimethylamino) propyl] carbodiimide. A practical and useful coupling agent is the commercially available (benzotriazol-1-yloxy) tris- (dimethylamino) phosphonium hexafluorophosphate, either by itself or in the presence of 1-hydroxybenzotriazole or 4-DMAP. Another practical and useful coupling agent is commercially available 2- (1H-benzotriazol-1-yl)-N, N, N',N'-tetramethyluronium tetrafluoroborate. Still another practical and useful coupling agent is commercially available O-(7-azabenzotriazol-1-yl)-N, N,N', N'-tetramethyluronium hexafluorophosphate.

30

The coupling reaction is conducted in an inert solvent, e. g. dichloromethane,

Ink. t. Patent- och reg.verket

2004-01-30

Huvudlexen: Kossan

M183

25

acetonitrile or dimethylformamide. An excess of a tertiary amine, e. g. diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine or 4-DMAP is added to maintain the reaction mixture at a pH of about 8. The reaction temperature usually ranges between 0 °C and 50 °C and the reaction time usually ranges between 15 min and 24 h.

The functional groups of the constituent amino acids generally must be protected during the coupling reactions to avoid formation of undesired bonds. The protecting groups that can be used are listed in Greene, "Protective Groups in Organic Chemistry", John Wiley & Sons, New York (1981) and "The Peptides: Analysis, Synthesis, Biology", Vol. 3, Academic Press, New York (1981), hereafter referred to simply as Greene, the disclosures of which are hereby incorporated by reference.

The α -carboxyl group of the C-terminal residue is usually protected as an ester that can be cleaved to give the carboxylic acid. Protecting groups that can be used include 1) alkyl esters such as methyl, trimethylsilyl and t.butyl, 2) aralkyl esters such as benzyl and substituted benzyl, or 3) esters that can be cleaved by mild base or mild reductive means such as trichloroethyl and phenacyl esters.

The α -amino group of each amino acid to be coupled must be protected. Any protecting group known in the art can be used. Examples of such groups include: 1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate groups such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate groups such as tertbutyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate groups such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl groups such as triphenylmethyl and benzyl; 6) trialkylsilyl such as trimethylsilyl; and 7) thiol containing groups such as phenylthiocarbonyl and dithiasuccinoyl. The preferred α -amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available.

Ink t Patent- och lag ver

2004-01-30

Läkemedelsverket

M183

26

The α -amino protecting group is cleaved prior to the next coupling step. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or acetonitrile or dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0 °C and room temperature usually 20-22 °C.

Any of the natural or non-natural amino acids having side chain functionalities will typically be protected during the preparation of the peptide using any of the above described groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities depend upon the amino acid and presence of other protecting groups in the peptide. In the selection of such protecting groups it is desirable that the group is not removed during the deprotection and coupling of the α -amino group.

For example, when Boc is used as the α -amino protecting group, the following side chain protecting groups are suitable: p-toluenesulfonyl (tosyl) moieties can be used to protect the amino side chain of amino acids such as Lys and Arg; acetamidomethyl, benzyl (Bn), or tert-butylsulfonyl moieties can be used to protect the sulfide containing side chain of cysteine; benzyl (Bn) ethers can be used to protect the hydroxy containing side chains of serine, threonine or hydroxyproline; and benzyl esters can be used to protect the carboxy containing side chains of aspartic acid and glutamic acid.

When Fmoc is chosen for the α -amine protection, usually tert. butyl based protecting groups are acceptable. For instance, Boc can be used for lysine and arginine, tert.butyl ether for serine, threonine and hydroxyproline, and tert-butyl ester for

Ink. t. Patent- och reg. verkst.

7704-01-3 0

Huvuddelen 17.0000

M183

27


aspartic acid and glutamic acid. Triphenylmethyl (Trityl) moiety can be used to protect the sulfide containing side chain of cysteine.

Once the inhibitor sequence is completed any protecting groups are removed in whatever manner is dictated by the choice of protecting groups. These procedures are well known to those skilled in the art.

In compounds of Formula I, the P2 unit comprises a nitrogen-containing ring residue which is substituted with the W and R⁸ moieties.

Synthesis of heterocyclic P2 building blocks

Compounds wherein W is O and R⁸ is alkyl, C₀-C₃ carbocyclyl, C₀-C₃-heterocyclyl can be prepared according to the procedure described by E. M. Smith et al. (J. Med. Chem. (1988), 31, 875-885), as depicted in Scheme 1, which illustrates the technique in a moiety wherein q and k are 1.



Scheme 1

Commercially available Boc-4-(R)-hydroxyproline, or any suitable hydroxy substituted proline analogue, such as an hydroxyproline derivative is treated with a base such as sodium hydride or potassium t.butoxide in a solvent like dimethylformamide and the resulting alkoxide is reacted with an alkylating agent, R⁸-X, wherein X is a suitable leaving group such as a halide like chloride, bromide or iodide, providing the desired substituted proline derivative.


Alternatively, when W is O or S and R⁸ is carbocyclyl such as phenyl or heterocyclyl such as heteroaryl, the P2 building blocks can also be prepared via a

M183

28

Mitsunobu reaction (Mitsunobu, 1981, Synthesis, January, 1-28; Rano et al., Tetrahedron Lett., 1995, 36, 22, 3779-3792; Krchnak et al., Tetrahedron Lett., 1995, 36, 5, 6193-6196; Richter et al., Tetrahedron Lett., 1994, 35, 27, 4705-4706) as shown in Scheme 2, which illustrates the technique in a moiety wherein q and k are

5 1.



Scheme 2


- 10 Treatment of the appropriate hydroxy substituted proline analogue, such as a hydroxypiperidoic acid, here shown as commercially available Boc-4-hydroxyproline methyl ester, with the desired alcohol or thiol (R⁸-WH) in the presence of triphenylphosphine and an activating agent like diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, provides the ester compound (2b).
- 15 Hydrolysis of the ester to the acid by standard procedures provides the P2 building block (2c).

20 Alcohol (2a) can alternatively be treated with phosgene thus providing the corresponding chloroformate which upon reaction with an amine, R⁸NH₂, in the presence of a base like sodium hydrogen carbonate or triethylamine, provides carbamates i.e. W is -OC(=O)NH-, whereas reaction of alcohol (2a) with an acylating agent, R⁸-CO-X, like an acid anhydride or acid halide for instance the acid chloride, to provide esters, i.e. W is -OC(=O)-.

M183

29

Various alcohols R^8 -OH, and alkylating agents R^8 -X are described in WO 00/09543 and WO00/59929. An example of the synthesis wherein R^8 is a substituted quinoline derivative is shown in Scheme 3.



Scheme 3

Friedel-Craft acylation of a suitable substituted aniline (3a), available either commercially or in the literature, using an acylating agent like acetyl chloride or the like in the presence of boron trichloride and aluminium trichloride in a solvent like dichloromethane provides (3b). Coupling of (3b) to a heterocyclic carboxylic acid (3c) under basic conditions, such as in pyridine, in the presence of an activating agent for the carboxylate group, for instance POCl_3 , followed by ring closure and dehydration under basic conditions like potassium *tert*-butoxide in *tert*-butanol provides quinoline derivative (3e). Quinoline derivative (3e) can be coupled in a Mitsunobu reaction to an alcohol as described above, or the hydroxy group can be displaced by a suitable leaving group such as a halide like chloride, bromide or iodide, by treatment of quinoline (3e) with an appropriate halogenating agent for example phosphoryl chloride or the like.

20

A variety of carboxylic acids with the general structure (3c) can be used in Scheme 3. These acids are available either commercially or in the literature. An example of the preparation of 2-(substituted)-amino-carboxy-aminothiazole derivatives, following the procedure by Berdikhina et al. Chem. Heterocycl. Compd. (Engl. Transl.) (1991),

Ink. t. Patent- och reg.verket


2004-01-30

Huvudstaden Köpenhamn

M183

30

427-433, is shown below.



Scheme 4

5

Thiourea (4c) with different alkyl substituents R' can be formed by reaction of the appropriate amine (4a) with tert.butylisothiocyanate in the presence of a base like diisopropylethylamine in a solvent like dichloromethane followed by removal of the tert. butyl group under acidic conditions. Subsequent condensation of thiourea derivative (4c) with 3-bromopyruvic acid provides the acid (4d).

10

P2 building blocks wherein the R⁸ substituent is attached via a nitrogen atom i.e. W is amine, amide or sulphonamide, can be prepared from aminoproline analogues achieved either from a suitable commercially available aminoproline, etc derivative or by transforming the hydroxy group of the corresponding hydroxy derivative into an azide group for example by transforming the hydroxy group into a suitable leaving group such as a mesylate or halogen like chloride, followed by substitution of the leaving group with azide or by the use of an azide transfer agent like diphenylphosphoryl azide (DPPA). Reduction of the azide by catalytic hydrogenation or any other suitable reduction method provides the amine. The amino derivative can be reacted with an alkylating agent of the general formula R⁸-X wherein R⁸ and X are as described for scheme 1, to form compounds wherein W is -NH-. Reaction of the aminoproline analogue with an acid of the general formula R⁸-COOH under standard amide coupling conditions provides compounds wherein W is -NHC(=O)-, whereas reaction of the aminoproline analogue with an appropriate derivative of sulphonic acid, R⁸-S(O)₂-X where X is a leaving group for example chloride, in the presence of a base, provides sulphonamides. It will be apparent that corresponding reactions will be available for P2 groups with other ring sizes and substitution pattern.

25

Ink. t. Patent- och registerverket


2004-01-30

M183

31

Huvudfaxen Kassar

4-Substituted heterocyclyl derivatives such as 4-substituted proline for use as P2 building blocks where W is $-CH_2-$ can be prepared as shown in Scheme 5, which illustrates the technique on a moiety where q and k is 1, according to the procedures described by J. Ezquerro et al., *Tetrahedron*, 1993, 38, 8665-8678 and C. Pedregal et al. *Tetrahedron Lett.*, 1994, 35, 2053-2056.



Scheme 5

Treatment of suitably acid protected pyrrolidone or piperidinone such as commercially available Boc-pyrroglutamic acid (5a) with a strong base such as lithium diisopropylamide in a solvent like tetrahydrofuran followed by addition of an alkylating agent R^8-CH_2-X where X is a suitable leaving group such as a halide like chloride or bromide, followed by reduction of the amide and deprotection of the ester gives the desired compound (5d).

Compounds with alternative ring size and/or position of the $W-R^8$ substituent of the proline derivatives in scheme 1, 2 and 5 may also be used in the preparation of compounds according to the present invention. For example, alkylation of commercially available 3-hydroxyproline provides compounds of the general formula (I) wherein k is 0 and q is 2. Correspondingly, alkylation of 5-hydroxyproline, prepared for example as described by Hallberg et al., *J. Med. Chem.* (1999), 4524-4537, provides compounds of the general formula (I) wherein k is 2 and q is 0.

Ink. 1. Patent- och reg.verket

7004 01 3 0

Huvudkontor Kasean

M183

32

Various methods for the preparation of hydroxylated 2-piperidine carboxylic acids are described in the literature see for instance Celestini et al., Org. Lett., (2002), 1367-1370, Hoarau et al., Tetrahedron: Asymmetry, (1996), 2585-2594, Zhu et al., Tetrahedron Lett., 41, (2000), 7033-7036. For example, the corresponding pyridine carboxylic acids can be reduced to provide hydroxylated 2-piperidine carboxylic acids. Enzymatical methods can also be used for the preparation of hydroxylated proline analogues. For example, a 3-hydroxy substituent can be introduced on commercially available 4, 5, and 6 membered heterocyclic acids by the use of proline 3-hydroxylase as described by Ozaki et al., Tet. Letters, 40, (1999), 5227-5230.

Additional P2 building blocks, especially for compounds of formula VI are described in Schemes 11-15 below.


Synthesis and introduction of P1 building blocks.

The amino acids used in the preparation of P1 fragments are available either commercially or in the literature, see for example WO 00/09543 and WO00/59929 from Boehringer-Ingelheim.

Scheme 6 shows an example of the preparation of a sulphonamide derivative to be used as a P1 fragment, and the subsequent coupling to a Boc protected P2 building block.

M183

33



Scheme 6

- The sulphonamide group can be introduced on a suitably protected amino acid (6a) by treatment of the amino acid with a coupling agent, for example N,N'-carbonyldiimidazole (CDI) or the like, in a solvent like THF followed by reaction with the desired sulphonamide (6b) in the presence of a strong base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Alternatively the amino acid can be treated with the desired sulphonamide (6b) in the presence of a base like diisopropyl ethylamine followed by treatment with a coupling agent like PyBOP® to effect the introduction of the sulphonamide group. Removal of the amino protecting group by standard methods and subsequent coupling to a P2 building block, prepared as described above, using standard methods for amide bond formation, like with a coupling agent as O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) in the presence of a base such as diisopropylamine in a solvent like dimethylformamide, gives Boc protected P2-P1 construct (6e). Alternatively, the sulphonamide group can be introduced at a later stage of the synthesis, for example as the last step. In this case the carboxylic acid is appropriately protected, for example as the methyl ester, and appropriately deprotected prior to the coupling of the sulphonamide group, for example with aqueous lithium hydroxide.

Ink. t. Patent- och reg.verket

SMA-01-30

M183


34

Hörsjöfjärn Persson

P1 building blocks for the preparation of compounds according to general formula I and VI wherein A is an ester or an amide can be prepared by reacting amino acid (6a) with the appropriate amine or alcohol respectively under standard conditions for amide bond or ester formation. P1 building blocks wherein A is CR^4R^4 are described in Oscarsson et al Bioorg Med Chem 2003 11(13) 2955-2963 and PCT/EP03/10595 filed 23.09.2003, the contents of which are incorporated by reference.

Synthesis of capped building blocks

The building blocks R^{16} -G-P3 and R^{16} -G-P4-P3 can be prepared as generally depicted in scheme 7.



Scheme 7


A suitable N-protected amino acid (7a) can be coupled with an amino capping group (R^{16} -NHRy) using standard peptide coupling conditions like with coupling agents such as HATU, DCC, HOBT or the like in the presence of a base such as DIEA or DMAP in a solvent like dichloromethane, chloroform or dimethylformamide or a mixture thereof and ester formation conditions like providing amides i.e. G is NHRy (7b). Alternatively, reaction of amino acid (7a) with a compound of general formula R^{16} -X where R^{16} is as defined above and X is a leaving group such as a halide, in

M183

35

the presence of a base like cesium carbonate or silver (I) oxide provides esters, i.e. G is O (7b). On the other hand, amino acid (7a) can be coupled to a second, suitably O-protected, amino acid (7d) using standard peptide coupling conditions as described above, providing (7e). Displacement of the ester group with a suitable capping group (7b) provides fragment (7f) useful for the preparation of compounds according to the present invention wherein m and n are 1.

When G is N-Ry, the capped P3 or P2 building block can also be prepared on solid support as exemplified in Scheme 8.



Scheme 8

An appropriate N-protected, for example Boc protected, amino acid (8a) can be immobilized on a solid support, here exemplified by Agronaut resin PS-TFP, by reacting the amino acid with the desired solid support in the presence of coupling reagent like N,N'-diisopropylcarbodiimide and a base like DMAP in a solvent like dichloromethane and dimethylformamide. The immobilized amino acid can then be cleaved from the support with a suitable capping group (8c) thus giving fragments useful for the preparation of compounds according to the present invention wherein m or n is 1. Optionally the amino protecting group can be removed followed by coupling of an appropriate amino acid using standard methods thus providing

Ink. t. Patent- och reg.verket

2004-01-30

M183

36


Haraldhagen Kase-an

fragments useful for the preparation of compounds according to the present invention wherein m and n are 1.

- 5 Hydrazine containing P3 and P3-P4 building blocks can be prepared by the use of tert. butyl carbazate instead of amino acid 7a and 8a in schemes 7 and 8 respectively thus providing intermediates for the synthesis of compounds wherein T is NRd.

Coupling of a capping group or a capped building block to the P2-P1 construct

- 10 The R^{16} -G, R^{16} -G-P3 or R^{16} -G-P4-P3 building block linked via a urea functionality to the P2-P1 construct, can be introduced as depicted in scheme 8, which illustrates the technique with a variant in which P2 is a heterocyclic residue.



Rx' and R11' have the same definitions as Rx and R11 respectively but are not part of a macrocycle. A' is a protected carboxylic acid, substituted amide or CR4R4'.

Scheme 9

15

A chlorocarbamate group can be formed onto the ring amine of the P2-P1 construct (9a) by removal of the amine protection group by standard procedures, like acidic treatment with for example TFA in dichloromethane or the like when the Boc group is used, followed by reaction of the free amine with phosgene in toluene in the

Ink. t. Patent och reg.verket

2004-01-30


M183

37

Huyulbass Karsan

presence of a base such as sodium hydrogen carbonate or triethylamine in a solvent like tetrahydrofuran. Subsequent reaction of the formed electrophilic center with the amino group of a R^{16} -G, R^{16} -G-P3 or R^{16} -G-P4-P3 building block (9c) in a solvent like dichloromethane in the presence of a base like sodium hydrogen carbonate provides (9d). Compounds of general formula (I) wherein E is C=S, S(=O) or S(=O)₂ can be prepared according to the above procedure but with the use of reagents like thiocarbonyl diimidazole, thionyl chloride or sulphuryl chloride respectively instead of phosgene.

- 10 The linkage between the P2 and P3 building blocks can also be via a carbamate group and a general route to such compounds is depicted in Scheme 10, which illustrates the technique with a variant in which P2 is a proline derivative.



Scheme 10

The desired, optionally protected, amino capping group (10a) is coupled to a hydroxy acid (10b) using standard peptide coupling techniques followed by reaction with the electrophilic P2 building block (10d) described above and optional deprotection provides construct (10e).

Ink. t. Patent- och reg.verket


22: -01- 3 0

Figure 2.2-1: Kerosene

M183

38

Compounds lacking a carboxy group in the P3 unit can be prepared as illustrated in Scheme 11, which illustrates the technique as applied to a compound of Formula I



R11' has the same definition as R11 but is not part of a macrocycle. A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

5 Scheme 11

Chlorocarbamoyl derivative (11a) can be reacted in a displacement reaction with an azide derivative (11b), prepared by methods known from the literature, in the presence of a base like sodium hydrogen carbonate to give (11c). X is as described for general formula (I). Reduction of the azide function for example by polymer bound triphenyl phosphine in a solvent like methanol or any other suitable reduction method provides intermediate (11d) which subsequently can be reacted with an acid under peptide coupling conditions or with an amine in a reductive amination reaction providing amides and secondary amines respectively.

Instead of using the azide derivative (11b) in the displacement reaction with chlorocarbamate (11a) the corresponding hydroxy derivative can be used. Subsequent reaction of the formed alcohol with a suitable acylating or alkylating agent using the appropriate conditions provides the ester and ether compounds respectively, i.e. G is O in general formula (I).


M183

39

Although Figure 11 has been described with reference to a compound of Figure I, it will be readily apparent that corresponding methodology is applicable for compounds of the Formula VI.

5

Alternatively the linkage between the P2 and P3 building blocks can be via a guanidine group and a general route to such compounds is depicted in Scheme 12.



R11' has the same definition as R11 but is not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

10

Scheme 12

15

Treatment of the P2-building block (12a) with thiocarbonyl diimidazole or the like in a solvent like dimethylformamide followed by condensation with sodium cyanamide in a solvent like ethanol affords the thiolate intermediate (12b). Reaction of intermediate (12b) with the desired building block, here shown as a capped P3 building block (12c) provides the cyanoguanidine derivative (12d). Other building blocks, R¹⁶-G or R¹⁶-G-P4-P3, can alternatively be coupled to the intermediate (12b).

Ink. t. Patent- och reg.verket

2004-01-30

Hans-Joachim Karsen

M183


40

Hydrolysis of the cyano group by treatment of (12d) with diluted hydrochloric acid gives the guanyurea derivative (12e).

- When R7, R7' and A' contains functional groups, these are suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

Carbocyclic P2 building blocks

- A typical route to saturated, carbocyclic P2 building blocks towards compounds of formula VI is shown in Scheme 13, which illustrates the technique with a variant wherein q' is 0 and k is 1.



Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle. A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

15 Scheme 13

- The saturated cycloalkyl scaffold (13b) can be prepared, for example, from 3,4-bis(methoxycarbonyl)cyclopentanone (13a), described by Rosenquist et al. in Acta Chem. Scand. 46 (1992) 1127-1129 by reduction of the keto group with a reduction agent like sodium borohydride in a solvent like methanol followed by hydrolysis of the esters and finally ring closure in acetic anhydride in the presence of pyridine. The

ink + Patent och reg.verket

· · · 30


12. 11. 1994

M183

41

provided bicyclic acid (13b) can then be coupled to the amine function of the desired P3 fragment (13c), P3-P4 fragment or capping group R^{16} -NHRy, using conventional peptide coupling conditions like with HATU and diisopropyl amine in a solvent like dimethyl formamide, giving (13d). Lactone opening of (13d) with for example lithium hydroxide provides the acid which subsequently can be coupled to the amino group of a P1 building block or a precursor of a desired P1 fragment (13e); using conventional peptide coupling conditions. The R^8 -substituent of the carbocycle can be introduced for example by a Mitsunobu reaction with the appropriate alcohol as described above or by any other suitable method previously described. When R^7 , R^{16} and A' contains functional groups, these are optionally suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

15 Scheme 14 shows an alternative route towards saturated compounds of formula VI where the building blocks are introduced in the reversed order, i.e. the P1 fragment is introduced before the capping group, P3 or P3-P4 building block.



Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle. A' is a protected carboxylic acid, substituted amide or CR₄R₄'.

Scheme 14

M183


42

Protection of the acid group of (14a) for example as the tert. butyl ester by treatment with di-tert. butyl dicarbonate in the presence of a base like dimethylaminopyridine and triethylamine in a solvent like dichloromethane provides ester (14b). Lactone opening and coupling of a P1 building block (14c) as described in scheme 13 or directly by the amine group of the P1 fragment provides (14d). Introduction of R⁸-substituent as described above followed by removal of the acid protection group by subjecting the ester to acidic conditions like trifluoroacetic acid and triethylsilane in a solvent like methylene chloride and finally coupling of the P3 building block (14e), P3-P4 building block or capping group R¹⁶-NHRy, as described above provides (f).

When R⁷, R^{7'} and A' contain functional groups, these are optionally suitably protected by methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

An unsaturated P2 building block towards the preparation of compounds of formula VI can be prepared as illustrated with cyclopentene below.

The cyclopentene scaffold is typically prepared as described in scheme 15.



Scheme 15

A bromination-elimination reaction of 3,4-bis(methoxycarbonyl)cyclopentanone (15a) as described by Dolby et al. in J. Org. Chem. 36 (1971) 1277-1285 followed by reduction of the keto functionality with a reduction agent like sodium borohydride provides the unsaturated hydroxy compound (15b). Selective ester hydrolysis using for example lithium hydroxide in a solvent like a mixture of dioxane and water provides hydroxy substituted cyclopentene derivative (15c).

Int. t. Patent- not recommended


2003-01-30

Hans-Joachim Roth

M183

43

A P2 building block wherein Rq is other than hydrogen, such as a methylated cyclopentene scaffold can be prepared as shown in scheme 16.



5 Scheme 16


Oxidation of commercially available 3-methyl-3-buten-1-ol (16a) by the use of an oxidation agent like pyridinium chlorochromate followed by treatment with acetyl chloride, bromine and methanol provides the α -bromo ester (16c). The afforded ester (16c) can then be reacted with the enolate (16e), achieved for example by treatment of the corresponding tert.butyl ester with a base such as lithium diisopropyl amide in a solvent like tetrahydrofuran, to give the alkylated compound (16f). The tert-butyl ester (16e) can be prepared by treatment of the corresponding commercially available acid (16d) where k' is 1 to 3 with di-tert.butyl dicarbonate in the presence of a base like dimethylaminopyridine. Cyclisation of (16f) by an olefin metathesis reaction performed as described above provides cyclopentene derivative (16g). Stereoselective epoxidation of (16g) can be carried out using the Jacobsen asymmetric epoxidation method to furnish the epoxide (16h). Finally, addition of a base like DBN (1,5-diazabicyclo-[4.3.0]non-5-ene) yields the alcohol (16i). Optionally the double bond of compound (16i) can be reduced for example by catalytic

M183

44

hydrogenation using a catalyst like palladium on carbon which provides the corresponding saturated compound.

- 5 The afforded cyclic scaffolds can then be used, as described above, to complete the inhibitor sequence. An example is shown in scheme 17.



Rx' and T' have the same definitions as Rx and T respectively but are not part of a macrocycle.
A' is a protected carboxylic acid, substituted amide or CR⁴R⁴'.

Scheme 17

10

- The amino group of a P1-building block or a suitable precursor thereof (17b) can be coupled to the acid of the cyclopentene derivative (17a) using standard amide coupling conditions followed by introduction of the R⁸-substituent for example by Mitsunobu conditions as described above to provide (17d). Hydrolysis of the remaining ester and subsequent amide coupling of a desired P3 or P3-P4 building block (17e) optionally followed by manipulations of the P1 part provides cyclopentene containing compounds (17f) according to general formula VI. When R⁷, R⁷' and A' contain functional groups, these are optionally suitably protected by
- 15

M183

45

methods recognized by persons skilled in the art, see for example Bodanzky or Greene cited above.

Formation of macrocyclic compounds

- 5 Compounds according to the present invention wherein an alkylene chain extending from the $R^7/R^{7'}$ cycloalkyl to R_x , R_d or R^{11} thus forming a macrocycle, can be prepared as described below. Suitable P1, P2 and P3 building blocks, or precursors thereof, are coupled together using the strategies described above, followed by a ring-closing reaction (macrocyclization). The substituent $W-R^8$ of the P2 building
- 10 block can be incorporated via a Mitsunobu reaction as described above, before or after formation of the macrocycle or the assembly can be done with the required substituted proline analogue or carbocycle. For macrocyclic structures extending from the $R^7/R^{7'}$ cycloalkyl to R^{11} , P3 amino acids containing the appropriate side chain can be prepared as described in WO00/59929.

15

A typical route to macrocyclic compounds is shown in Scheme 18 which illustrates the technique applied to a compound having a heterocyclic P2 and a spiro-cyclopropyl P1, where the macrocycle incorporates the P3 side chain.


Int. t. Patent- not required

2004-01-30

Inventor: K. K. K.

M183

46



Scheme 18


Coupling of proline derivative (18a) with the appropriate, acid protected, amino acid (18b) using the conditions described above provides (18c). Formation of the macrocycle can then be carried out via an olefin metathesis reaction using a Ru-based catalyst such as the one reported by Miller, S.J., Blackwell, H.E.; Grubbs, R.H. J. Am. Chem. Soc. 118, (1996), 9606-9614, Kingsbury, J. S., Harrrity, J. P. A., Bonitatebus, P. J., Hoveyda, A. H., J. Am. Chem. Soc. 121, (1999), 791-799 and Huang et al., J. Am. Chem. Soc. 121, (1999), 2674-2678. It will also be recognized that catalysts containing other transition metals such as Mo can be used for this reaction. Optionally the double bond is reduced and/or the ethyl ester is hydrolysed by standard hydrogenation and/or hydrolysis methods respectively well known in the art. Alternatively the methyl ester can be selectively hydrolysed followed by coupling of a R^{16} -G-P4 building block by standard peptide coupling conditions. The procedure described in Scheme 18 can also be applied to the corresponding carbocyclic analogues described above. When the linker contains a nitrogen atom

M183

47

the ring closure can be carried out by reductive amination as described in WO0059929.

- Hydrazine containing macrocyclic structures can be prepared by the use of a carbazate derivative, N-alkylated with the appropriate chain, as the P3 unit.
- Carbazate derivatives can be prepared as described in Scheme 19




10 Scheme 19

- Oxidation of the appropriate alcohol (19a) with a suitable oxidation method like for example with N-methyl morpholine oxide and tetrapropylammonium perruthenate in a solvent like dichloromethane provides ketone (19b). Reductive alkylation of
- tert.butyl carbazate with the afforded ketone gives the P3 building block (19c). This P3 building block can subsequently be coupled to any of the described P2-P1 building blocks. Scheme 20 exemplifies the coupling of a hydrazine containing P3 building block to a cyclopentane scaffold followed by macrocyclisation.

M183

48



Scheme 20

Coupling of the carbamate derivative (20b) with a P2-P1 building block (20a) using standard peptide coupling conditions provides intermediate (20c). Ring closure of (20c) by an olefin metathesis reaction as described above gives the macrocyclic compound (20d).

- 10 The term "N-protecting group" or "N-protected" as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis" (John Wiley & Sons, New York, 1981), which is hereby incorporated by reference.
- 15 N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxycarbonyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like, carbamate forming groups such as benzyloxycarbonyl,
- 20 p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,

Ink t. Patient- not required

11-01-00

Pharmaceutical Division

M183

49

2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl,
3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,
2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl,
1-(p-biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-
5 dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl,
diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl,
methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl,
4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl,
adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl, and the like; alkyl
10 groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl
groups such as trimethylsilyl and the like. Favoured N-protecting groups include
formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl,
t-butoxycarbonyl (BOC) and benzyloxycarbonyl (Cbz).

15 Hydroxy protecting group as used herein refers to a substituent which protects
hydroxyl groups against undesirable reactions during synthetic procedures such as
those O-protecting groups disclosed in Greene, "Protective Groups In Organic
Synthesis," (John Wiley & Sons, New York (1981)). Hydroxy protecting groups
comprise substituted methyl ethers, for example, methoxymethyl, benzyloxymethyl,
20 2-methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, t-butyl and other lower alkyl
ethers, such as isopropyl, ethyl and especially methyl, benzyl and triphenylmethyl;
tetrahydropyranyl ethers; substituted ethyl ethers, for example, 2,2,2-trichloroethyl;
silyl ethers, for example, trimethylsilyl, t-butyl dimethylsilyl and t-butyl diphenylsilyl;
and esters prepared by reacting the hydroxyl group with a carboxylic acid, for
25 example, acetate, propionate, benzoate and the like.

In treating conditions caused by flavivirus such as HCV, the compounds of formula I
or VI are typically administered in an amount to achieve a plasma level of around
100 to 5000 nM, such as 300 to 2000 nM. This corresponds to a dosage rate,
30 depending on the bioavailability of the formulation, of the order 0.01 to 10 mg/kg/day,
preferably 0.1 to 2 mg/kg/day. A typical dosage rate for a normal adult will be around

M183

50

0.05 to 5 g per day, preferably 0.1 to 2 g such as 500-750 mg, in one to four dosage units per day. As with all pharmaceuticals, dosage rates will vary with the size and metabolic condition of the patient as well as the severity of the infection and may need to be adjusted for concomitant medications.

5

As is good prescribing practice with antiviral therapy, the compounds of formula I are typically coadministered with other HCV therapies to avoid the generation of drug escape mutants. Examples of such additional HCV antiviral therapies include ribavirin, interferons, including pegylated interferons. Additionally a number of nucleoside analogues and protease inhibitors are in the development and will be amenable to co-administration with the compounds of the invention.

10

While it is possible for the active agent to be administered alone, it is preferable to present it as part of a pharmaceutical formulation. Such a formulation will comprise the above defined active agent together with one or more acceptable carriers or excipients and optionally other therapeutic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient.

15

The formulations include those suitable for rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration, but preferably the formulation is an orally administered formulation. The formulations may conveniently be presented in unit dosage form, e.g. tablets and sustained release capsules, and may be prepared by any methods well known in the art of pharmacy.

20

25

Such methods include the step of bringing into association the above defined active agent with the carrier. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. The invention extends to methods for preparing a pharmaceutical composition comprising

30

Int. t. Patent- not reg. verho

2004-01-30

Date of filing

M183

51

bringing a compound of Formula I or VI or its pharmaceutically acceptable salt in conjunction or association with a pharmaceutically acceptable carrier or vehicle. If the manufacture of pharmaceutical formulations involves intimate mixing of pharmaceutical excipients and the active ingredient in salt form, then it is often
5 preferred to use excipients which are non-basic in nature, i.e. either acidic or neutral. Formulations for oral administration in the present invention may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active agent; as a powder or granules; as a solution or a suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water
10 liquid emulsion or a water in oil liquid emulsion and as a bolus etc.

With regard to compositions for oral administration (e.g. tablets and capsules), the term suitable carrier includes vehicles such as common excipients e.g. binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone
15 (Povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as magnesium stearate, sodium stearate and other metallic stearates, stearic acid,
20 glycerol stearate, silicone fluid, talc waxes, oils and colloidal silica. Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may be desirable to add a colouring agent to make the dosage form readily identifiable. Tablets may also be coated by methods well known in the art.

25 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active agent in a free flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Moulded tablets may be made by moulding in a
30 suitable machine a mixture of the powdered compound moistened with an inert liquid

M183

52

diluent. The tablets may be optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active agent.

Other formulations suitable for oral administration include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.

The compounds of formula I or VI can form salts which form an additional aspect of the invention. Appropriate pharmaceutically acceptable salts of the compounds of formula I include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, isethionate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, tartrate, lactobionate, pivalate, camphorate, undecanoate and succinate, organic sulphonic acids such as methanesulphonate, ethanesulphonate, 2-hydroxyethane sulphonate, camphorsulphonate, 2-naphthalenesulphonate, benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids.

Prodrugs of the compounds of formula I are those compounds which following administration to a patient release a compound of the formula I in vivo generally following hydrolysis in the gut, liver or plasma. Typical prodrugs are pharmaceutically acceptable ethers and especially esters (including phosphate esters) of hydroxy functions, pharmaceutically acceptable amides or carbamates of amine functions or pharmaceutically acceptable esters of carboxy functions. Preferred pharmaceutically acceptable esters include alkyl esters, including acetyl, ethanoyl, butyryl, t-butyryl, stearyl and pivaloyl, phosphate esters and sulphonic esters (ie those derived from

M183




53

RSO₂OH, where R is lower alkyl or aryl). Pharmaceutically acceptable esters include lower alkyl ethers and the ethers disclosed in WO00/47561, especially methoxyaminoacyl and ethoxyaminoacyl.


- 5 The compounds of the invention have various steric centres and the invention extends to racemates and enantiomers at each of these steric centres.

- Typically, the stereochemistry of the groups corresponding to the P3 and P4 side chains (ie R¹⁵ and/or R¹¹) will correspond to an L-amino acid configuration, although
10 the invention also extends to D-isomers at one or both of these centres.


- The stereochemistry of the backbone component of the cyclic P2 group (i.e. spanning the carbonyl of the P1 amide bond and the carbonyl or E extending of P3 will typically correspond to L-proline. The stereochemistry of the P2 ring atom to
15 which W is bonded is typically as shown:




- In compounds of the invention wherein R7 and R7' together define a spiroalkyl group, such a spiro-cycloalkyl will typically comprise an R^{7'a} substituent on the spiro-cyclopropyl ring which is orientated syn to A:
20



or



and



or anti to A:


Ink. t. Patent- och register

2004-01-30


Huvudtaxen Krossen

M183


54



Conveniently, the spiro carbon of such a spiro-cyclopropyl ring has the R configuration:



Conveniently an R^{7'a} substituent on a spiro-cyclopropyl ring adjacent to A is in a syn-orientation in the following absolute configuration:



Particularly preferred variants have R^{7'a} include ethyl, hence the asymmetric carbon atoms at position 1 and 2 have the R, R configuration.

Alternative preferred R^{7'a} include vinyl, hence the asymmetric carbon atoms at position 1 and 2 have the R, S configuration.

Where the compound of the invention is a macrocycle comprising a J group, J is preferably a diastereomer represented by partial structures (i) or (ii):


Int. t. Patent- not reg.

2004-01-31

Patent- not reg.

M183

55



especially where J is syn to A.

5 Detailed description of the embodiments

Various embodiments of the invention will now be described by way of illustration only with reference to the following non-limiting examples.

10 Example 1

7-Methoxy-2-phenyl-quinolin-4-ol (1).

To a stirred round bottled flask with toluene (100 mL) ethyl benzoyl acetate (18.7 g, 97 mmol) and *m*-anisidine (12 g, 97 mmol) was added. 4 M HCl in dioxane (0.5 mL) was added and the reaction mixture was refluxed for 6 h (140 °C). The mixture was co-evaporated with toluene. To the crude mixture diphenyl ether (50 mL) was added and the mixture was heated to 280 °C for 2 h. When the theoretical amount ethanol (6 mL) was collected in a Dean Stark trap the heating was stopped and the mixture was cooled to rt. The crude mixture was dissolved in CH₂Cl₂ (100 mL) and stirred for 30 min. The formed precipitate was filtered off and dried which gave 1 (4.12 g, 16.4 mmol, 17 %): pale yellow powder.

¹H (300 MHz, DMSO-D₆): δ 3.8 (s, 3H), 6.24 (s, 1H), 6.88-6.96 (dd, 1H, *J* = 9.07 Hz, *J* = 2.47 Hz), 7.19 (d, 1H, *J* = 2.19 Hz), 7.56 (t, 3H, *J* = 2.19 Hz), 7.8 (dd, 2H, *J* = 7.14 Hz, *J* = 2.19 Hz), 8.0 (d, 1H, *J* = 9.06 Hz); ¹³C (75.5 MHz, DMSO-D₆): δ 55.3, 99.6, 106.9, 113.1, 119.1, 126.4, 127.5, 128.8, 130.2, 134.1, 142.2, 149.4, 161.8, 176.4.

Ink. t. Patent- och reg. ve

2004-01-30

Förordning om Kassar


M183

56

Example 2

(Rac)-4-oxocyclopent-2-ene-1, 2-dicarboxylic acid dimethyl ester (2).

(1*R*, 2*S*)-4-oxo-cyclopentane-1, 2-dicarboxylic acid dimethyl ester (4.8 g, 23.8 mmol)
5 and CuBr₂ (11.9 g, 53.2 mmol) were dissolved in dry THF (70 mL) and the mixture
was refluxed for two hours at 90 °C. The formed CuBr was filtrated off and the
organic phase was concentrated. CaCO₃ (2.7 g, 27.2 mmol) and DMF (70 mL) were
added and the mixture was held at 100 °C for one hour. The dark brown mixture was
poured over ice (35 g) and the formed precipitate was filtrated off. The aqueous layer
10 was extracted with ethyl acetate (1 x 300mL + 3 x 150 mL). The organic phases
were dried, filtrated and concentrated. Purification by flash chromatography
(toluene/EtOAc 9:1) gave 2 (2.1 g, 46 %) as yellow crystals

Example 3

15 ((1*S*,4*R*) & (1*R*,4*S*))-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid dimethyl ester
(3).

To a cold solution (-30 °C) of 2 (3.18 g, 16.1 mmol) dissolved in MeOH (23 mL),
20 NaBH₄ (0.66 g, 17.5 mmol) was added. After nine minutes the excess of NaBH₄ was
destroyed by adding brine (80 mL). The mixture was concentrated and extracted with
ethyl acetate (4 x 80 mL). The organic phases were dried, filtrated and concentrated
and gave 3 (3.0 g, 92 %) as a yellow oil.

Example 4

25 (1*S*,4*R*) & (1*R*,4*S*)-4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid 2-methyl ester
(4).


M183

57

To an ice-cold solution of 3 (3.4 g, 22 mmol) dissolved in dioxane and water (1:1, 110ml), LiOH (0.52 g, 22 mmol) was added. After two and a half hours the mixture was co-evaporated with toluene and methanol. Purification by flash chromatography (toluene/Ethyl acetate 3:1 + 1 % HOAc) gave the title compound (1.0 g, 27 %) as yellow-white crystals.

¹H-NMR (300 MHz, CD₃OD): δ 1.78-1.89 (m, 1H), 2.70-2.84 (m, 1H), 3.56-3.71 (m, 1H), 3.76 (s, 3H), 4.81-4.90 (m, 1H), 6.76-6.81 (m, 1H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 38.0, 48.0, 52.4, 75.7, 137.0, 146.2, 165.0 178.4.

Example 5



((3*S*,5*R*) & (3*R*,5*S*))-5-((*S*)-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-hydroxycyclopent-1-enecarboxylic acid methyl (5).

To an ice cooled solution of 4 (0.20 g, 1.1 mmol) and 2-amino-pentanoic acid tert.butyl ester (0.24 g, 1.4 mmol) in DMF (7 mL), DIPEA (0.18 g, 1.4 mmol) and HATU (0.53 g, 1.4 mmol) were added. After two hours the solution was concentrated and purified using column chromatography (toluene/ethyl acetate 3:1). This gave the title compound as a yellow oil (0.22 g, 63 %).

¹H-NMR (300 MHz, CDCl₃): δ 0.84-0.96 (m, 3H), 1.14-1.39 (m, 2H), [(1.44 & 1.49) s, 9H], 1.50-1.60 (m, 1H), 1.61-1.85 (m, 1H), 1.97-2.10 (m, 1H), 2.11-2.28 (m, 1H), 3.57-3.68 (m, 1H), [(3.73 & 3.76) s, 3H], 4.30-4.50 (m, 1H), 4.63-4.73 (m, 1H), 6.80-6.95 (m, 1H), 6.95-7.00 (m, 1H).

Example 6


Link 1. Patent- och registrerings

771-01-30

Pharmaceuticals

M183


58



((3S,5R) & (3R,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl ester (6).

- 5 Reaction of 4 (141 mg, 76 mmol) according to the method described for the preparation of 5 using L-2-amino-N-butyl ester instead of 2-amino-pentanoic acid tert.butyl ester gave the title compound as a slightly yellow oil (171 mg, 69 %).
- 10 ¹H-NMR (300 MHz, CDCl₃): δ 0.89-0.98 (m, 3H), [(1.42 & 1.44) s, 9H], 1.60-1.78 (m, 1H), 1.79-1.95 (m, 1H), 1.99-2.11 (m, 1H), 2.18-2.30 (m, 1H), 3.58-3.65 (m, 1H), [3.75 & 3.78) s, 3 H], 4.22-4.39 (m, 1H), 4.61-4.66 (m, 1H), 6.77-6.90 (m, 1H), 6.91-6.92 (m, 1H).

15 Example 7



((3S,5R) & (3R,5S))-5-((1R,2S)-1-tert-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-hydroxy-cyclopent-1-enecarboxylic acid methyl ester (7).

Reaction of 4 (50 mg, 37 mmol) according to the method described for the preparation of 5 using (1R, 2S)-1-amino-2-vinyl-cyclopropane carboxylic acid tert.butyl ester instead of 2-amino-pentanoic acid tert.butyl ester provided the title compound as a slightly yellow oil (50 mg, 38 %).

Mik. L. Polanski och m.fl. verkst

13012-01-000


M183

59

Mik. L. Polanski och m.fl. verkst

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ [(1.38 & 1.42) s, 9H], 1.75-1.83 (m, 1H), 2.00-2.21 (m, 3H), 3.55-3.63 (m, 1H), [(3.77 & 3.82) s, 3H], 4.20-4.38 (m, 1H), 4.65-4.80 (m, 1H), 5.13-5.20 (m, 1H), 5.22-5.38 (m, 1H), 5.60-5.82 (m, 1H), 6.95-6.96 (m, 2H).

5 Example 8



((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (8).

- 10 To an ice cooled solution of 5 (0.23 g, 0.67 mmol) in dry THF, 7-methoxy-2-phenyl-quinolin-4-ol (0.22 g, 0.88 mmol) and triphenylphosphine (0.23 g, 0.88 mmol) were added. Then DIAD (0.19 g, 0.92 mmol) was dissolved in THF (2 mL) and added dropwise to the solution. After one hour the mixture was concentrated and purified using flash chromatography (toluene/ethyl acetate 3:1). This gave the title compound
- 15 as a white powder (0.30 g, 77 %).

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.88-1.00 (m, 3H), 1.18-1.43 (m, 2H), [(1.45 & 1.50) s, 9H], 1.53-1.65 (m, 1H), 1.66-1.85 (m, 1H), 2.29-2.43 (m, 1H), 3.10-3.25 (m, 1H), [(3.79 & 3.83) s, 3H], 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.38-4.50 (m, 1H), 6.03-6.13 (m, 1H), 6.65-6.90 (m, 1H), 7.04-7.18 (m, 3H), 7.40-7.56 (m, 4H), 8.00-8.12 (m, 3H).


Example 9

Fig. 1

01 3 0

M183

60




((3*R*,5*R*) & (3*S*,5*S*))-5-((*S*)-1-*tert*-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (9).

- 5 Reaction of 6 (132 mg, 40 mmol) according to the method described for the preparation of 8 gave the title compound as a yellow oil (137 mg, 61 %).

¹H-NMR (300 MHz, CDCl₃): δ 0.83-0.98 (m, 3H), [(1.42 & 1.44) s, 9H], 1.65-1.78 (m, 1H), 1.80-1.97 (m, 1H), 2.30-2.40 (m, 1H), 3.05-3.20 (m, 1H), [(3.78 & 3.80) s, 3H],
10 3.94 (s, 3H), 3.95-4.01 (m, 1H), 4.38-4.44 (s, 1H), 6.05-6.15 (m, 1H), 6.80-6.94 (m, 1H), 7.02-7.15 (m, 3H), 7.38-7.55 (m, 4H), 7.97-8.18 (m, 3H).

Example 10



- 15 ((3*R*,5*R*) & (3*S*,5*S*))-5-((1*R*,2*S*)-1-*tert*-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid methyl ester (10).

- 20 Reaction of 7 (41 mg, 116 mmol) according to the method described for the preparation of 8 provided the title compound as a yellow oil.

Ink. t. Parent: not reg. verified

2004-01-30


H. Hoffmann-Kremer

M183

61

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 1.52-1.57 (m, 1H), 1.58 (m, 9H), 1.80-1.83 (m, 1H), 2.00-2.17 (m, 1H), 2.20-2.38 (m, 1H), 3.20-3.37 (m, 1H), 3.80 (s, 3H), 3.81-3.98 (m, 1H), 3.99 (s, 3H), 5.12-5.20 (m, 1H), 5.22-5.40 (m, 1H), 5.83-5.80 (m, 1H), 6.05-6.20 (m, 1H), 7.00-7.21 (m, 4H), 7.40-7.58 (m, 4H), 8.02-8.18 (m, 3H).

5


Example 11

((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (11).

10

The methyl ester 8 (0.35 g, 0.61 mmol) was dissolved in dioxane/water (1:1, 7ml) and LiOH (0.031 g, 1.3 mmol) was added. The reaction was stirred over night and then co-concentrated. This gave the lithium salt of 11 (0.32 g, 90 %) as a brown powder.

15

Example 12

((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (12)

Ink. t. Patent- och reg.verket

2004-01-30


M183

62

Hälsö, 100000

Reaction of 9 (225 mg, 40 mmol) according to the method described for the preparation of 11 provided the title compound as a yellow salt (157 mg, 72 %).

Example 13




5

((3R,5R) & (3S,5S))-5-((1R,2S)-1-tert-Butoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarboxylic acid (13).

Reaction of 10 (35 mg, 59 mmol) according to the method described for the preparation of 11 (33 mg, 97 %) provided the title compound as a yellow salt.

10

Example 14



15

(S)-2-(((1S,4S) & (1R,4R))-2-((S)-1-((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl)-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid tert-butyl ester (14).

The acid 12 (38.4 mg, 0.070 mmol) and (2-amino-3-methyl-butrylamino)-cyclohexyl acetic acid methyl ester (26.6 mg, 0.098 mmol) were dissolved in DMF (1.5 mL) and

01223 847894

Ink i. Patent- och reg.verket

732-01-30

M183


63

H. J. W. M. Krasen

cooled in an ice-bath. DIPEA (17.1 μ L, 0.098 mmol) and HATU (37.4 mg, 0.098 mmol) were added. After ninety minutes the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 6:1). Further purification was performed on HPLC (90 % MeOH + 0.2 % TEA). The diastereomeric mixture 14 was concentrated and gave a slightly yellow oil (20.6 mg, 37 %). After lyophilisation 14 was collected as a white powder.

$^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.93-1.02 (m, 9H), 1.03-1.25 (m, 4H), 1.44 (s, 9H), 1.65-1.86 (m, 9H), 2.05-2.10 (m, 1H), 2.22-2.40 (m, 1H), 3.05-3.20 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.18-4.22 (m, 1H), 4.38-4.60 (m, 3H), 6.01-6.10 (m, 1H), 6.61-6.70 (m, 2H), 6.80-6.85 (m, 1H), 7.05-7.18 (m, 2H), 7.40-7.58 (m, 5H), 8.00-8.13 (m, 3H). $^{13}\text{C-NMR}$ (75.5 MHz, CDCl_3): δ 9.7, 18.4, 19.2, [25.9 & 26.1], [28.2 & 28.5], 29.6, 32.0, 37.3, 41.0, 46.2, 50.7, 52.4, 54.4, 55.8, 57.2, 58.5, 82.0, 82.8, 98.4, 110.2, 118.4, 120.1, 123.2, 127.9, 128.2, 128.9, 129.5, 131.2, 135.1, 135.2, 142.7, 144.2, 161.6, 164.3, 164.7, 170.9, 171.4, 172.4. MALDI-TOF m/z 821.56 [(M + Na) $^+$ calcd for $\text{C}_{45}\text{H}_{58}\text{N}_4\text{NaO}_9$ 821.41].

Example 15



(S)-2-((((1R,4R) & (1S,4S))-2-((R)-1-(((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl)-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl)-amino}-butyric acid *tert*-butyl ester (15).


M183

64

Reaction of 12 (20 mg, 37 mmol) according to the method described for the preparation of 14 using (2-amino-3-methyl-butrylamino)-(R)-cyclohexyl acetic acid methyl ester Instead of (2-amino-3-methyl-butrylamino)-(S)-cyclohexyl acetic acid methyl ester, gave the title compound (19 mg, 66 %) as a white powder.

¹H-NMR (300 MHz, CDCl₃): δ 0.91-0.98 (m, 3H), 0.99-1.10 (m, 6H), 1.11-1.38 (m, 4H), [(1.43 & 1.45) s, 9H], 1.45-1.94 (m, 9H), 2.05-2.18 (m, 1H), 2.22-2.40 (m, 1H), 3.16-3.24 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.04-4.18 (m, 1H), 4.36-4.57 (m, 3H), 6.00-6.08 (m, 1H), 6.13-6.21 (m, 1H), 6.62-6.70 (m, 1H), 6.81-6.85 (m, 1H), 7.05-7.18 (m, 3H), 7.41-7.57 (m, 4H), 8.02-8.13 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ 9.3, 18.2, 19.0, [25.5 & 25.9], [28.0 & 28.3], 29.4, 31.4, 32.1, 35.7, 40.7, 50.4, 52.2, 54.2, 55.5, 57.0, 58.2, 81.8, 82.4, 98.2, 107.5, 115.0, 118.1, 122.9, 127.6, 128.7, 128.8, 128.9, 129.2, 135.1, 140.4, 142.2, 151.4, 161.3, 163.9, 170.4, 170.9, 171.2, 172.0. MALDI-TOF *m/z* 821.60 [(M + Na)⁺ calcd for C₄₅H₅₈N₄NaO₉⁺ 821.41].

Example 16



(S)-2-((((3R,5R) & (3S,5S))-5-((S)-1-tert-Butoxycarbonyl-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino)-3-methylbutyric acid methyl ester (16).

Reaction of 12 (24 mg, 44 mmol) according to the method described for the preparation of 14 using D-valine methyl ester instead of (2-amino-3-methyl-


M183

66

butyrylamino)cyclohexyl acetic acid methyl ester, gave the title compound (27 mg, 97 %) as a white powder.

¹H-NMR (300 MHz, CDCl₃): δ 0.82-0.99 (m, 9H), [(1.42 & 1.44) s, 9H] 1.65-1.95 (m, 2H), 2.18-2.25 (m, 1H), 2.26-2.40 (m, 1H), 3.20-3.25 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.15-4.19 (m, 1H), 4.36-4.43 (m, 1H), 4.64-4.75 (m, 1H), 6.03-6.15 (m, 1H), 6.80-6.85 (m, 2H), 7.10-7.20 (m, 3H), 7.42-7.58 (m, 4H), 8.0-8.10 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ 9.7, [18.2 & 19.1], 25.7, [28.1 & 28.2], 32.0, 35.6, 50.4, 52.4, 54.5, 55.7, 57.6, 81.7, 82.7, 98.4, 107.7, 115.2, 118.4, 123.2, 127.8, 129.0, 129.2, 129.5, 134.8, 135.0, 140.4, 142.5, 151.6, 159.6, [161.1 & 161.5], 164.6, 171.1, 172.2. MALDI-TOF *m/z* 682.51[(M + Na)⁺ calcd for C₃₇H₄₅N₃NaO₈⁺ 682.31].

Example 17



(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid *tert*-butyl ester (17).

Compound 17 (28.6 mg, 59 %) was prepared from 12 (33 mg, 60 mmol) according to the method for the preparation of 14 using 2-amino-N-(2,5-dimethoxy-phenyl)-N-ethyl-3-methyl butyramide instead of (2-amino-3-methyl-butylamino)-cyclohexyl acetic acid methyl ester. This gave the title compound as a white powder.


¹H-NMR (300 MHz, CDCl₃): δ 0.75-0.95 (m, 9H) 1.05-1.18 (m, 3H), [(1.42 & 1.44) s, 9H], 1.60-1.95 (m, 3H), 2.20-2.40 (m, 1H), 3.20-3.34 (m, 1H), 3.60-3.80 (m, 2H),

M183

66

[3.62-3.65 (m, 3H)], [3.79-3.82 (m, 3H)], 3.98 (s, 3H), 4.02-4.18 (m, 1H), 4.30-4.44 (m, 2H), 6.05-6.18 (m, 1H), 6.60-6.63 (m, 1H), 6.77-6.80 (m, 2H), 6.85-6.93 (m, 2H), 7.12-7.20 (m, 2H), 7.35-7.60 (m, 5H), 8.02-8.20 (m, 3H). ^{13}C -NMR (75.5 MHz, CDCl_3): δ [9.6 & 9.7], [12.5 & 12.8], [17.1 & 17.5], [19.4 & 19.5], 25.6, [28.0 & 28.1], 32.4, 35.8, 43.0, 44.3, [50.2 & 50.3], 54.3, [54.8 & 55.0 & 55.2 & 55.5], [55.6 & 55.7 & 55.9 & 56.0], 81.7, 82.8, 98.4, 106.9, [112.4 & 112.5], 113.7, 115.0, 116.2, 115.9, 116.3, 118.4, [123.0 & 123.1], [127.7 & 127.8], 128.8, 128.9, 129.5, 130.1, [134.1 & 134.2], 142.6, 149.1, 149.4, 153.4, 158.9, [161.4 & 161.6], [163.2 & 163.5], 170.9, [171.3 & 171.5], 172.3. MALDI-TOF m/z 831.62 $[(M + \text{Na})^+]$ calcd for $\text{C}_{46}\text{H}_{56}\text{N}_4\text{NaO}_9^+$ 831.39].

Example 18



(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-butyric acid *tert*-butyl ester (18).

Compound 18 (16.1 mg, 26 %) was prepared from 12 (43.2 mg, 0.077 mmol) according to the method for the preparation of 14 using (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester instead of (2-amino-3-methyl-butyrylamino)-cyclohexyl acetic acid methyl ester. Flash column chromatography was performed in toluene/ethyl acetate 3:1 instead of 6:1. This gave the title compound as a white powder.

Ink. t. Patent- och reg.verket

7 114 -01- 3 0

Företagsnamn: Karsan



M183

67

¹H-NMR (300 MHz, CDCl₃): δ 0.77-0.83 (m, 3H), [(0.92 & 0.93) s, 9H] 0.94-1.20 (m, 4 H), [(1.36 & 1.38) s, 9H], 1.42-1.76 (m, 8H), 2.20-2.38 (m, 1H), 2.81-2.96 (m, 1H), 3.20-3.22 (m, 1H), 2.78 (s, 3H), [(3.83 & 3.85) s, 3H], 3.97-4.02 (m, 1H), 4.17-4.21 (m, 1H), 4.22-4.37 (m, 2H), 5.85-5.97 (m, 1H), [6.76-6.78 (m, 0.5H)], [6.80-6.82 (m, 0.5H)], 6.98-7.05 (m, 3H), 7.23-7.41 (m, 6H), 7.82-7.99 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ [9.4 & 9.5], [25.4 & 25.5], 25.8, [26.5 & 26.6], [27.9 & 28.0], [28.4 & 28.5], 29.3, [35.4 & 35.7], [36.0 & 36.4], [40.5 & 40.7], [50.2 & 50.5], [52.1 & 52.2], [54.1 & 54.3], 55.5, [57.0 & 57.3], [60.4 & 60.7], [81.8 & 82.0], [82.4 & 82.5] 98.1, 107.5, 116.0, 118.1, 123.0, 127.5, 128.7, 128.8, 129.2, 134.9, 135.8, 141.9, 142.5, 151.3, 159.4, [160.9 & 161.3], [163.7 & 163.9], [169.9 & 170.0] [170.0 & 171.3], [172.5 & 172.4]. MALDI-TOF *m/z* 835.68 [(M + Na)⁺ calcd for C₄₆H₆₀N₄NaO₉⁺ 835.43].

Example 19

15



(S)-2-[[[(1*R*,4*R*)-2-[(*S*)-1-[[[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (19a) and
(S)-2-[[[(1*S*,4*S*)-2-[(*S*)-1-[[[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid tert-butyl ester (19b).

The acid 11 (0.051 g, 0.087 mmol) and (2-amino-3-methyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (0.054 g, 0.21 mmol) were dissolved in DMF (1.5 mL) and

M183

68

cooled in an ice-bath. DIPEA (16 mg, 0.12 mmol) and HATU (47 mg, 0.13 mmol) were added. After two and a half hours the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 3:1). Further purification was performed on HPLC (90 % MeOH + 0.2 % TEA). This gave after co-concentration the two diastereomers 19a (9.4 mg, 13 %) and 19b (5.3 mg, 7 %) as slightly yellow syrups. After lyophilisation 19a and 19b were collected as white powders;

¹H-NMR (300 MHz, CDCl₃): δ 0.86-0.93 (m, 3H), 0.94-1.00 (m, 6H), 1.00-1.41 (m, 7H), 1.46 (s, 9H), 1.50-1.88 (m, 8H), 2.05-2.20 (m, 1H), 2.20-2.37 (m, 1H), 3.12-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.05-4.20 (m, 1H), 4.40-4.55 (m, 3H), 6.02-6.18 (m, 1H), 6.30 (d, *J* = 8.52 Hz, 1H), 6.63 (s, 1H), 6.76 (d, *J* = 8.51 Hz, 1H), 7.06-7.16 (m, 2H), 7.42-7.56 (m, 6H), 8.00-8.12 (m, 3H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.0, 18.4, 19.3, 26.1, 28.3, 28.5, 29.7, 31.9, 34.9, 36.0, 41.0, 50.7, 52.4, 53.3, 55.7, 57.2, 58.6, 82.0, 82.7, 98.4, 105.7, 107.7, 115.2, 118.4, 123.2, 125.3, 127.9, 129.0, 129.1, 135.1, 138.0, 142.4, 151.6, 159.4, 161.6, 164.3, 170.7, 171.2, 172.3. 19b: ¹H-NMR (300 MHz, CDCl₃): δ 0.90-1.04 (m, 9H), 1.04-1.43 (m, 7H), 1.47 (s, 9H), 1.50-1.87 (m, 8H), 2.10-2.27 (m, 1H), 2.33-2.45 (m, 1H), 3.10-3.20 (m, 1H), 3.73 (s, 3H), 3.96 (s, 3H), 4.02-4.10 (m, 1H), 4.36-4.53 (m, 3H), 6.00-6.16 (m, 1H), 6.30 (d, *J* = 8.52 Hz, 1H), 6.73 (s, 1H), 6.86 (d, *J* = 7.96 Hz, 1H), 7.08-7.16 (m, 2H), 7.36-7.56 (m, 5H), 8.03-8.11 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.0, 18.6, 19.2, 26.1, 28.2, 28.7, 29.7, 34.5, 36.1, 36.6, 40.8, 50.5, 52.4, 53.4, 55.7, 57.3, 59.1, 64.8, 82.3, 98.4, 105.8, 107.8, 115.3, 118.4, 123.2, 127.8, 129.0, 129.4, 135.2, 142.2, 144.9, 151.0, 151.6, 159.2, 164.3, 164.3, 170.2, 171.6, 171.9.

Example 20



Ink 1. Patent- och register

2004-01-30

Förhandsbetalt

M183

69



(S)-2-([(1R,4R)-2-((R)-1-(((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl)-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-pentanoic acid tert-butyl ester (20a) and

5 (S)-2-([(1S,4S)-2-((R)-1-(((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl)-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-pentanoic acid tert-butyl ester (20b).

Method A: The carboxylic acid 11 (57 mg, 0.10 mmol) was dissolved in warm (50 °C) dry THF (2 mL). (2-Amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (50 mg, 0.12 mmol), DIPEA (30 mg, 0.23 mmol), DCC (25 mg, 0.12 mmol) and HOBt (17 mg, 13 mmol) were added. After two hours the mixture was concentrated and added to a short column (toluene/Ethyl acetate 1:3 + 3 % AcOH). Then it was further purified on HPLC using 90 % MeOH + 0.2 % TEA. The diastereomeric products were not separated. After HPLC the solution was co-concentrated with toluene and methanol to give 20 (28 mg, 34%).

Method B: To an ice-cold solution of 11 (60 mg, 0.10 mmol) and (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (42 mg, 0.15 mmol) DIPEA (19 mg, 0.15 mmol) and HATU (62 mg, 0.16 mmol) were added. After two and a half hours the mixture was concentrated and purified using column chromatography. (toluene/Ethyl acetate 3:1). The diastereomeric mixture was separated using HPLC (90 % MeOH + 0.2 % TEA). This gave 20a (6 mg, 6 %) and 20b (9 mg, 10%).

Patent Application

1-01-00


Patent Application

M183

70

20a: $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.82-0.90 (m, 3H), 1.01 (s, 9H), 1.05-1.40 (m, 7H), 1.46 (s, 9H), 1.50-1.80 (m, 8H), 2.20-2.35 (m, 1H), 3.07-3.25 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.11 (d, $J = 7.96$ Hz, 1H), 4.38-4.52 (m, 3H), 6.03-6.12 (m, 1H), 6.24 (d, $J = 8.79$ Hz, 1H), 6.63 (s, 1H), 6.82 (d, $J = 9.06$ Hz, 1H), 7.07-7.27 (m, 2H), 7.36 (d, $J = 7.96$ Hz, 1H), 7.41-7.55 (m, 4H), 8.01-8.10 (m, 3H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 14.0, 18.8, 26.1, 26.8, 28.2, 28.6, 29.6, 34.9, 35.6, 36.2, 40.9, 50.7, 52.4, 53.3, 55.7, 57.3, 60.8, 82.0, 82.7, 98.4, 105.2, 107.7, 115.2, 118.4, 123.2, 127.9, 129.0, 129.4, 131.1, 135.1, 138.4, 142.4, 153.3, 159.6, 161.6, 164.2, 170.1, 171.3, 172.2. 20b: $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.90-0.98 (m, 3H), 1.04 (s, 9H), 1.08-1.40 (m, 7H), 1.44 (s, 9H), 1.55-1.90 (m, 8H), 2.20-2.38 (m, 1H), 3.10-3.22 (m, 1H), 3.73 (s, 3H), 3.97 (s, 3H), 4.02-4.15 (m, 1H), 4.35-4.48 (m, 3H), 6.00-6.08 (m, 1H), 6.72 (s, 1H), 6.90 (d, $J = 9.06$ Hz, 1H), 7.09-7.20 (m, 3H), 7.44-7.55 (m, 5H), 8.03-8.11 (m, 3H).

15

Example 21

(1R,2S)-1-((((1R,4R) & (1S,4S))-2-((S)-1-(((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-2-vinyl-cyclopropanecarboxylic acid *tert*-butyl ester (21).

The acid 13 (35 mg, 0.060 mmol) and (2-amino-3,3-dimethyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (22 mg, 0.080 mmol) were dissolved in dry THF

Int. Patent- cash reg.

2.10.01-31-31

Patent- cash reg.



M183

71

(1.5 mL) and warmed to 50 °C. HOBt (11 mg, 0.080 mmol) and DCC (31 mg, 0.15 mmol) were added. After one hour the mixture was co-concentrated with toluene and methanol and then purified by flash column chromatography (toluene/ethyl acetate 1:1). Further purification was performed on HPLC (80 % MeOH + 0.2 % TEA. The diastereomeric mixture 21 was concentrated and gave a slightly yellow oil (26.4 mg, 53 %). After lyophilisation 21 was collected as a white powder.

¹H-NMR (300 MHz, CDCl₃): δ [(0.98 & 1.00), s, 9H], 1.01-1.38 (m, 5H), [(1.39 & 1.40) s, 9H], 1.52-1.63 (m, 4H), 1.65-1.80 (m, 4H), 1.90-2.05 (m, 1H), 2.20-2.40 (m, 1H), 3.02-3.20 (m, 1H), [(3.66 & 3.67) s, 3H], 3.98 (s, 3H), 3.99-4.02 (m, 1H), 4.30-4.45 (m, 2H), 5.05-5.11 (m, 1H), 5.20-5.30 (m, 1H), 5.60-5.81 (m, 1H), 6.03-6.17 (m, 1H), 6.77-6.82 (m, 1H), 6.95-7.22 (m, 5H), 7.40-7.50 (m, 4H), 8.01-8.10 (m, 3H). ¹³C-NMR (75.5 MHz, CDCl₃): δ 22.3, [25.7 & 25.8], [26.4 & 26.5], [28.0 & 28.4] 29.2, 32.7, 33.3, [35.3 & 35.4], 36.0, [40.2 & 40.3], 40.7, 52.0, 55.4, [57.2 & 57.4] [60.4 & 60.5], [87.6 & 87.7], [82.3 & 82.5], 98.4, 107.0, 114.9, [117.4 & 117.5], 118.1, 122.9, 127.6, 128.6, 128.9, 129.2, [133.6 & 133.8], 135.9, 136.9, 140.1, [141.4 & 141.6], 151.1, 159.6, [160.9 & 161.3], [164.2 & 164.6], 168.9, 170.3, [172.1 & 172.6]. MALDI-TOF *m/z* 859.77 [(M + Na)⁺ calcd for C₄₈H₆₀N₄NaO₉⁺ 859.43].

20 Example 22



(S)-2-[[[(1R,4R)-2-[(R)-1-[[[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid (22a) and

Int. Patent - epo no:

2004-01-3

Priority - epo no:

M183

72

(S)-2-[[[(1S,4S)-2-[(R)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-pentanoic acid (22b).



- 5 The tert.butyl ester 20 (28 mg, 0.034 mmol), TES (8.7 mg, 0.075 mmol), DCM (1 mL) and TFA (1 mL) were mixed in a round bottomed flask. Two hours later the mixture was concentrated and the diastereomers were separated on HPLC using 65 % MeOH + 0.2 % TEA as mobile phase. This gave 22a (15 mg, 55 %) and 22b (12 mg, 45 %) as slightly yellow syrups. After lyophilisation the title compounds were
- 10 collected as white powders.

- 22a: $[\alpha]^{22}_D + 155.8$; $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.90-0.97 (m, 3H), 1.03 (s, 9H), 1.05-1.50 (m, 7H), 1.50-1.80 (m, 8H), 2.43-2.55 (m, 1H), 2.77-2.90 (m, 1H), 3.68 (s, 3H), 3.96 (s, 3H), 4.20-4.30 (m, 2H), 4.31-4.40 (m, 1H), 4.45-4.50 (m, 1H), 6.03-6.11 (m, 1H), 6.98 (s, 1H), 7.12-7.19 (m, 1H), 7.36 (s, 1H), 7.41 (d, $J = 2.2$ Hz, 1H), 7.50-7.60 (m, 3H), 8.03-8.10 (m, 3H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 13.1, 19.1, 26.1, 28.7, 28.9, 29.5, 34.3, 34.8, 35.9, 40.1, 50.8, 51.2, 54.8, 55.0, 57.9, 60.7, 83.5, 99.1, 106.0, 115.2, 118.2, 123.3, 127.8, 128.0, 128.7, 128.8, 129.7, 135.2, 139.8, 143.7, 150.6, 160.1, 162.2, 165.2, 171.7, 172.2, 173.4. 22b: $[\alpha]^{22}_D - 72.3$; $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.90-0.97 (m, 3H), 1.02 (s, 9H), 1.07-1.35 (m, 7H), 1.53-1.90 (m, 8H), 2.46-2.61 (m, 1H), 2.76-2.88 (m, 1H), 3.69 (s, 3H), 3.96 (s, 3H), 4.15-4.35 (m, 2H), 4.37-4.41 (m, 1H), 4.42-4.47 (m, 1H), 6.02-6.12 (m, 1H), 7.02 (s, 1H), 7.16 (dd, $J = 2.47, 9.34$ Hz, 1H), 7.32 (s, 1H), 7.40 (d, $J = 2.47$ Hz, 1H), 7.48-7.58 (m, 3H), 8.03-8.12 (m, 3H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 13.0, 18.8, 25.9, 26.0, 28.8, 29.4, 34.2, 34.8, 36.3, 39.9, 48.8, 50.5, 51.1, 54.8, 57.9, 60.5, 82.8, 99.0, 106.0, 115.1, 118.2, 123.1, 127.8, 127.9, 128.7, 129.0, 129.5, 136.7, 139.8, 142.8, 150.6, 160.1, 162.0, 162.2, 164.7, 172.1, 173.5.

Example 23

M183

73



(S)-2-(((1R,4R)-2-((R)-1-(((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (23a) and (S)-2-(((1S,4S)-2-((R)-1-(((R)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (23b).

Compound 23a (6.6 mg, 50 %) and compound 23b (1.3 mg, 10 %) were prepared from 15 (14 mg, 0.018 mmol) according to the method for the preparation of 22a and 22b. This gave the title compounds as white powders.

23a: $^1\text{H-NMR}$ (300 MHz, CD_3OD): 0.88-1.02 (m, 9H), 1.02-1.40 (m, 7H), 1.55-1.97 (m, 6H), 2.01-2.10 (m, 1H), 2.38-2.52 (m, 1H), 2.88-3.00 (m, 1H), 3.77 (s, 3H), 3.98 (s, 3H), 4.08-4.20 (m, 1H), 4.22-4.40 (m, 3H), 6.03-6.18 (m, 1H), 6.86-6.99 (m, 1H), 7.08-7.20 (m, 1H), 7.23 (s, 1H), 7.40-7.43 (m, 1H), 7.45-7.70 (m, 3H), 8.02-8.20 (m, 3H). $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 9.0, 17.6, 18.2, 24.5, 25.3, 28.1, 28.8, 30.9, 35.4, 39.4, 49.6, 51.1, 54.7, 57.2, 58.0, 82.4, 98.5, 105.5, 114.5, 117.7, 122.7, 127.2, 127.3, 128.2, 129.0, 135.6, 136.4, 141.7, 149.9, 159.5, 161.2, 161.4, 164.0, 171.0, 171.7, 172.4. 23b: $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.9-1.20 (m, 9H), 1.21-1.53 (m, 7H), 1.55-1.93 (m, 6H), 2.05-2.20 (m, 1H), 2.41-2.50 (m, 1H), 2.96-3.05 (m, 1H), 3.77 (s, 3H), 4.00 (s, 3H), 4.05-4.40 (m, 4H), 6.05-6.18 (m, 1H), 6.90-6.95 (m, 1H), 7.05-7.22 (m, 2H), 7.50-7.65 (m, 4H), 8.01-8.16 (m, 3H).

Example 24


Int. t. Patent- cch reg

7.2.2004 -01- 3

1.1.2004 -01- 3

M183

74



(S)-2-[[[(1R,4R) & (1S,4S)]-2-[(S)-1-[(S)-Carboxy-cyclohexyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (24).

5

The tert.butyl ester 14 (13.4 mg, 0.017 mmol), TES (4.83 mg, 0.042 mmol), DCM (2 mL) and TFA (2 mL) were mixed in a round bottomed flask. One hour later the mixture was concentrated and purified by HPLC using 65 % MeOH + 0.2 % TEA as mobile phase. This gave 24 (4.3 mg, 34 %) as a slightly yellow syrup. After

10

lyophilisation 24 was collected as a white powder.

15

$^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.91-0.99 (m, 9H), 1.00-1.28 (m, 4H), 1.55-1.78 (m, 9H), 1.92-1.95 (m, 1H), 2.00-2.05 (m, 1H), 2.93-3.01 (m, 1H), 3.75 (s, 3H), 3.97 (s, 3H), 4.10-4.40 (m, 4H), 6.05-6.15 (m, 1H), 6.88-6.94 (m, 1H), 7.05-7.10 (m, 2H), 7.41-7.43 (m, 1H), 7.44-7.55 (m, 2H), 8.62-8.68 (m, 1H), 8.69-8.79 (m, 1H), 7.97-8.05 (m, 2H). $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD): δ 9.2, 18.5, 25.5, [29.0 & 29.2], [30.0 & 30.5], 35.3, 37.7, 39.7, 46.2, 50.0, [51.4 & 51.5], 53.6, 55.1, 57.1, 58.4, 83.1, 98.9, 104.9, 114.6, 118.3, 123.0, 123.4, 127.5, 128.4, 128.5, 129.7, 135.0, 142.1, 145.7, 146.2, 159.2, 161.9, 164.3, 171.5, 171.9, 172.2. MALDI-TOF m/z 791.27 [(M + K) $^+$


20

calcd for $\text{C}_{42}\text{H}_{48}\text{KN}_4\text{O}_9^+$ 791.31].

Example 25

M183

75



(S)-2-[[[(3R,5R) & (3S,5S)-5-((S)-1-Carboxy-propylcarbamoyl)-3-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-1-enecarbonyl]-amino]-3-methyl-butyl]carbamate (25).


5

Compound 25 (8.0 mg, 60 %) was prepared from 16 (13.8 mg, 0.022 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.

10 $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 0.83-1.02 (m, 9H), 1.68-1.80 (m, 1H), 1.82-2.02 (m, 1H), 2.10-2.22 (m, 1H), 2.40-2.60 (m, 1H), 2.81-2.95 (m, 1H), 3.75 (s, 3H), 4.00 (s, 3H), 4.18-4.22 (m, 1H), 4.27-4.40 (m, 2H), 6.05-6.12 (m, 1H), 6.99-7.02 (m, 1H), 7.16-7.21 (m, 1H), 7.38 (s, 1H), 7.40-7.43 (m, 1H), 7.48-7.61 (m, 3H), 7.98-8.12 (m, 3H).

15

Example 26



M183

76

Link to Patent Office

1. 11-31-3


1. 11-31-3

(S)-2-([[(1R,4R) & (1S,4S)]-2-[(S)-1-[(2,5-Dimethoxy-phenyl)-ethyl-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino)-butyric acid (26).

- 5 Compound 26 (5.7 mg, 36 %) was prepared from 17 (16.7 mg, 0.021 mmol) according to the method for the preparation of 24 which gave the title compound as a white powder.

¹H-NMR (300 MHz, CD₃OD): δ 0.75-0.81 (m, 6H), 0.82-0.98 (m, 3H), 1.00-1.10 (m, 3H), 1.60-2.00 (m, 3H), 2.40-2.56 (m, 1H), 2.80-2.88 (m, 1H), 3.18-3.24 (m, 1H), 3.40-3.46 (m, 1H), [3.67-3.80 (m, 6H)], 3.97 (s, 3H), 4.10-4.20 (m, 1H), 4.21-4.40 (m, 2H), 6.02-6.17 (m, 1H), 6.75-6.82 (m, 1H), 6.84-7.01 (m, 3H), 7.10-7.20 (m, 1H), 7.30-7.37 (m, 1H), 7.40-7.43 (m, 1H), 7.50-7.60 (m, 3H), 8.00-8.17 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ 9.6, [11.8 & 12.0], [17.2 & 17.4], 18.9, 25.0, 32.3, 35.7, 43.3, 44.2, [50.3 & 50.5], [54.5 & 54.8 & 54.9 & 55.0], [55.1 & 55.2 & 55.3 & 56.0], 58.7, 83.6, 99.3, 105.5, [112.5 & 112.7], 114.3, [15.1 & 115.2], 116.7, 116.1, 118.4, [123.3 & 123.4], 125.2, [128.0 & 128.1, 128.8, 129.1, 129.8, [135.1 & 135.3], 139.2, [143.3 & 144.4], 149.2, [149.6 & 149.9], 153.8, 159.9, 162.4, [163.9 & 164.5], 172.1, 172.8, [173.6 & 173.7]. MALDI-TOF *m/z* 775.30 [(M + Na)⁺ calcd for C₄₂H₄₈N₄NaO₉⁺ 775.33].

Example 27



Ink t. Patent- och reg. verk

2004-01-30

Läkemedelsverket

MI83

77


(S)-2-((((1R,4R) & (1S,4S))-2-((S)-1-(((S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl)-2,2-dimethyl-propylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl)-amino)-butyric acid (27).

- 5 Compound 27 (6.0 mg, 72 %) was prepared from 18 (8.6 mg, 0.011 mmol) according to the method for the preparation of 24. Purification by HPLC (60 % methanol + 0.2 % TEA) gave the title compound as a white powder.

¹H-NMR (300 MHz, CD₃OD): δ 0.88-0.95 (m, 3H), 0.96 (s, 9H), 0.97-1.24 (m, 4H),
10 1.57-1.62 (m, 3H), 1.58-1.78 (m, 4H), 1.79-1.99 (m, 1H), 2.35-2.44 (m, 2H), 2.85-2.98 (m, 1H), [(3.67 & 3.69) s, 3H], 3.94 (s, 3H), 4.10-4.20 (m, 1H), 4.30-4.40 (m, 3H), 6.00-6.09 (m, 1H), [6.80-6.82 (m, 0.5H)] [6.85-6.87 (m, 0.5H)], 7.05-7.19 (m, 2H), 7.38-7.55 (m, 4H), 7.95-8.07 (m, 3H). ¹³C-NMR (75.5 MHz, CD₃OD): δ [9.1 & 9.2], [24.7 & 24.9], [25.4 & 25.5], [25.9 & 26.0], [28.3 & 28.4], 28.9, [34.8 & 34.9],
15 [35.6 & 35.9], [39.6 & 39.7], [49.9 & 50.1], [51.4 & 51.2], [53.9 & 54.0] 55.0, [57.2 & 57.4], 60.0, [82.1 & 82.5], 98.6, 106.2, 114.7, 117.8, 122.7, 127.5, 127.7, [128.4 & 128.5], 129.1, 135.3, 136.3, 141.6, 142.0, 150.5, 159.8, [161.0 & 161.3] [164.0 & 164.1], [171.6 & 171.9], [172.2 & 172.3], [173.0 & 173.2]. MALDI-TOF *m/z* 779.43 [(M + Na)⁺ calcd for C₄₂H₅₂N₄NaO₉⁺ 779.36].

20

Example 28




M183

79

Compound 29 (1.3 mg, 26 %) was prepared from 19b (5.3 mg, 0.065 mmol) according to the method for the preparation of 28. This gave the title compound as a white powder.

- 5 ¹H-NMR (300 MHz, CD₃OD): δ 0.85-1.00 (m, 9H), 1.00-1.23 (m, 7H), 1.50-1.78 (m, 8H), 2.05-2.23 (m, 1H), 2.50-2.66 (m, 1H), 2.70-2.85 (m, 1H), 3.69 (s, 3H), 3.92 (s, 3H), 4.02-4.16 (m, 1H), 4.20-4.25 (m, 1H), 4.35-4.40 (m, 2H), 6.09 (m, 1H), 7.00 (s, 1H), 7.12-7.18 (dd, *J* = 2.47, 2.19 Hz, 1H), 7.30 (s, 1H), 7.40 (d, *J* = 2.42 Hz, 1H), 7.48-7.74 (m, 3H), 8.03-8.10 (m, 3H); ¹³C-NMR (75.6 MHz, CDCl₃): δ 11.7, 16.5,
10 17.0, 24.4, 27.2, 27.9, 29.0, 29.1 37.5, 41.8, 49.7, 50.5, 53.3, 56.3, 63.5, 66.5, 81.0, 100.3, 101.0, 105.7, 113.6, 121.6, 126.3, 127.1, 127.9, 130.1, 131.4, 135.6, 138.7, 141.1, 150.4, 160.2, 160.5, 165.3, 173.0, 173.6, 173.7

Example 30



- (1*R*,2*S*)-1-[[[(1*R*,4*R*)-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (30a) and
20 (1*R*,2*S*)-1-[[[(1*S*,4*S*)-2-[(*S*)-1-[(*S*)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopent-2-enecarbonyl]-amino]-2-vinyl-cyclopropane-carboxylic acid (30b).

Link to Patent: cch regusio

2004-01-30

Patent No. 2004/001223

M183


80

Compound 30a (6.3 mg, 49 %) and compound 30b (5.6 mg, 43 %) were synthesized from 21 (13.8 mg, 0.0016 mmol) according to the method of the preparation of 22a and 22b. 30a and 30b: White powder.

- 5 30a: $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 1.02 (s, 9H), 1.03-1.43 (m, 5H), 1.61-1.95 (m, 8H), 2.11-2.21 (m, 1H), 2.43-2.58 (m, 1H), 2.97-3.04 (m, 1H), 3.78 (s, 3H), 4.01 (s, 3H), 4.02-4.17 (m, 1H), 4.25-4.40 (m, 2H), 5.10-5.20 (m, 1H), 5.27-5.40 (m, 1H), 6.77-6.94 (m, 1H), 6.10-6.20 (m, 1H), 6.97 (s, 1H), 7.18 (dd, $J = 2.5, 9.2$ Hz, 1H), 7.22 (s, 1H), 7.46 (d, $J = 2.5$ Hz, 1H), 7.52-7.65 (m, 3H), 8.00-8.18 (m, 3H). $^{13}\text{C-NMR}$
- 10 (75.5 MHz, CD_3OD): δ 13.5, 25.3, 25.7, 28.3, 28.7, 29.0, 32.8, 34.6, 35.3, 39.3, 49.7, 51.1, 54.6, 57.2, 59.8, 82.1, 98.4, 105.8, 114.5, 116.3, 117.6, 122.6, 127.2, 128.1, 128.2, 128.8, 130.2, 133.7, 136.0, 139.5, 141.5, 150.3, 159.7, 161.0, 161.2, 163.4, 171.6, 172.5. MALDI-TOF m/z 803.56 [$(\text{M} + \text{Na})^+$ calcd for $\text{C}_{44}\text{H}_{62}\text{N}_4\text{NaO}_9^+$ 803.36].
- 15 30b: $^1\text{H-NMR}$ (300 MHz, CD_3OD): δ 1.03 (s, 9H), 1.04-1.42 (m, 5H), 2.60-2.90 (m, 8H), 2.17-2.22 (m, 1H), 2.40-2.55 (m, 1H), 2.96-3.10 (m, 1H), 3.77 (s, 3H), 4.01 (s, 3H), 4.05-4.16 (m, 1H), 4.30-4.40 (m, 2H), 5.15-5.20 (m, 1H), 5.25-5.40 (m, 1H), 5.78-5.95 (m, 1H), 6.10-6.20 (m, 1H), 6.98 (s, 1H), 7.17 (dd, $J = 2.5, 9.1$ Hz, 1H), 7.26 (s, 1H), 7.46 (d, $J = 2.5$ Hz, 1H), 7.50-7.65 (m, 3H), 8.03-8.28 (m, 3H). $^{13}\text{C-NMR}$
- 20 (75.5 MHz, CD_3OD): δ 13.7, 26.0, 26.3, 28.8, 29.4, 29.6, 34.0, 35.2, 35.8, 40.1, 50.6, 51.7, 55.3, 57.8, 60.6, 83.0, 99.1, 106.3, 115.2, 117.0, 118.3, 123.2, 127.9, 128.0, 128.8, 129.6, 130.6, 134.4, 136.1, 140.0, 142.5, 150.8, 160.3, 161.8, 162.0, 165.7, 172.3, 173.0

Example 31

25



trans-(3*R*,4*R*)-Bis(methoxycarbonyl)cyclopentanol (31).

Int. l. Patent- och registrerings-

2004-01-30

Dokumentation

M183

81

Sodium borohydride (1.11 g, 0.029 mol) was added to a stirred solution of (1R, 2S)-4-oxo-cyclopentane-1,2-dicarboxylic acid dimethyl ester (4.88 g, 0.0244 mol) in methanol (300 mL) at 0 °C. After 1 h the reaction was quenched with 90 mL brine, concentrated and extracted with ethyl acetate. The organic phases were pooled, dried, filtered and concentrated. The crude product was purified by flash column chromatography (toluene/ethyl acetate 1:1) to give 31 (3.73 g, 76%) as a yellow oil.

Example 32



3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid (32).

Sodium hydroxide (1M, 74 mL, 0.074 mol) was added to a stirred solution of 31 (3.73 g, 0.018 mol) in methanol (105 mL) at room temperature. After 4 h, the reaction mixture was neutralized with 3M HCl, evaporated and co-evaporated with toluene several times. Pyridine (75 mL) and Ac₂O (53 mL) were added and the reaction mixture was allowed to shake overnight at room temperature. The mixture was then co-evaporated with toluene and purified by flash column chromatography (ethyl acetate + 1% acetic acid) to give 32 (2.51 g, 88%) as a yellow oil.

Example 33



3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid *tert*-butyl ester (33)

DMAP (14 mg, 0.115 mmol) and Boc₂O (252 mg, 1.44 mmol) was added to a stirred solution of 32 (180 mg, 1.15 mmol) in 2 mL CH₂Cl₂ under inert argon atmosphere at 0 °C. The reaction was allowed to warm to room temperature and was stirred overnight. The reaction mixture was concentrated and the crude product was purified


M183

82

by flash column chromatography (toluene/ethyl acetate gradient 15:1, 9:1, 6:1, 4:1, 2:1) to give 33 (124 mg, 51%) as white crystals.

¹H-NMR (300 MHz, CD₃OD) δ 1.45 (s, 9H), 1.90 (d, *J* = 11.0 Hz, 1H), 2.10-2.19 (m, 3H), 2.76-2.83 (m, 1H), 3.10 (s, 1H), 4.99 (s, 1H); ¹³C-NMR (75.5 MHz, CD₃OD) δ 27.1, 33.0, 37.7, 40.8, 46.1, 81.1, 81.6, 172.0, 177.7.

Example 34




10 (1*R*,2*R*,4*S*)-2-((1*R*,2*S*)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid *tert*-butyl ester (34)

Compound 33 (56 mg, 0.264 mmol) was dissolved in dioxane/ water 1:1 (5 mL) and the mixture was cooled to 0 °C. 1 M lithium hydroxide (0.52 mL, 0.520 mmol) was added and the mixture was stirred at 0 °C for 45 minutes, after which the mixture was neutralized with 1M hydrochloric acid and evaporated and coevaporated with toluene. The residue was dissolved in DMF (5 mL) and (1*R*,2*S*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride (60 mg, 0.313 mmol) and diisopropylethylamine (DIEA) (138 μ L, 0.792 mmol) were added and the solution was cooled to 0 °C. HATU (120 mg, 0.316 mmol) was added and the mixture was stirred for 0.5 h at 0 °C and for an additional 2 h at room temperature. The mixture was then evaporated and extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/ EtOAc 1:1) provided compound 34 (86 mg, 89 %) as a colorless oil.

Example 35

M183


83



(1*R*,2*R*,4*R*)-2-((1*R*,2*S*)-1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid *tert*-butyl ester (35)

- 5 Compound 34 (73 mg, 0.199 mmol) was dissolved in dry THF (4 mL) and 2-phenyl-7-methoxy-4-quinolinol (86 mg, 0.342 mmol) and triphenylphosphine (141 mg, 0.538 mmol) were added. The mixture was cooled to 0°C and DIAD (0.567 mmol) dissolved in 1 mL THF was added dropwise. The mixture was stirred for 48 h at room temperature. The solvent was evaporated and the crude product was purified
- 10 by flash column chromatography gradient elution (toluene/ EtOAc 9:1, 6:1, 4:1) to give compound 35 (81 mg, 68 %).

Example 36



- 15 Boc-L-*tert*-leucine-OH (36).

Triethylamine (890 μ L, 6.40 mmol) was added dropwise to a stirred solution of L-*tert*-leucine (300 mg, 2.29 mmol) and di-*tert*-butyl dicarbonate (599 mg, 2.74 mmol) in dioxane/ water 1:1 (8 mL) and the solution was stirred overnight. The mixture was

20 extracted with petroleum ether (2x) and the aqueous phase was cooled to 0 °C and carefully acidified to pH 3 by slow addition of 4M NaHSO₄·H₂O. The acidified water phase was extracted with EtOAc (3x) and the combined organic phases were washed with brine (2x) and was then dried, filtered and concentrated to give

Ett Patent- och reg.

01-31

För att se till att


M183

84

compound 36 (522 mg, 99 %) as a colorless powder. No further purification was needed.

¹H-NMR (300 MHz, CD₃OD) δ 0.99 (s, 9H), 1.44 (s, 9H), 3.96 (s, 1H); ¹³C-NMR (75.5 MHz, CD₃OD) δ 27.1, 28.7, 34.9, 68.0, 80.5, 157.8, 174.7.

Example 37



((S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamic acid *tert*-butyl ester (37).

10

Boc-Chg-OH (387 mg, 1.50 mmol) was coupled to methylamine hydrochloride (111 mg, 1.65 mmol) using the same HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine and concentrated. Purification by flash column chromatography (EtOAc) provided compound 37 (307 mg, 76 %) as a colorless solid.

15

¹H-NMR (300 MHz, CDCl₃) δ 0.91-1.13 (m, 2H), 1.14-1.31 (m, 3H), 1.44 (s, 9H), 1.61-1.80 (m, 6H), 2.80 (d, *J* = 4.7 Hz, 3H), 3.91 (dd, *J* = 7.1, 9.1 Hz, 1H), 5.23 (b, 1H), 6.52 (bs, 1H); ¹³C-NMR (75.5 MHz, CDCl₃) δ 25.9, 26.0, 26.1, 28.3, 28.5, 29.6, 40.5, 59.5, 79.7, 155.9, 172.4.

20

Example 38


Ink. t. Patent- not registered

2004-01-30

15:00:00

M183

85



{{(S)-1-[[[(S)-Cyclohexyl-methylcarbamoyl-methyl]-carbamoyl]-2,2-dimethyl-propyl)-carbamic acid *tert*-butyl ester (38)

- 5 To a solution of compound 37 (98 mg, 0.362 mmol) in methylene chloride (3 mL) were added triethylsilane (115 mL, 0.742 mmol) and TFA (3 mL). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The deprotected amine was dissolved in DMF (5 mL) and coupled to compound 36 (84 mg, 0.363 mmol) using the same HATU coupling conditions as in
- 10 the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification by flash column chromatography (toluene/ EtOAc 1:1) provided compound 38 (128 mg, 92 %) as a colorless solid.

- ¹H-NMR (300 MHz, CDCl₃) δ 0.99 (s, 9H), 1.02-1.30 (m, 5H), 1.44 (s, 9H), 1.58-1.77 (m, 4H), 1.78-1.89 (m, 2H), 2.79 (d, *J* = 4.7 Hz, 3H), 4.11 (d, *J* = 9.3 Hz, 1H), 4.33 (app. t, *J* = 8.5 Hz, 1H), 5.65 (b, 1H), 7.25 (b, 1H), 7.39 (b, 1H); ¹³C-NMR (75.5 MHz, CDCl₃) δ 25.9, 25.9, 26.0, 26.2, 26.8, 28.4, 29.0, 29.7, 34.5, 39.7, 58.4, 62.4, 79.4, 156.0, 171.4, 171.8.

20 Example 39


Link to Patent- each registered

2004-01-09

Patent No. 2004/000111

M183

86



(1R,2S)-1-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methylcarbamoyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (39)

5

To a solution of compound 35 (30 mg, 0.050 mmol) in methylene chloride (1.5 mL) were added triethylsilane (21 μ L, 0.132 mmol) and TFA (1.5 mL). The mixture was stirred for 2 h at room temperature and was then evaporated and coevaporated with toluene. The amine 38 (1.3 eq) was deprotected in the same manner as compound 35 and was then coupled to deprotected compound 35 using the same HATU coupling conditions as in the synthesis of 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification using HPLC (MeOH/ water 9:1 + 0.2% triethylamine) provided compound 39 (30 mg, 74%) as a colorless solid.

10

15

$^1\text{H-NMR}$ (300 MHz, CD_3OD) δ 0.81-1.14 (m, 4H), 0.99 (s, overlapped, 9H), 1.21 (t, J = 7.1 Hz, 3H), 1.35-1.51 (m, 4H), 1.52-1.65 (m, 3H), 1.66-1.72 (m, 2H), 2.03-2.20 (m, 2H), 2.24-2.39 (m, 1H), 2.46-2.56 (m, 1H), 2.66 (s, 3H), 2.72-2.85 (m, 1H), 3.39-3.48 (m, 2H), 3.90 (s, 3H), 4.03-4.15 (m, 3H), 4.44 (s, 1H), 5.09 (dd, J = 1.9, 10.3 Hz, 1H), 5.19-5.27 (m, 1H), 5.25 (dd, overlapped, 1H), 5.79 (ddd, J = 8.8, 10.3, 17.2 Hz, 1H), 6.99 (s, 1H), 7.07 (dd, J = 2.5, 9.1, Hz, 1H), 7.29 (d, J = 2.5 Hz, 1H), 7.43-7.52 (m, 3H), 7.86-7.98 (m, 2H), 8.05 (d, J = 9.3 Hz, 1H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD) δ 14.7, 23.4, 26.0, 26.9, 27.1, 27.3, 30.1, 30.7, 35.0, 35.4, 38.3, 38.8, 40.9, 41.0, 47.9, 55.9, 59.6, 62.0, 62.4, 79.8, 99.9, 107.3, 116.4, 118.0, 119.1, 124.4, 128.9, 129.8, 130.5, 135.3, 141.3, 152.1, 161.1, 162.4, 163.0, 171.6, 172.5, 173.7, 175.2, 176.8.

20

25

Läk. Patent- och registrerings


2004-01-30

Förordning om Patenter

M183

87

Maldi-TOF-spectrum: (M+H)⁺ calcd: 810.4, found: 810.5; (M+Na)⁺ calcd: 832.4, found: 832.4; (M+K)⁺ calcd: 848.5, found: 848.4.

Example 40

5

(1R,2S)-1-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methylcarbamoyl-methyl]-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (40)

10

To a solution of compound 39 (20 mg, 0.025 mmol) in THF/MeOH/water 2:1:1 (2 mL) at 0 °C was added 1M LiOH (175 µL, 0.175 mmol) and the solution was allowed to attain room temperature and was stirred for 48 h. The solution was acidified to pH 3 with 1M HCl and was then evaporated and coevaporated with toluene. The crude product was purified by HPLC (MeOH/ water 6:4 + 0.5% TFA followed by MeOH/ water 4:1 + 0.2% TFA) to give compound 40 (13 mg, 67 %) as a colorless solid.

15

¹H-NMR (300 MHz, CD₃OD) δ 0.82-0.98 (m, 1H), 1.01 (s, 9H), 1.05-1.26 (m, 3H), 1.34-1.43 (m, 1H), 1.49-1.77 (m, 8H), 2.10-2.21 (m, 1H), 2.28-2.42 (m, 2H), 2.50-2.61 (m, 1H), 2.64 (s, 3H), 2.68-2.81 (m, 1H), 3.36-3.45 (m, 2H), 4.04-4.11 (m, 1H), 4.06 (s, overlapped, 3H), 4.27 (d, J = 8.8 Hz, 1H), 5.10 (dd, J = 1.8, 10.3 Hz, 1H), 5.28 (dd, J = 1.8, 17.2 Hz, 1H), 5.59-5.68 (m, 1H), 5.82 (ddd, J = 9.1, 10.3, 17.2 Hz, 1H), 7.44 (dd, J = 2.5, 11.8 Hz, 1H), 7.50 (s, 1H), 7.53 (d, J = 2.5 Hz, 1H), 7.69-7.78 (m, 3H), 8.02-8.07 (m, 2H), 8.39 (d, J = 9.3 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD) δ 23.5, 26.0, 26.9, 27.2, 27.3, 30.0, 30.7, 34.7, 35.3, 37.0, 38.7, 41.0, 41.3, 47.4, 56.9, 59.4, 62.7, 83.9, 100.4, 102.2, 116.2, 117.7, 121.7, 126.7, 129.8, 130.8, 133.4, 133.9, 135.6, 143.5, 158.0, 166.6, 168.6, 172.5, 173.4, 173.6, 175.4, 176.4. Maldi-

20

25

K. J.

... ..

... ..

M183

88

TOF-spectrum: (M+H)⁺ calcd: 782.4, found: 782.2; (M+Na)⁺ calcd: 804.4, found: 804.2; (M+K)⁺ calcd: 820.5, found: 820.2.

Example 41


5

3-Oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid methyl ester (41)

10 Compound 32 (1.014 g, 6.60 mmol) was dissolved in acetone (35 mL) before methyl iodide (13.68 g, 96.4 mmol) and silver(I)oxide (1.61 g, 6.95 mmol) were added. After stirring for 3h the mixture was filtered through celite and the filtrate was evaporated before purification by flash column chromatography (toluene/ethyl acetate 4:1) was performed yielding the methyl ester 41 (702 mg, 64 %) as white crystals.

15

¹H-NMR (300 MHz, CDCl₃): δ 1.96 (d, J = 10.7 Hz, 1H), 2.21-2.25 (m, 3H), 2.91-2.95 (m, 1H), 3.16 (s, 1H), 3.75 (s, 3H), 4.98 (app. s, 1H).

Example 42

20

(1R,2R,4S)-2-((S)-1-tert-Butoxycarbonyl-butylcarbamoyl)-4-hydroxycyclopentanecarboxylic acid methyl ester (42)

25

Compound 41 (263 mg, 1.55 mmol) and H-Nva-OtBu (420 mg, 2.42 mmol) were dissolved in dry THF (20 mL). DIEA (530 μL, 3.04 mmol) and 2-hydroxypyridine (260 mg, 2.73 mmol) were added and the mixture was refluxed for five days. The solvent was evaporated and the crude product was purified by flash column chromatography (toluene/ EtOAc 1:2) to give 42 (510 mg, 96%).

M.L. Fiedler et al.

2004-01-30

J. Pharm. Med.


M183

90

Compound 43 (38 mg, 0.066 mmol) was dissolved in dioxane/ water 1:1 (4 mL) and the solution was cooled to 0 °C and 1 M LiOH (132 µl, 0.132 mmol) was added. The temperature was raised to room temperature and the solution was stirred for 2 hours
5 after which it was neutralized by addition of 1M HCl and evaporated and coevaporated with toluene. The residue and deprotected amine 38 (1.1 eq) was dissolved in DMF and coupled using the standard HATU coupling conditions as in the synthesis of compound 34. The crude product was extracted with EtOAc, washed with brine, dried, filtered and concentrated. Purification with HPLC (MeOH/
10 water 9:1 + 0.2% TEA) provided compound 44 (44 mg, 81 %) as a colorless solid.

¹H-NMR (CDCl₃, 300 MHz) rotamers (5:1) δ 0.79 (t, *J* = 7.3 Hz, 3H), 0.85-1.19 (m, 3H), 0.93 (s, overlapped, 9H), 1.20-1.35 (m, 2H), 1.39 (s, 1.5 H), 1.43 (s, 7.5 H), 1.54-1.79 (m, 6H), 2.06-2.28 (m, 3H), 2.39-2.51 (m, 2H), 2.66-2.78 (m, 1H), 2.74 (d, overlapped, *J* = 4.7 Hz, 3H), 3.42-3.68 (m, 2H), 3.84 (s, 2.5 H), 3.88 (s, 0.5 H), 4.19
15 (t, *J* = 8.9 Hz, 1H), 4.39-4.59 (m, 1H), 4.68 (d, *J* = 9.6 Hz, 1H), 5.04-5.14 (m, 1H), 6.77 (s, 1H), 6.88-7.06 (m, 2H), 7.26-7.47 (m, 6H), 7.53 (b, 1H), 7.85-7.97 (m, 3H);
¹³C-NMR (75.5 MHz, CDCl₃) δ 13.7, 18.7, 25.6, 25.7, 26.0, 26.7, 28.0, 28.9, 29.7, 34.5, 34.7, 37.7, 38.0, 39.2, 46.6, 47.7, 52.7, 55.3, 58.5, 60.3, 77.9, 81.7, 98.0,
20 107.4, 115.0, 117.9, 122.8, 127.4, 128.6, 129.0, 140.2, 151.2, 158.9, 160.6, 161.1, 170.9, 171.6, 171.8, 172.7, 173.3. Maldi-TOF-spectrum: (M+H)⁺ calcd: 828.5, found: 828.6; (M+Na)⁺ calcd: 850.5, found: 850.6; (M+K)⁺ calcd: 866.6, found: 866.6.

Example 45




Ink. t. Patent- och registeret

2004-01-30

Hälsöföretag, Hälsofarm

M183

91



(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-
2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-
5 cyclopentanecarbonyl]-amino]-pentanoic acid (45)

Compound 44 (21 mg, 0.025 mmol) was dissolved in CH_2Cl_2 (1.5 mL) and triethylsilane (10 μL , 0.063 mmol) and TFA (1.5 mL) were added. The solution was stirred for 2 hours at room temperature after which the solvents were evaporated and
10 coevaporated with toluene to provide compound 45 (20 mg, 100 %) as a colorless solid.

$^1\text{H-NMR}$ (300 MHz, CD_3OD) δ 0.93 (t, overlapped, 3H), 0.98 (s, 9H), 0.99-1.25 (m, 4H), 1.30-1.49 (m, 3H), 1.50-1.90 (m, 8H), 2.25-2.39 (m, 2H), 2.54-2.62 (m, 1H),
15 2.64 (s, 3H), 2.72-2.87 (m, 1H), 3.34-3.57 (m, 3H), 4.02-4.13 (m, 1H), 4.06 (s, overlapped, 3H), 4.27-4.36 (m, 1H), 4.37-4.47 (m, 1H), 5.57-5.66 (m, 1H), 7.45 (dd, J = 2.3, 9.2 Hz, 1H), 7.48 (s, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.69-7.79 (m, 3H), 8.01-8.07 (m, 2H), 8.42 (d, J = 9.3 Hz, 1H); $^{13}\text{C-NMR}$ (75.5 MHz, CD_3OD) δ 14.0, 20.2,
26.0, 26.9, 27.2, 30.1, 30.7, 34.6, 35.3, 37.2, 39.1, 41.2, 47.7, 53.7, 56.9, 59.4, 59.5,
20 62.5, 83.7, 100.4, 101.3, 102.2, 116.2, 121.7, 126.7, 129.8, 130.8, 133.3, 133.9, 143.5, 157.9, 166.6, 168.5, 172.5, 173.6, 175.3, 175.4, 175.5.

Maldi-TOF-spectrum: $(\text{M}+\text{H})^+$ calcd: 772.4, found: 772.6; $(\text{M}+\text{Na})^+$ calcd: 794.4, found: 794.6; $(\text{M}+\text{K})^+$ calcd: 810.5, found: 810.6.

Int. Patent: not reported

1994-01-30

Page: 1 of 1

M183

92

Example 46

Hept-6-enal (46)

- 5 To a solution of hept-6-en-1-ol (1 mL, 7.44 mmol) and N-methylmorpholine N-oxide (1.308 g, 11.17 mmol) in DCM (17 mL) was added ground molecular sieves (3.6 g, 4 Å). The mixture was stirred for 10 min at room temperature under nitrogen atmosphere before tetrapropylammonium perruthenate (TPAP) (131 mg, 0.37 mmol) was added. After stirring for additional 2.5 h the solution was filtered through celite.
- 10 The solvent was then carefully evaporated and the remaining liquid was purified by flash column chromatography (DCM) to give the volatile aldehyde 46 (620 mg, 74%) as an oil.

Example 47

- 15 *N*-Hept-6-en-(*E*)-ylidenehydrazinecarboxylic acid *tert*-butyl ester (47)

- To a solution of 46 (68 mg, 0.610 mmol) and *tert*-butyl carbazate (81 mg, 0.613 mmol) in MeOH (5 mL) was added ground molecular sieves (115 mg, 3 Å). The mixture was stirred for 3 h after which it was filtered through celite and evaporated.
- 20 The residue was dissolved in dry THF (3 mL) and AcOH (3 mL). NaBH₃CN (95 mg, 1.51 mmol) was added and the solution was stirred over night. The reaction mixture was diluted with saturated NaHCO₃ solution (6 mL) and EtOAc (6 mL). The organic phase was washed with brine, saturated NaHCO₃, brine, dried over MgSO₄ and evaporated. The cyanoborane adduct was hydrolyzed by treatment with MeOH (3 mL) and 2 M NaOH (1.9 mL). The mixture was stirred for 2 h and the MeOH was
- 25 evaporated. H₂O (5 mL) and DCM (5 mL) were added and the water phase was extracted three times with DCM. The combined organic phases were dried and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 9:1 with 1 % triethylamine and toluene/ethyl acetate 6:1 with 1 % triethylamine) provided
- 30 47 (85 mg, 61 %) as an oil.

M183

93

Example 48

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*R*)-2-(*N*-*tert*-Butoxycarbonyl-*N*-hept-6-enyl-hydrazinocarbonyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (48)

5

Scaffold molecule 35 (135 mg, 0.225 mmol) and triethylsilane (71 μ L, 0.447 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (TFA) (2 mL) was added. The mixture was stirred for 2 h and thereafter co-evaporated with toluene in order to remove the TFA. The residue was dissolved in DMF (3 mL) and 47 (60 mg, 10 0.263 mmol) and DIEA (118 μ L, 0.677 mmol) were added. The temperature was lowered to 0° C and the coupling reagent *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) (94 mg, 0.247 mmol) was added. The cold solution was allowed to stir for half an hour and then for additional 16 h in 15 room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure. The residue was thereafter dissolved in ethyl acetate and the organic phase was washed three times with brine, dried, filtered and evaporated. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 48 (140 mg, 82 %) as an oil.

20 ¹H-NMR (300 MHz, CDCl₃, 40° C): δ 1.22 (t, *J* = 7.1 Hz, 3H), 1.28-1.42 (m, 6H), 1.46 (s, 9H), 1.52-1.62 (m, 2H), 1.82-1.91 (m, 1H), 1.96-2.16 (m, 3H), 2.18-2.34 (m, 2H), 2.42-2.56 (m, 1H), 2.58-2.72 (m, 1H), 3.42 (app. bs, 3H), 3.66-3.84 (m, 1H), 3.92 (s, 3H), 4.15 (q, *J* = 7.1 Hz, 2H), 4.88-5.02 (m, 2H), 5.07-5.18 (m, 2H), 5.20-5.32 (m, 1H), 5.63-5.84 (m, 2H), 6.62 (bs, 1H), 6.94 (s, 1H), 7.09 (dd, *J* = 2.6, 9.2 Hz, 1H), 25 7.36-7.51 (m, 4H), 7.99-8.10 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 14.3, 23.0, 26.4, 26.6, 28.3, 28.6, 33.2, 33.5, 35.6, 37.6, 40.6, 44.7, 47.1, 48.6, 55.5, 61.5, 81.9, 98.4, 107.9, 114.5, 115.6, 118.1, 123.2, 127.6, 128.3, 128.7, 129.1, 133.6, 138.7, 140.7, 151.5, 154.5, 159.2, 160.9, 161.5, 170.5, 174.2, 176.3.

30 Example 49

M183

94

(Z)-(1*R*,4*R*,6*S*,16*R*,18*R*)-14-*tert*-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0^{4,6}]nonadec-7-ene-4-carboxylic acid ethyl ester (49)

- 5 A solution of 48 (158 mg, 0.209 mmol) in dry DCM (25 mL) was bubbled with argon for 5 min. To the stirred solution under argon atmosphere was then added a solution of Hoveyda-Grubbs catalyst 2nd generation (11 mg, 0.018 mmol) in dry DCM (5 mL). The mixture was stirred at reflux under argon atmosphere for 16 h. The solvent was evaporated and purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine)
- 10 yielded 49 (107 mg, 70 %) as a colorless solid.

¹H-NMR (300 MHz, CD₃OD): δ 1.03-1.22 (m, 1H), 1.28 (t, *J* = 7.1 Hz, 3H), 1.32-1.44 (m, 4H), 1.49 (s, 9H), 1.55-1.73 (m, 2H), 1.81-1.91 (m, 1H), 2.04-2.28 (m, 3H), 2.30-2.52 (m, 3H), 2.53-2.70 (m, 1H), 2.86-3.00 (m, 1H), 3.34-3.44 (m, 1H), 3.46-3.62 (m, 1H), 3.95 (s, 3H), 4.19 (q, *J* = 7.1 Hz, 2H), 4.32-4.48 (m, 1H), 5.20-5.33 (m, 1H), 5.34 (bs, 1H), 5.58-5.70 (m, 1H), 7.10 (s, 1H), 7.14 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.39 (d, *J* = 2.5 Hz, 1H), 7.45-7.55 (m, 3H), 8.00 (d, *J* = 8.0 Hz, 2H), 8.17 (d, *J* = 9.3 Hz, 1H);

15 ¹³C-NMR (75.5 MHz, CD₃OD): δ 14.6, 23.4, 27.5, 27.7, 28.0, 28.5, 30.7, 36.1, 38.1, 42.5, 45.6, 56.0, 62.7, 79.9, 82.8, 100.2, 107.4, 116.6, 119.1, 124.5, 126.5, 128.9, 129.8, 130.5, 135.8, 141.5, 152.2, 156.4, 161.3, 162.5, 163.1, 171.9, 175.8, 179.0.

20 MALDI-TOF-spectrum: (M+H)⁺ calcd: 727.4, found: 727.5.

Example 50

(Z)-(1*R*,4*R*,6*S*,16*R*,18*R*)-14-*tert*-Butoxycarbonylamino-18-(7-methoxy-2-phenyl-quinolin-4-yloxy)-2,15-dioxo-3,14-diaza-tricyclo[14.3.0.0^{4,6}]nonadec-7-ene-4-carboxylic acid (50)

25

To a solution of 49 (27 mg, 0.037 mmol) in THF/MeOH/H₂O 2:1:1 (5 mL) was added 1 M LiOH (300 μL, 0.300 mmol). The solution was stirred for 24 h at room

30 temperature and finally for one hour at reflux. After acidification to pH 3-4 with 1 M

M183

95

HCl and evaporation the residue was purified by HPLC (MeOH/H₂O 80:20 and MeOH/H₂O 90:10) providing 50 (12 mg, 46 %) as a colorless solid.

¹H-NMR (300 MHz, CD₃OD): δ 1.06-1.24 (m, 1H), 1.26-1.42 (m, 3H), 1.48 (s, 9H),
5 1.62-1.73 (m, 3H), 1.80-1.90 (m, 1H), 2.02-2.15 (m, 1H), 2.15-2.40 (m, 4H), 2.43-
2.64 (m, 1H), 2.54-2.68 (m, 1H), 2.88-3.00 (m, 1H), 3.35-3.48 (m, 1H), 3.49-3.66 (m,
1H), 3.96 (s, 3H), 4.32-4.48 (m, 1H), 5.25-5.42 (m, 2H), 5.56-5.68 (m, 1H), 7.14 (s,
1H), 7.17 (dd, J = 2.5, 9.1 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 7.46-7.58 (m, 3H), 8.00
(d, J = 8.0 Hz, 2H), 8.19 (d, J = 9.1 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 23.6,
10 26.8, 27.8, 28.3, 28.5, 30.5, 35.8, 38.1, 43.0, 45.5, 56.0, 80.2, 82.7, 100.4, 106.9,
116.6, 119.2, 124.7, 127.4, 129.0, 129.8, 130.7, 134.8, 140.9, 151.6, 156.5, 161.1,
163.0, 163.4, 173.8, 175.7, 179.3.

Example 51

15 ((S)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propyl)-carbamic acid tert-butyl ester (51).

To a cold solution of 36 (133 mg, 0.575 mmol), cyclopentylamine (64 µL, 0.648 mmol) and DIEA (301 µL, 1.73 mmol) in DMF (3 mL) was added the coupling reagent HATU (240 mg, 0.631 mmol). The mixture was stirred for half an hour and
20 for additional two hours at room temperature. The solvent was removed by heating the reaction flask in a water bath under diminished pressure and the residue was dissolved in ethyl acetate, after which the organic phase was washed three times with brine, dried, filtered and evaporated. Purification by flash column chromatography (toluene/ethyl acetate 4:1) provided 51 (140 mg, 82 %) as colorless
25 crystals.

¹H-NMR (300 MHz, CDCl₃): δ 0.95 (s, 9H), 1.28-1.48 (m, overlapped, 2H), 1.40 (s, 9H), 1.49-1.71 (m, 4H), 1.86-2.01 (m, 2H), 3.76 (b, 1H), 4.09-4.23 (m, 1H), 5.32 (b, 1H), 5.91 (b, 1H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 23.6, 23.7, 26.5, 28.3, 32.6, 33.1,
30 34.5, 51.0, 62.2, 79.4, 155.9, 170.3.

Int. Patent (ch. 10)

5000-01-30

1000000000

M183

96

Example 52

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (52)

5

Compound 51 (298 mg, 0.048 mmol) and 35 (16 mg, 0.054 mmol) was deprotected and coupled according to the method for the preparation of 39. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 52 (22 mg, 63 %) as a colorless solid.

10

¹H-NMR (CDCl₃, 300 MHz): δ 0.97 (s, 9H), 1.21 (t, *J* = 7.1 Hz, 3H), 1.26-1.37 (m, 1H), 1.38-1.46 (m, 2H), 1.48-1.58 (m, 4H), 1.78-1.85 (m, 1H), 1.86-2.02 (m, 3H), 2.03-2.19 (m, 1H), 2.28-2.40 (m, 2H), 2.41-2.54 (m, 1H), 2.64-2.78 (m, 1H), 3.10-3.24 (m, 1H), 3.30-3.44 (m, 1H), 3.95 (s, 3H), 4.04-4.21 (m, 3H), 5.12 (dd, *J* = 1.7, 10.3 Hz, 1H), 5.14-5.22 (m, 1H), 5.28 (dd, *J* = 1.7, 17.0 Hz, 1H), 5.59 (b, 1H), 5.75 (ddd, *J* = 8.8, 10.3, 17.0 Hz, 1H), 6.66-6.82 (m, 2H), 6.99 (s, 1H), 7.09 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.41-7.55 (m, 4H), 7.99-8.09 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 14.3, 22.9, 23.6, 23.6, 26.7, 32.7, 33.2, 33.7, 34.8, 35.9, 36.6, 40.2, 46.4, 47.5, 51.3, 55.5, 61.1, 61.4, 78.0, 98.4, 107.1, 115.2, 117.9, 118.2, 123.1, 127.6, 128.8, 129.3, 133.5, 159.1, 161.4, 169.4, 169.9, 173.1, 174.0. MALDI-TOF-spectrum: (M+H)⁺ calcd: 725.4, found: 725.6; (M+Na)⁺ calcd: 747.4, found: 747.6; (M+K)⁺ calcd: 763.3, found: 763.5.

15

20

Example 53

25

(1*R*,2*S*)-1-[[[(1*R*,2*R*,4*S*)-2-[(*S*)-1-Cyclopentylcarbamoyl-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (53).

30

To a solution of 52 (14 mg, 0.019 mmol) in dioxane/H₂O 1:1 (4 mL) was added 1 M LiOH (115 µL, 0.115 mmol). The solution was stirred for 24 h at room temperature. Thereafter an additional portion of LiOH (75 µL, 0.075 mmol) was added and the

M183

97

solution was stirred for another 24 h. After acidification to approximately pH 3 with 1 M HCl and co-evaporation with toluene the residue was purified by HPLC (MeOH/H₂O 70:30 with 0.2 % TFA) yielding 53 (8 mg, 60 %) as a colorless solid.

- 5 ¹H-NMR (300 MHz, CD₃OD): δ 0.98 (s, 9H), 1.28-1.48 (m, 3H), 1.49-1.76 (m, 5H),
1.78-1.94 (m, 2H), 2.10-2.24 (m, 1H), 2.26-2.45 (m, 2H), 2.50-2.62 (m, 1H), 2.66-
2.79 (m, 1H), 3.35-3.48 (m, 2H), 3.94-4.03 (m, 1H), 4.06 (s, 3H), 4.16-4.24 (m, 1H),
5.10 (dd, *J* = 1.8, 10.3 Hz, 1H), 5.29 (dd, *J* = 1.8, 17.2 Hz, 1H), 5.62 (b, 1H), 5.82
10 (ddd, *J* = 9.1, 10.3, 17.2 Hz, 1H), 7.43 (dd, *J* = 2.5, 9.3 Hz, 1H), 7.50 (s, 1H), 7.50-
7.69 (dd, overlapped, 1H), 7.67-7.80 (m, 3H), 8.01-8.11 (m, 2H), 8.39 (d, *J* = 9.3 Hz,
1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 24.7, 24.7, 27.3, 33.1, 33.6, 34.7, 35.4, 36.9,
38.7, 41.0, 47.4, 52.3, 56.9, 62.3, 83.9, 100.4, 102.3, 116.2, 117.7, 121.6, 126.7,
129.8, 130.8, 133.4, 133.8, 135.6, 143.5, 158.0, 166.5, 168.6, 171.9, 173.4, 175.2,
176.4. MALDI-TOF-spectrum: (M+H)⁺ calcd: 697.4, found: 697.3; (M+Na)⁺ calcd:
15 718.7, found: 719.3; (M+K)⁺ calcd: 735.3, found: 735.3.

Example 54

(S)-*tert*-Butoxycarbonylamino-cyclohexyl-acetic acid methyl ester (54)

- 20 To a solution of Boc-Chg-OH (53 mg, 0.206 mmol) in acetone (3 mL) were added
methyl iodide (195 μL, 3.1 mmol) and silver (I) oxide (53 mg, 0.229 mmol). The
mixture was allowed to stir over night in a reaction flask that was covered with
aluminium foil. Thereafter the solution was filtered through celite and evaporated.
Purification by flash column chromatography (toluene/ethyl acetate 15:1) provided
25 methyl ester 54 (56 mg, 100 %) as a colorless oil.

¹H-NMR (300 MHz, CDCl₃): δ 1.00-1.34 (m, 5H), 1.44 (s, 9H), 1.54-1.82 (m, 6H),
3.73 (s, 3H), 4.20 (dd, *J* = 2.8, 5.0 Hz, 1H), 5.05 (bs, 1H); ¹³C-NMR (75.5 MHz,
CDCl₃): δ 26.0, 28.2, 28.3, 29.5, 41.1, 52.0, 58.3, 79.7, 165.6, 172.9.

30

Example 55

M183

98

(S)-((S)-2-Benzoyloxycarbonylamino-3-methyl-butyrylamino)-cyclohexyl-acetic acid methyl ester (55)

Compound 54 (93 mg, 0.343 mmol) was deprotected and coupled to Z-Val-OH (95 mg, 0.378 mmol) according to the method for the preparation of 39. Flash column chromatography (toluene/ethyl acetate 4:1) gave 55 (131 mg, 94 %) as a colorless solid.

¹H-NMR (300 MHz, CDCl₃): δ 0.92-1.30 (m, 11H), 1.54-1.88 (m, 6H), 2.02-2.18 (m, 1H), 3.72 (s, 3H), 4.05-4.18 (m, 1H), 4.52 (dd, J = 3.0, 5.5 Hz, 1H), 5.12 (s, 2H), 5.49 (bs, 1H), 6.52 (bs, 1H), 7.34 (s, 5H); ¹³C-NMR (75.6 MHz, CDCl₃): δ 17.8, 19.0, 25.8, 28.2, 29.3, 31.2, 40.5, 51.9, 56.8, 60.0, 66.8, 127.7, 127.9, 128.1, 128.3, 136.2, 156.3, 171.3, 172.2.

15 Example 56

(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid *tert*-butyl ester (56).

20 To a solution of 55 (40 mg, 0.099 mmol) in ethanol (95%) (7.5 mL) was added palladium on active carbon (10 %, 40 mg) and the mixture was hydrogenated under pressure at room temperature for 2 h. The mixture was filtered through celite and evaporated. Compound 43 (38 mg, 0.083 mmol) was dissolved in dioxane/H₂O 1:1 (3 mL) and the mixture was cooled to 0° C before 1 M LiOH (140 µL, 0.140 mmol) was added to the stirred solution. After 1h the mixture was neutralized with 1 M hydrochloric acid and the solvent was evaporated and co-evaporated with toluene. The residue was coupled to deprotected 55 using the same HATU coupling conditions as in the synthesis of compound 48. Purification by HPLC (MeOH/H₂O 90:10 with 0.2 % triethylamine) gave 56 (56 mg, 88 %) as a colorless solid.

30

M183

99

¹H-NMR (300 MHz, CDCl₃): δ 0.82-0.96 (m, 9H), 0.82-1.22 (m, overlapped, 6H), 1.23-1.40 (m, 2H), 1.44 (s, 9H), 1.50-1.69 (m, 4H), 1.71-1.87 (m, 2H), 1.95-2.06 (m, 1H), 2.07-2.22 (m, 1H), 2.28-2.54 (m, 3H), 2.60-2.75 (m, 1H), 3.08-3.28 (m, 1H), 3.30-3.49 (m, 1H), 3.70 (s, 3H), 3.94 (s, 3H), 4.28-4.38 (m, 1H), 4.41-4.57 (m, 2H), 5.17 (b, 1H), 6.64-6.70 (m, 2H), 6.74 (b, 1H), 6.95 (s, 1H), 7.09 (dd, *J* = 2.5, 9.1 Hz, 1H), 7.39-7.55 (m, 6H), 7.98-8.10 (m, 3H); ¹³C-NMR (75.5 MHz, CDCl₃): δ 13.7, 18.1, 18.6, 19.2, 25.9, 28.0, 28.2, 29.6, 30.7, 34.6, 36.5, 37.6, 40.8, 47.4, 47.5, 52.1, 52.8, 55.5, 56.8, 58.9, 77.8, 82.0, 98.3, 107.5, 115.3, 118.1, 123.1, 127.5, 128.7, 129.1, 140.5, 151.4, 159.2, 160.7, 161.3, 171.0, 171.5, 172.3, 172.8, 173.0. MALDI-TOF-spectrum: (M+H)⁺ calcd: 815.5, found: 815.7; (M+Na)⁺ calcd: 837.4, found: 837.6; (M+K)⁺ calcd: 853.4, found: 853.6.

Example 57

(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl)-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-pentanoic acid (57)

Tert.butyl ester 56 (28 mg, 0.034 mmol) and triethylsilane (14 μL, 0.088 mmol) was dissolved in DCM (2 mL) after which trifluoroacetic acid (2 mL) was added and the mixture was stirred for 2 h. Co-evaporation with toluene gave 57 (26 mg, 100 %) as a colorless solid.


¹H-NMR (300 MHz, CD₃OD): δ 0.86-1.00 (m, 9H), 1.01-1.24 (m, 4H), 1.36-1.46 (m, 2H), 1.48-1.75 (m, 8H), 1.70-1.89 (m, overlapped, 1H), 1.96-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.49-2.64 (m, 1H), 2.72-2.91 (m, 1H), 3.26-3.40 (m, overlapped, 1H), 3.50-3.68 (m, overlapped, 1H), 3.62 (s, 3H), 4.05 (s, 3H), 4.09-4.17 (m, 1H), 4.17-4.25 (m, 1H), 4.35-4.45 (m, 1H), 5.62 (b, 1H), 7.44 (dd, *J* = 2.2, 9.3 Hz, 1H), 7.49 (s, 1H), 7.53 (d, *J* = 2.2 Hz, 1H), 7.65-7.78 (m, 3H), 7.98-8.06 (m, 2H), 8.41 (dd, *J* = 2.8, 9.3 Hz, 1H); ¹³C-NMR (CD₃OD, 75.5 MHz): δ 13.9, 18.8, 19.7, 20.2, 27.0, 29.7, 30.5, 31.8, 34.6, 37.7, 38.9, 41.1, 47.8, 52.3, 53.6, 56.9, 58.8, 58.9, 60.3, 83.8, 100.4, 102.2, 116.2, 121.6, 126.7, 129.8, 130.8, 133.3, 133.8, 143.5, 157.9,

M183

100

166.5, 168.5, 173.3, 173.9, 175.5, 175.5, 175.6. MALDI-TOF-spectrum: (M+H)⁺ calcd: 759.4, found: 759.7; (M+Na)⁺ calcd: 781.4, found: 781.7; (M+K)⁺ calcd: 797.4, found: 797.7.

5 Example 58



(S)-2-[[[(1R,2R,4S)-2-[(S)-1-[(S)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid (58).

The procedure described in example 42 was followed but with the use of L-2-amino-N-butyric acid tert.butyl ester instead of H-Nva-OtBu. The afforded compound was then reacted as described in example 43 which gave (1R,2R,4R)-2-[(S)-1-tert-butoxycarbonyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester. Coupling of this compound with 55 as described in example 56 followed by esterhydrolysis as described in example 57 gave 58 as a colourless solid.

¹H-NMR (300 MHz, CD₃OD): δ 0.82-0.99 (m, 9H), 0.82-1.40 (m, overlapped, 6H), 1.48-1.78 (m, 6H), 1.80-1.95 (m, 1H), 1.97-2.12 (m, 1H), 2.22-2.40 (m, overlapped, 2H), 2.51-2.64 (m, 1H), 2.71-2.90 (m, 1H), 3.16-3.39 (m, overlapped, 1H), 3.49-3.59 (m, 1H), 3.63 (s, 3H), 3.95 (s, 3H), 4.12-4.23 (m, 2H), 4.28-4.38 (m, 1H), 5.31 (b, 1H), 7.43 (dd, J = 2.2, 9.3 Hz, 1H), 7.47 (s, 1H), 7.51 (s, 1H), 7.66-7.89 (m, 3H), 7.99-8.07 (m, 2H), 8.42 (d, J = 9.1 Hz, 1H); ¹³C-NMR (75.5 MHz, CD₃OD): δ 10.7, 18.8, 19.7, 25.8, 27.0, 27.0, 29.7, 30.5, 31.8, 37.7, 38.9, 41.2, 47.9, 52.3, 55.3, 56.9,

Patent application

2004-01-30


Patent application

M183

101

58.8, 60.6, 83.6, 100.7, 102.2, 116.3, 121.5, 126.7, 129.8, 130.8, 133.7, 133.8, 143.9, 158.2, 166.4, 168.3, 173.3, 173.8, 175.2, 175.5, 175.6. MALDI-TOF-spectrum: (M+H)⁺ calcd: 745.4, found: 744.9; (M+Na)⁺ calcd: 767.4, found: 766.9; (M+K)⁺ calcd: 783.5, found: 782.9.

5

Example 59

10 (S)-2-[[[(1R,2R,4S)-2-[(R)-1-[(R)-Cyclohexyl-methoxycarbonyl-methyl]-carbamoyl]-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarbonyl]-amino]-butyric acid (59)

The procedure described in example 54 was followed but with the use of Boc-D-cyclohexylglycine instead of Boc-L-cyclohexylglycine. The afforded compound was then reacted as described in example 55 followed by coupling with (1R,2R,4R)-2-((S)-1-tert-Butoxycarbonyl-pentylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester as described in example 56. Removal of the ester group as described in example 57 gave compound 59 as a colourless solid.

20

¹H-NMR (CD₃OD, 300 MHz): δ 0.82-1.02 (m, 9H), 1.04-1.42 (m, 6H), 1.52-1.80 (m, 6H), 1.80-1.96 (m, overlapped, 1H), 2.00-2.14 (m, 1H), 2.29-2.46 (m, 2H), 2.51-2.65 (m, 1H), 2.68-2.84 (m, 1H), 3.24-3.39 (m, overlapped, 1H), 3.47-3.60 (m, 1H), 3.67 (s, 3H), 4.07 (s, 3H), 4.18-4.27 (m, 2H), 4.28-4.38 (m, 1H), 5.64 (app. bs, 1H), 7.44 (d, J = 2.3, 6.9 Hz, 1H), 7.42 (s, 2H), 7.67-7.81 (m, 3H), 8.04 (d, J = 7.8 Hz, 2H), 8.41 (d, J = 9.1 Hz, 1H); ¹³C-NMR (CD₃OD, 75.5 MHz): δ 10.8, 18.5, 19.6, 25.7,

25

Int. Patent - och registrering

2004-01-30

Förordning om

M183

102

27.1, 27.1, 30.1, 30.6, 31.9, 37.3, 38.2, 41.1, 47.8, 52.3, 55.4, 56.9, 59.0, 59.1, 60.2, 83.8, 100.5, 102.2, 116.3, 121.6, 126.8, 129.8, 130.8, 133.6, 133.8, 143.7, 158.1, 166.5, 168.5, 173.4, 173.8, 175.4, 175.7, 175.7. MALDI-TOF-spectrum: (M+H)⁺ calcd: 745.4, found: 745.4; (M+Na)⁺ calcd: 767.4, found: 767.4; (M+K)⁺ calcd: 783.5, found: 783.3.

Example 60

N-Boc-4R-(2-phenyl-7-methoxyquinoline-4-oxo)proline (60).

- 10 To a stirred solution of N-Boc-trans-4-hydroxy-L-proline (3.9 g, 16.9 mmol) in DMSO (90mL) was added potassium tert.butoxide (4.5 g, 40.1 mmol). After 1 hrs 4-chloro-2-phenyl-7-methoxy quinoline (4.5g, 16.7 mmol) was added and stirred at RT for 12 hrs. The mixture was diluted with water (180 mL), washed with ethyl acetate (1x30mL) and neutralized with 1N HCl. The solid was filtered, washed with water and
- 15 dried giving (4.65g, 10mmol) of product. >95% purity by HPLC. M+H⁺ 464.2.

Example 61

2-(1-Ethoxycarbonyl-2-vinyl-cyclopropylcarbamoyl)-4-(7-methoxy-2-phenyl-quinoline-4-yloxy)-pyrrolidine-1-carboxylic acid tert.butyl ester (61).

20

- To a solution of 1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (41 mg, 0.26 mmol), 60 (11 mg, 0.22 mmol), HATU (204 mg, 0.54 mmol) in DMF (4 mL) was added diisopropylethylamine (187 μ L, 1.08 mmol). After stirring at RT for 1 hrs, dichloromethane (4 mL) was added. The solution was washed with aqueous
- 25 NaHCO₃ (sat) and with two portions of water. The organic layer was dried and concentrated. The product was pure enough (>95 % by HPLC) to be used in the next step. M+H⁺ 602.2.

Example 62

- 30 1-[[4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester (62).

M183

103

Compound 61 was kept in TFA-DCM 1:2 (3 mL) at RT for 60 min. Toluene (3 mL) was added. The sample was co-evaporated to dryness. Purity by HPLC >95%. M+H⁺ 502.4.

5 Example 63

1-[[1-[1-(2-Hydroxy-indan-1-yl)carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino)-2-vinyl-cyclopropanecarboxylic acid ethyl ester (63).

10 To a solution of compound 62 (0.13 mmol) in THF (2 mL), was added a large excess of NaHCO_3 (s) and a solution of phosgene in toluene (1.6 M, 600 μL). After 10 min of agitation the slurry was filtered and concentrated to dryness. The solid was redissolved in dichloromethane and a large excess of NaHCO_3 (s) and 2-Amino-*N*-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butyramide (0.65 mmol) was added. The slurry
15 was agitated for 24-40 hrs at RT. The slurry was filtered, concentrated and subjected to silica column chromatography (gradient elution from 100 % DCM to MeOH/DCM 2:98) to give the title compound (89.6 mg, 0.11 mmol). Purity by HPLC >95%. $\text{M}+\text{H}^+$ 790.3.

20 Example 64

1-[1-[1-(2-Hydroxy-indan-1-ylcarbamoyl)-2,2-dimethyl-propyl]-4-(6-methoxy-3-phenyl-naphthalen-1-yloxy)-pyrrolidin-2-yl]-2-vinyl-cyclopropanecarboxylic acid (64).

25 To a solution of 63 (76.7mg, 0.097mmol) in THF-MeOH 2:3 (2 mL) was added 1M LiOH 5 equiv. The solution was kept at 60 °C for 60 min. After cooling to RT, HOAc 15-30 eq. was added followed by toluene (2 mL) and then concentrated to dryness. The residue was taken up in DCM and washed with water. The organic layer was dried and concentrated to give the title compound (72 mg, 0.094 mmol). Purity >95% by HPLC M+H⁺ 762.2.

30

Example 65

Int. t. Patent - est. no. 01223 847894

01223 847894

M183

104

Int. t. Patent - est. no. 01223 847894

N-(2-Hydroxy-indan-1-yl)-2-[4-(6-methoxy-3-phenyl-naphthalen-1-yloxy)-2-(1-phenylmethanesulfonylaminoacetyl-2-vinyl-cyclopropyl)-pyrrolidin-1-yl]-3,3-dimethyl-butamide (65).

- 5 To solution of 64 (25 mg, 0.033 mmol) in chloroform (1 mL) was added benzenesulfonamide (10.5 mg, 0.066 mmol) followed by diisopropylethylamine (34 μ L, 0.197 mmol). The solution was stirred at RT for 10 min and then at -20 °C for 30 min. PyBOP (76 mg, 0.13 mmol) was then added as a solid. The solution was kept at -20 °C for 48 hours. The solution was then poured into aqueous NaHCO₃ (sat.) and
- 10 washed with water. The organic layer was dried, concentrated and subjected to purification by HPLC, affording the title compound as a white solid.

Example 66

Resin bound 2-*tert*-butoxycarbonylamino-3,3-dimethylbutyric acid (66).

15

- To Argonaut resin PS-TFP (1.38 mmol/g, 10 g) and 2-*tert*-butoxycarbonylamino-3,3-dimethyl-butylric acid (4.5 g, 20.7 mmol) was added dichloromethane (40 mL) and DMF (10 mL). To this mixture was added DMAP (1 g, 8.28 mmol) and then DIC (9.5 mL, 60.7 mmol). After 3 hrs of agitation at RT the resin was filtered and washed
- 20 successively with DMF, THF, DCM, THF, DCM and ether and then dried in a vacuum.

Example 67

- 25 [1-(2-Hydroxy-indan-1-ylcarbonyl)-2,2-dimethyl-propyl]-carbamic acid *tert*-butyl ester (67).

- To a portion of 66 (200 mg) in DCM aminoindanol (0.14 mmol) was added. The mixture was agitated for 2 hrs. The liquid was filtered off and the resin washed with 2x DCM. The combined liquids were combined and concentrated to dryness to afford
- 30 the title compound (20.5 mg, 0.055 mmol) Purity >95% by HPLC. M+H⁺ 363.15.

Ink. t. Patent- och reg.

2004-01-30

17:00:00

M183

105

^{13}C NMR δ_{C} (100 MHz; CDCl_3 ; Me_4Si) 27.0, 28.5, 34.2, 39.8, 50.8, 57.9, 68.2, 73.7, 124.8, 125.6, 127.4, 128.5, 140.4, 171.6. ^1H NMR δ_{H} (400 MHz; CDCl_3 ; Me_4Si) 1.07 (9H, s, CCH_3), 1.44 (9H, s, OCCH_3), 2.93 (1H, dd, J_{gem} 16.4 Hz, $J_{3,2}$ 2.3 Hz, CH_2), 3.15 (1H, dd, J_{gem} 16.4 Hz, $J_{3,2}$ 5.2 Hz, CH_2).

5

Example 68

2-Amino-*N*-(2-hydroxy-indan-1-yl)-3,3-dimethyl butyramide (68).

Compound 67 was kept in DCM-TFA 2:1 (2 mL) for 60 min at RT. The solution was co-evaporated with toluene to dryness.

10

Example 69

(2-*tert*-Butoxycarbonylamino-3,3-dimethyl-butylamino)-cyclohexyl-acetic acid methyl ester (69).

15

To a solution of 2-*tert*-butoxycarbonylamino-3,3-dimethyl butyric acid (500 mg, 2.16 mmol), Amino-cyclohexyl-acetic acid methyl ester (444 mg, 2.59 mmol) and HATU (2 g, 5.40 mmol) in DMF (20 mL) was added diisopropylethylamine (1.88 mL, 10.8 mmol). The solution was stirred for 1 hrs at r.t. and diluted with dichloromethane (40 mL). This solution was washed with aqueous. NaHCO_3 (sat.) and water (x2), dried and concentrated. The product was >95 % pure. $\text{M}+\text{H}^+$ 385.4.

20

Example 70

{1-[(Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propyl}-carbamic acid *tert*-butyl ester (70).

25

To compound 69 in EtOH-THF 1:2 was added a large excess of methylamine (30% in water) and left at rt. for 2 weeks. The solution was concentrated to dryness and the residue subjected to a short silica gel column eluted with 2% MeOH in dichloromethane to give a pure (>95%) product $\text{M}+\text{H}^+$ 384.5.

30

Example 71


M183

106

2-Amino-N-(cyclohexyl-methylcarbamoyl-methyl)-3,3-dimethyl-butylamide (71).

Compound 70 was kept in dichloromethane-trifluoroacetic acid 2:1 for 1 h at rt and concentrated to dryness. The residue was dried in a vacuum for 16 hrs. Reversed
5 phase C18 HPLC showed >95% purity $M+H^+$ 283.1.

Example 72



(1R,2S)-1-(((2S,4R)-1-((1S,2R)-2-Hydroxy-Indan-1-ylcarbamoyl)-4-(7-methoxy-2-
10 phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino)-2-vinyl-
cyclopropanecarboxylic acid (72).

Compound 62 was treated as described for the preparation of 63 but with the use of
(1S,2R)-cis-1-amino-2-Indanol Instead of 2-amino-N-(2-hydroxyindan-1-yl)-3,3-
15 dimethyl butylamide followed by ester hydrolysis as described for the preparation of
compound 64 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 649.1.

Example 73


Eli Lilly and Company

2004-01-30

Project: 01223

MI83

107




(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (73).

5

N-(tert-butoxycarbonyl)-L-valine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 712.3.

10

Example 74



(1R,2S)-1-[[[(2S,4R)-1-[(1R)-2-Hydroxy-1-phenyl-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (74).

15

[illegible]

... -C1-3


1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

M183

108

Compound 62 was treated as described for the preparation of 63 but with the use of (R)-2-phenylglycinol Instead of 2-amino-N-(2-hydroxyindan-1-yl)-3,3-dimethyl butyramide instead of 2-amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butyramide followed by ester hydrolysis as described for the preparation of compound 64 which gave the title compound. Purity by HPLC >95%. M+H⁺ 637.1.

Example 75



10 (1R,2S)-1-[[[(2S,4R)-1-[[[(1S)-Cyclohexyl-(cyclohexylmethyl-carbamoyl)-methyl]-
carbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-
2-vinyl-cyclopropanecarboxylic acid (75).

N-(tert-butoxycarbonyl)-L-cyclohexylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. M+H⁺ 752.4.

20 Example 76


Int. Patent - not yet published

2004-01-30

12:07:11

M183


109



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-2-Cyclohexyl-1-(cyclohexylmethyl-carbamoyl)-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (76).

- 5 N-(tert-butoxycarbonyl)-L-cyclohexylalanine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave
- 10 the title compound. Purity by HPLC >95%. $M+H^+$ 766.4.

Example 77



- 15 (1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (77).


- 20 N-(tert-butoxycarbonyl)-L-tert-butylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for

M183

110

68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 726.3.

5 Example 78



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-(Cyclohexylmethyl-carbamoyl)-2-phenyl-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (78).


10

N-(tert-butoxycarbonyl)-L-phenylalanine was attached to the resin as described for the preparation of compound 66 followed by reaction with cyclohexanemethylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved

15 from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 760.4.

Example 79

M183



(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-3-phenyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (79).


5

N-(tert.butoxycarbonyl)-L-phenethylglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-cis-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the

10

chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. $M+H^+$ 810.4.

Example 80



15

(1R,2S)-1-[[[(2S,4R)-1-[(1S)-1-Benzylcarbamoyl-2-methyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (80).

Link L Patient- and mg water

. 27.1.01-3.0


P. 27.1.01-3.0

M183

112

N-(tert-butoxycarbonyl)-L-valine was attached to the resin as described for the preparation of compound 66 followed by reaction with benzylamine as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 83 which gave the title compound. Purity by HPLC >95%, M+H⁺ 706.2.

Example 81




(1R,2S)-1-([(2S,4R)-1-([(1S)-1-((1R)-2-Hydroxy-1-phenyl-ethylcarbamoyl)-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino)-2-vinyl-cyclopropanecarboxylic acid (81).

N-(tert-butoxycarbonyl)-L-tert-butyglycine was attached to the resin as described for the preparation of compound 66 followed by reaction with (R)-2-phenylglycinol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which gave the title compound. Purity by HPLC >95%. M+H⁺ 750.3.

Example 82

113


M183



(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1R)-indan-1-ylcarbamoyl]-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]amino]-2-vinyl-cyclopropanecarboxylic acid (82).

- 5 (2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1R)-1-aminoindane as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
- 10 chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (12.5 mg, 28 % yield), Purity by HPLC >90%. $M+H^+$ 732.2.

Example 83



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S)-indan-1-ylcarbamoyl]-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]amino]-2-vinyl-cyclopropanecarboxylic acid (83).


- 20 (2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S)-1-

M183

114

aminoindane as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (22 mg, 49 % yield), Purity by HPLC >90% M+H⁺ 732.2.

Example 84




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-(2-hydroxyethylcarbamoyl)-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (84).

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with 2-aminoethanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (3 mg, 8 % yield), Purity by HPLC >90% M+H⁺ 660.2.

Example 85

115

M183



(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (85).


5

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the

10

chlorocarbonate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (10 mg, 22 % yield), Purity by HPLC >90% M+H⁺ 748.2.

Example 86



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1R, 2S)-2-Hydroxy-indan-1-ylcarbamoyl]-2-methylpropylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (86).

20

(2S)-*tert*-butoxycarbonylamino-3-methylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1R,2S)-1-

F. L. Polak et al.

11-01-03


Pharm. Res.

M183

116

amino-2-Indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (11 mg, 24 % yield), Purity by HPLC >75% $M+H^+$ 748.


Example 87



(1R, 2S)-1-[[[(2S, 4R)-1-[[Cyclohexyl-(S)-((1S, 2R)-2-hydroxy-indan-1-ylcarbonyl)-methyl]-carbonyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (87).

(2S)-tert.butoxycarbonylamino-cyclohexylacetic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (7.5 mg, 16 % yield), Purity by HPLC >95% $M+H^+$ 788.3.

Example 88




M183

117

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (88).

- 5 (2S)-*tert*-butoxycarbonylamino-3,3-dimethylbutyric acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (12 mg, 26 % yield), Purity by HPLC >95% M+H⁺ 762.3.

Example 89



- 15 (1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-3,3-dimethyl-butylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (89).

- 20 (2S)-*tert*-butoxycarbonylamino-4,4-dimethylpentanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (14.2 mg, 30 % yield), Purity by HPLC >95% M+H⁺ 776.3.
- 25

Example 90


P.L. F. 01-01-04

01-01-04

P.L. F. 01-01-04

M183

118




(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(1S, 2R)-2-Hydroxy-indan-1-ylcarbamoyl]-2-phenylethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (90).

5

(2S)-*tert*-butoxycarbonylamino-3-phenylpropanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the
10 chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (2.4 mg, 5 % yield), Purity by HPLC >95% M+H⁺ 796.2.

Example 91.



15

(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-2-Cyclohexyl-1-[(1S, 2R)-2-hydroxy-indan-1-ylcarbamoyl]-ethylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (91).

20

(2S)-*tert*-Butoxycarbonylamino-3-cyclohexylpropanoic acid was attached to the resin as described for the preparation of compound 66 followed by reaction with (1S,2R)-

Patent Application

2004-01-30


12-11-04

M183

119

1-amino-2-indanol as described for the preparation of 67 and removal of the Boc group as described for 68. The afforded compound was then reacted with the chlorocarbamate achieved from 62 as described for the preparation of 63 which, after purification by HPLC, gave the title compound (12.3 mg, 26 % yield), Purity by HPLC >95% M+H⁺ 802.3.

Example 92



(1R, 2S)-1-[[[(2S, 4R)-1-[(1S)-1-[(S)-(Cyclohexyl-methylcarbamoyl-methyl)-carbamoyl]-2,2-dimethyl-propylcarbamoyl]-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino]-2-vinyl-cyclopropanecarboxylic acid (92).

Compound 62 was treated as described for the preparation of 63 but with the use of 71 instead of 2-amino-N-(2-hydroxy-indan-1-yl)-3,3-dimethyl-butylamide followed by ester hydrolysis as described for the preparation of compound 64 which, after purification by HPLC, gave the title compound (8.6 mg, 18 % yield). Purity by HPLC >95%, M+H⁺ 783.3.

Assays

The compounds of the invention are conveniently assayed for activity against the NS3 protease of flavivirus such as HCV using conventional in vitro (enzyme) assays or cell culture assays.

M183

121

- 1a (H77C) and 87% identical to genotype 1b (J4L6S). The infectious clones, H77C (1a genotype) and J4L6S (1b genotype) can be obtained from R. Purcell (NIH) and the sequences are published in Genbank (AAB67036, see Yanagi, M., Purcell, R.H., Emerson, S.U. and Bukh. Proc. Natl. Acad. Sci. U.S.A. 94 (16) 8738-8743 (1997);
- 5 AF054247, see Yanagi, M., St Claire, M., Shapiro, M., Emerson, S.U., Purcell, R.H. and Bukh, J. Virology 244 (1), 161 (1998)).

- The BMS, H77C and J4L6S strains are used for production of recombinant NS3/4A protease complexes. DNA encoding the recombinant HCV NS3/4A protease
- 10 complex (amino acids 1027 to 1711) for these strains were manipulated as described by P. Gallinari et al. (see Gallinari P, Paolini C, Brennan D, Nardi C, Steinkuhler C, De Francesco R. Biochemistry. 38(17):562032, (1999)). Briefly, a three-lysine solubilizing tail was added at the 3'-end of the 3' NS4A coding region. The cysteine in the P1 position of the NS4A-NS4B cleavage site (amino acid 1711)
- 15 was changed to a glycine to avoid the proteolytic cleavage of the lysine tag. Furthermore, a cysteine to serine mutation can be introduced by PCR at amino acid position 1454 to prevent the autolytic cleavage in the NS3 helicase domain. The variant DNA fragment can be cloned in the pET21b bacterial expression vector (Novagen) and the NS3/4A complex can be expressed in Escherichia coli strain
- 20 BL21 (DE3) (Invitrogen) following the protocol described by P. Gallinari et al. (see Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R., J Virol. 72(8):6758-69 (1998)) with modifications. Briefly, NS3/4A expression can be induced with 0.5mM Isopropyl beta-D thiogalactopyranoside (IPTG) for 22hr at 20°C. A typical fermentation (10 l) yields approximately 80g of wet cell paste. The
- 25 cells are resuspended in lysis buffer (10 mL/g) consisting of 25mM N-(2-Hydroxyethyl)Piperazine-N'-(2-Ethane Sulfonic acid) (HEPES), pH7.5, 20% glycerol, 500mM Sodium Chloride (NaCl), 0.5% Triton-X100, 1 ug/ml lysozyme, 5mM Magnesium Chloride (MgCl₂), 1 ug/ml DnaseI, 5mM beta-Mercaptoethanol (BME), Protease inhibitor - Ethylenediamine Tetraacetic acid (EDTA) free (Roche),
- 30 homogenized and incubated for 20 mins at VC. The homogenate is sonicated and clarified by ultra-centrifugation at 235000 g for 1 hr at 4°C.

Ex. 1 Patent Application

2001-01-30

Protein Purification

M183

122

Imidazole is added to the supernatant to a final concentration of 15mM and the pH adjusted to 8. The crude protein extract is loaded on a Nickel Nitrilotriacetic acid (Ni-NTA) column pre-equilibrated with buffer B (25mM 20 HEPES, pH8 20% glycerol, 500mM NaCl, 0.5% Triton-X100, 15mM imidazole, 5mM BME). The sample is loaded at a flow rate of 1mL/min. The column is washed with 15 column volumes of buffer C (same as buffer B except with 0.2% Triton-X100). The protein is eluted with 5 column volumes of buffer D (same as buffer C except with 200mM imidazole).

- 10 NS3/4A protease complex-containing fractions are pooled and loaded on a desalting column Superdex-S200 pre-equilibrated with buffer D (25mM HEPES, pH7.5, 20% glycerol, 300mM NaCl, 0.2% Triton-X100, 10mM BME). Sample is loaded at a flow rate of 1mU/min. NS3/4A protease complex30 containing fractions are pooled and concentrated to approximately 0.5mg/ml. The purity of the NS3/4A protease
- 15 complexes, derived from the BMS, H77C and J4L6S strains, are typically judged to be greater than 90% by SDS-PAGE and mass spectrometry analyses.

The enzyme is generally stored at -80°C, thawed on ice and diluted prior to use in assay buffer. The substrate used for the NS3/4A protease assay, is conveniently

20 RET S 1 (Resonance Energy Transfer Dipeptide Substrate; AnaSpec, Inc. cat # 22991)(FRET peptide), described by Tallini et al. in Anal. Biochem. 240(2):6067 (1996). The sequence of this peptide is loosely based on the NS4A/NS4B natural cleavage site except there is an ester linkage rather than an amide bond at the cleavage site. The peptide substrate is incubated with one of the three recombinant

25 NS3/4A complexes, in the absence or presence of a compound of the present invention, and the formation of fluorescent reaction product was followed in real time using a Cytofluor Series 4000. Useful reagents are as follow: HEPES and Glycerol (Ultrapure) can be obtained from GIBCO-BRL. Dimethyl Sulfoxide (DMSO) is obtained from Sigma. Beta-Mercaptoethanol is obtained from Bio Rad.

30

Inkjet Print - color

2004-01-30 6

Page 7 of 7

M183

123

Assay buffer: 50m.M HEPES, pH7.5; 0. 15M NaCl; 0. 1% Triton; 15 % Glycerol; 10mM BME. Substrate: 2 uM final concentration (from a 2mM stock 20 solution in DMSO stored at -20'C). HCV NS3/4A type 1a (1b), 2-3 nM final concentration (from a 5uM stock solution in 25mM HEPES, pH7.5, 20% glycerol, 300m.M NaCl, 0.2% Triton-X100, 10mM BME). For compounds with potencies approaching the assay limit, the assay can be made more sensitive by adding 50 ug/ml BSA to the assay buffer and/or reducing the end protease concentration to 300 pM.

The assay is conveniently performed in a 96-well polystyrene black plate from Falcon. Each well contains 25ul NS3/4A protease complex in assay buffer, 50ul of a compound of the present invention in 10% DMSO/assay buffer and 25ul substrate in assay buffer. A control (no compound) is also prepared on the same assay plate. The enzyme complex is mixed with compound or control solution, typically for 1 min before initiating the enzymatic reaction by the addition of substrate. The assay plate is generally read immediately using a spectrophotometer such as a Cytofluor Series 4000 (Perspective Biosystems). The instrument is conveniently set to read an emission of 340nm and excitation of 490nm at 25'C. Reactions are generally followed for approximately 15 minutes.

The percent inhibition can be calculated with the following equation.

$$100 - [(dF_{inh}/dF_{con}) \times 100]$$

where dF is the change in fluorescence over the linear range of the curve. A nonlinear curve fit is applied to the inhibition-concentration data, and the 50% effective concentration (IC_{50}) is calculated by the use software such as Excel XI-fit software using the equation:

$$y = A + ((B - A) / (1 + ((C/x)^D)))$$

Various compounds of the invention exemplified above displayed IC_{50} s in the range 1nM to 6.9 micromolar and ED_{50} s in the sub-micromolar to micromolar range.

Int. Patent Application

1 24 61 3 0


1 24 61 3 0

M183

124

Claims

1. A compound of the formula I:



5

wherein

A is COOR^1 , $\text{CONHSO}_2\text{R}^2$, CONHR^3 , or $\text{CR}^4\text{R}^{4'}$ wherein;

R^1 is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl;

R^2 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl;

10

R^3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $-\text{OC}_1\text{-C}_6$ alkyl, $-\text{OC}_0\text{-C}_3$ alkylcarbocyclyl, $-\text{OC}_0\text{-C}_3$ alkylheterocyclyl;

R^4 is $=\text{O}$, halo, amino, or OH ;

$\text{R}^{4'}$ is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl; wherein

15

R^2 , R^3 , and $\text{R}^{4'}$ are each optionally substituted with from 1 to 3 times with halo, oxo, nitrile, azido, nitro, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_0\text{-C}_3$ alkylcarbocyclyl, $\text{C}_0\text{-C}_3$ alkylheterocyclyl, $\text{NH}_2\text{CO-}$, Y-NRaRb , Y-O-Rb , Y-C(=O)Rb , Y-C(=O)NRaRb , Y-NRaC(=O)Rb , $\text{Y-NHSO}_p\text{Rb}$, $\text{Y-S(=O)}_p\text{Rb}$, $\text{Y-S(=O)}_p\text{NRaRb}$, Y-C(=O)ORb , Y-NRaC(=O)ORb ;

where Y is a bond or $\text{C}_1\text{-C}_3$ alkyl;

20

Ra is H or $\text{C}_1\text{-C}_3$ alkyl;

Rb is H or $\text{C}_1\text{-C}_6$ alkyl;

p is 1 or 2;

Link 1 Patent- not published

2004-01-30

M183

125

R^7 is C_1 - C_6 alkyl, C_1 - C_3 alkyl C_3 - C_7 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with 1-3 halo atoms, amino or $-SH$;

$R^{7'}$ is H or taken together with R^7 to form a C_3 - C_6 cycloalkyl ring optionally substituted with $R^{7'a}$ wherein;

- 5 $R^{7'a}$ is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, C_2 - C_6 alkenyl or J; any of which may be optionally substituted with halo;

q is 0 to 3 and k is 0 to 3; where $q+k \geq 1$;

W is $-CH_2-$, $-O-$, $-OC(=O)NH-$, $-OC(=O)-$, $-S-$, $-NH-$, $-NR^8$, $-NHSO_2-$ or $-NHC(=O)-$;

- 10 R^8 is a ring system containing 1 or 2 saturated or unsaturated rings each of which has 4-7 ring atoms and 0 to 2 hetero atoms selected from S, O and N, the ring system being optionally spaced from W by a C_1 - C_3 alkyl group; or R^8 is C_1 - C_6 alkyl, any of which R^8 groups can be optionally mono, di, or tri substituted with R^9 , wherein

- 15 R^9 is independently halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-(C=O)NRaRb$, $Y-NRaC(=O)Rb$, $Y-NHSO_pRb$, $Y-S(=O)_pRb$, $Y-S(=O)_pNRaRb$, $Y-C(=O)ORb$, $Y-NRaC(=O)ORb$; wherein the carbocyclyl or heterocyclyl is optionally substituted with R^{10} ; wherein

- 20 R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di- substituted with C_1 - C_6 alkyl, sulfonyl, $(C_1$ - C_3 alkyl)sulfonyl, NO_2 , OH, SH, halo, haloalkyl, carboxyl, amide, $(C_1$ - C_3 alkyl)amide, or heteroaryl optionally substituted with C_1 - C_6 alkyl;

R^8 is H, C_1 - C_3 alkyl;

E is $-C(=O)-$, $-C(=S)-$, $-S(=O)_2-$, $-S=O-$, $-C=N-Rf$;

Rf is H, $-CN$, $-C(=O)NRaRb$; $-C(=O)C_1$ - C_3 alkyl

- 25 X is $-NRx-$ where Rx is H, or C_1 - C_5 alkyl; or in the case where where E is $-(C=O)-$ X can also be $-O-$;

30 R^{11} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO- , $Y-NRaRb$, $Y-O-Rb$, $Y-C(=O)Rb$, $Y-(C=O)NRaRb$, $Y-NRaC(=O)Rb$, $Y-NHSO_pRb$, $Y-S(=O)_pRb$, $Y-S(=O)_pNRaRb$, $Y-C(=O)ORb$, $Y-NRaC(=O)ORb$;

Pat. Pending - not for sale

ZINC-01-00

Product Name

M183

126

when $R^{7'}$ taken together with R^7 forms a C_3 - C_6 cycloalkyl, then one of R_x or R^{11} can also be J;

J is a 3 to 10-membered saturated or unsaturated alkylene chain extending from the $R^7/R^{7'}$ cycloalkyl to R_x or R^{11} to form a macrocycle, which chain is optionally

- 5 interrupted by one to three heteroatoms independently selected from: -O-, -S- or -NR¹²- wherein 0 to 3 carbon atoms in the chain are optionally substituted with R^{14} ; wherein;

R^{12} is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or COR¹³;

R^{13} is C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl;

- 10 R^{14} is independently selected from H, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, hydroxy, halo, amino, oxo, thio, or C_1 - C_6 thioalkyl;

R_u and R_z are independently H or C_1 - C_3 alkyl;

m is 0 or 1; n is 0 or 1;

U is =O or is absent;

- 15 R^{15} is H, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylaryl, C_0 - C_3 alkylheteroaryl, C_0 - C_3 alkylcyclo C_3 - C_6 alkyl, NH_2CO -, $Y-NR_aR_b$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NR_aR_b$, $Y-NR_aC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNR_aR_b$, $Y-C(=O)OR_b$, $Y-NR_aC(=O)OR_b$;

- 20 G is -O-, -NR_y- or -NHNH- where R_y is H or C_1 - C_3 alkyl;

R^{16} is H; or C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, any of which can be substituted with halo, oxo, nitrile, azido, nitro, C_1 - C_6 alkyl, C_0 - C_3 alkylcarbocyclyl, C_0 - C_3 alkylheterocyclyl, NH_2CO -, $Y-NR_aR_b$, $Y-O-R_b$, $Y-C(=O)R_b$, $Y-(C=O)NR_aR_b$, $Y-NR_aC(=O)R_b$, $Y-NHSO_pR_b$, $Y-S(=O)_pR_b$, $Y-S(=O)_pNR_aR_b$, $Y-C(=O)OR_b$, $Y-NR_aC(=O)OR_b$;

- 25 or a pharmaceutically acceptable salt or prodrug thereof.

2. A compound according to claim 1 with the formula IIa, IIb or IIc


127 Patent not required at

127-01-3-9


127-01-3-9

M183


127




IIa



IIb




IIc




IIaa

where e is 1 or 2.


3. A compound according to claim 1 with the formula IIIa, IIIb or IIIc




IIIa



IIIb



IIIc



IIIaa

where e is 0 to 2.


4. A compound according to claim 1, with the formula IIId, IIIf or IIIf

01223 847894


100-51-3 in
100-51-3 in

M183


128




111d



IIIe




III F




111fa


5. A compound according any preceding claim, wherein X is -NR_x.
- 5 6. A compound according to any preceding claim with the partial structure Ia or Ib;



1a



16





122

where e is 1 or 2


7. A compound according to any preceding claim, wherein E is $-\text{C}(=\text{O})-$ or $-\text{C}=\text{NRf}$.
8. A compound with the formula VI

M183

130



10. A compound according to claim 8 with the formula VIII.



5

11. A compound according to claim 8 with the structure VIIc or VIId

01223 847894



Int. Patent application

PCT/CA-01-30


Priority claim from

M183


131



12. A compound according to any of claims 8 to 11, wherein Rz is H.
- 5 13. A compound according to any of claims 8 to 12 with the partial structure:




14. A compound according to any of claims 8 to 12 with the partial structure



M183


132

15. A compound according to claim 14, with the formula Xa or Xb:





5

16. A compound according to claim 14, with the formula Xla:



17. A compound according to claim 14, with the formula Xlb or Xlc



10

18. A compound according to any of claims 8 to 17, where Rq is H or methyl

M183

133

19. A compound according to any preceding claim wherein R^7 is H and R^7 is n-ethyl, n-propyl, cyclopropylmethyl, cyclobutylmethyl, 2,2-difluoroethyl, or mercaptomethyl.

5 20. A compound according to claim 19, wherein R^7 is n-propyl or 2,2-difluoroethyl.

21. A compound according to any of claims 1 to 18 wherein R^7 and R^{7a} together define a spiro-cyclopropyl or spiro-cyclobutyl ring, both optionally mono or di-substituted with R^{7a} wherein;

10 R^{7a} is C_1 - C_6 alkyl, C_3 - C_5 cycloalkyl, or C_2 - C_6 alkenyl, any of which is optionally substituted with halo or J.

22. A compound according to claim 21 wherein the ring is a spiro-cyclopropyl ring substituted with R^{7a} wherein;

15 R^{7a} is ethyl, vinyl, cyclopropyl, 1- or 2-bromoethyl, 1-or 2-fluoroethyl, 2-bromovinyl or 2-fluorethyl.

23 A compound according to claim 21, wherein J is a 3 to 8-membered saturated or unsaturated alkylene chain optionally containing one to two heteroatoms
20 independently selected from: -O-, -S- or -NR¹²-, wherein R^{12} is H, C_1 - C_6 alkyl, such as methyl, or -C(=O) C_1 - C_6 alkyl, such as acetyl.

24. A compound according to claim 24 wherein J is a 5 to 8-membered saturated or unsaturated, all carbon alkylene chain.

25 25. A compound according to claim 23 or 24 wherein J is saturated or mono-unsaturated.

26. A compound according to claim 23, 24 or 25, wherein J is substituted with R^{14} , wherein R^{14} is H or C_1 - C_6 alkyl.

27. A compound according to claims 23-26 with the formula XIIa, XIIb or XIIc





154. 1. 1967-07-10

7-31-31-3

1944. 1945. 1946. 1947. 1948. 1949. 1950. 1951. 1952. 1953. 1954. 1955. 1956. 1957. 1958. 1959. 1960. 1961. 1962. 1963. 1964. 1965. 1966. 1967. 1968. 1969. 1970. 1971. 1972. 1973. 1974. 1975. 1976. 1977. 1978. 1979. 1980. 1981. 1982. 1983. 1984. 1985. 1986. 1987. 1988. 1989. 1990. 1991. 1992. 1993. 1994. 1995. 1996. 1997. 1998. 1999. 2000. 2001. 2002. 2003. 2004. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018. 2019. 2020. 2021. 2022. 2023. 2024. 2025. 2026. 2027. 2028. 2029. 2030. 2031. 2032. 2033. 2034. 2035. 2036. 2037. 2038. 2039. 2040. 2041. 2042. 2043. 2044. 2045. 2046. 2047. 2048. 2049. 2050. 2051. 2052. 2053. 2054. 2055. 2056. 2057. 2058. 2059. 2060. 2061. 2062. 2063. 2064. 2065. 2066. 2067. 2068. 2069. 2070. 2071. 2072. 2073. 2074. 2075. 2076. 2077. 2078. 2079. 2080. 2081. 2082. 2083. 2084. 2085. 2086. 2087. 2088. 2089. 2090. 2091. 2092. 2093. 2094. 2095. 2096. 2097. 2098. 2099. 2100. 2101. 2102. 2103. 2104. 2105. 2106. 2107. 2108. 2109. 2110. 2111. 2112. 2113. 2114. 2115. 2116. 2117. 2118. 2119. 2120. 2121. 2122. 2123. 2124. 2125. 2126. 2127. 2128. 2129. 2130. 2131. 2132. 2133. 2134. 2135. 2136. 2137. 2138. 2139. 2140. 2141. 2142. 2143. 2144. 2145. 2146. 2147. 2148. 2149. 2150. 2151. 2152. 2153. 2154. 2155. 2156. 2157. 2158. 2159. 2160. 2161. 2162. 2163. 2164. 2165. 2166. 2167. 2168. 2169. 2170. 2171. 2172. 2173. 2174. 2175. 2176. 2177. 2178. 2179. 2180. 2181. 2182. 2183. 2184. 2185. 2186. 2187. 2188. 2189. 2190. 2191. 2192. 2193. 2194. 2195. 2196. 2197. 2198. 2199. 2200. 2201. 2202. 2203. 2204. 2205. 2206. 2207. 2208. 2209. 2210. 2211. 2212. 2213. 2214. 2215. 2216. 2217. 2218. 2219. 2220. 2221. 2222. 2223. 2224. 2225. 2226. 2227. 2228. 2229. 2230. 2231. 2232. 2233. 2234. 2235. 2236. 2237. 2238. 2239. 2240. 2241. 2242. 2243. 2244. 2245. 2246. 2247. 2248. 2249. 2250. 2251. 2252. 2253. 2254. 2255. 2256. 2257. 2258. 2259. 2260. 2261. 2262. 2263. 2264. 2265. 2266. 2267. 2268. 2269. 2270. 2271. 2272. 2273. 2274. 2275. 2276. 2277. 2278. 2279. 2280. 2281. 2282. 2283. 2284. 2285. 2286. 2287. 2288. 2289. 2290. 2291. 2292. 2293. 2294. 2295. 2296. 2297. 2298. 2299. 2300. 2301. 2302. 2303. 2304. 2305. 2306. 2307. 2308. 2309. 2310. 2311. 2312. 2313. 2314. 2315. 2316. 2317. 2318. 2319. 2320. 2321. 2322. 2323. 2324. 2325. 2326. 2327. 2328. 2329. 2330. 2331. 2332. 2333. 2334. 2335. 2336. 2337. 2338. 2339. 2340. 2341. 2342. 2343. 2344. 2345. 2346. 2347. 2348. 2349. 2350. 2351. 2352. 2353. 2354. 2355. 2356. 2357. 2358. 2359. 2360. 2361. 2362. 2363. 2364. 2365. 2366. 2367. 2368. 2369. 2370. 2371. 2372. 2373. 2374. 2375. 2376. 2377. 2378. 2379. 2380. 2381. 2382. 2383. 2384. 2385. 2386. 2387. 2388. 2389. 2390. 2391. 2392. 2393. 2394. 2395. 2396. 2397. 2398. 2399. 2400. 2401. 2402. 2403. 2404. 2405. 2406. 2407. 2408. 2409. 2410. 2411. 2412. 2413. 2414. 2415. 2416. 2417. 2418. 2419. 2420. 2421. 2422. 2423. 2424. 2425. 2426. 2427. 2428. 2429. 2430. 2431. 2432. 2433. 2434. 2435. 2436. 2437. 2438. 2439. 2440. 2441. 2442. 2443. 2444. 2445. 2446. 2447. 2448. 2449. 2450. 2451. 2452. 2453. 2454. 2455. 2456. 2457. 2458. 2459. 2460. 2461. 2462. 2463. 2464. 2465. 2466. 2467. 2468. 2469. 2470. 2471. 2472. 2473. 2474. 2475. 2476. 2477. 2478. 2479. 2480. 2481. 2482. 2483. 2484. 2485. 2486. 2487. 2488. 2489. 2490. 2491. 2492. 2493. 2494. 2495. 2496. 2497. 2498. 2499. 2500. 2501. 2502. 2503. 2504. 2505. 2506. 2507. 2508. 2509. 2510. 2511. 2512. 2513. 2514. 2515. 2516. 2517. 2518. 2519. 2520. 2521. 2522. 2523. 2524. 2525. 2526. 2527. 2528. 2529. 2530. 2531. 2532. 2533. 2534. 2535. 2536. 2537. 2538. 2539. 2540. 2541. 2542. 2543. 2544. 2545. 2546. 2547. 2548. 2549. 2550. 2551. 2552. 2553. 2554. 2555. 2556. 2557. 2558. 2559. 2560. 2561. 2562. 2563. 2564. 2565. 2566. 2567. 2568. 2569. 2570. 2571. 2572. 2573. 2574. 2575. 2576. 2577. 2578. 2579. 2580. 2581. 2582. 2583. 2584. 2585. 2586. 2587. 2588. 2589. 2590. 2591. 2592. 2593. 2594. 2595. 2596. 2597. 2598. 2599. 2600. 2601. 2602. 2603. 2604. 2605. 2606. 2607. 2608. 2609. 2610. 2611. 2612. 2613. 2614. 2615. 2616. 2617. 2618. 2619. 2620. 2621. 2622. 2623. 2624. 2625. 26

M183

134




where e is 1 or 2,

- 5 28. A compound according to claims 23 to 26 with the structure XIIg, XIIga, XIIh or XIIi.

MI83

135



29. A compound according to claims 23-26 with the formula XIIIa, XIIIaa or XIIIb




Int. Patent No. 02/000000

No. 02/000000




Date of filing: 02/00/00

M183

136



30. A compound according to claim 27, 28 or 29 with the partial structure



31. A compound according to claims 23 to 26 with the formula XIVa, XIVb or XIVc




Dr. J. Point-oh-ah-ah

7. - 51-30

(continued)

M183

137



- 33. A compound according to claims 23 to 26 with the formula XIVd, XIVe or XIVf:**




Int. Patent request

PCT/US 01/00000


PCT/US 01/00000

M183

138



33. A compound according to claim 31 or 32 with the partial structure:



5

34. A compound according to claim 32 or 33 with the partial structure:


Int. Patent (PCT) No. 01/223 847

PCT No. 01/223 847

PCT No. 01/223 847

M183

139



35. A compound according to claim 34, wherein Rq is methyl or H.

5 36. A compound according to any preceding claim, wherein A is $-\text{CR}^4\text{R}^4$.

37. A compound according to claim 36, wherein R^4 is C_1 - C_8 alkyl.

38. A compound according to claim 35, wherein R^4 is C_1 - C_3 alkylaryl or C_1 -
10 C_3 alkylheteroaryl.

39. A compound according to claim 37 or 38, wherein the alkyl moiety of R^4 is C_1 -
 C_3 alkanyl or C_2 - C_3 alkenyl.

15 40. A compound according to claim 41 or 42, wherein the aryl moiety of R^4 is optionally substituted phenyl.

41. A compound according to claim 38 or 39, wherein the heteroaryl moiety of R^4 is optionally substituted benzothiazole.

20

42. A compound according to claims 36 to 41, wherein R^4 is $-\text{NH}_2$, fluoro or chloro.

43. A compound according to claims 36 to 41, wherein R^4 is $-\text{OH}$.

25

44. A compound according to claims 35 to 41, wherein R^4 is $=\text{O}$.

45. A compound according to claims 1 to 35, wherein A is CONHR^3 .

01223 847894

Int. t. Patent- och reg.

2004-01-31

Patent- och reg.

M183

140

46. A compound according to claim 45, wherein R^3 is optionally substituted C_0 - C_3 alkylaryl, C_0 - C_3 alkylheteroaryl, OC_0 - C_3 alkylaryl or OC_0 - C_3 alkylheteroaryl.

5 47. A compound according to claim 46, wherein R^3 is optionally substituted C_0 - C_3 alkylaryl or C_0 - C_3 alkylheteroaryl.

48. A compound according to claims 1 to 35, wherein A is $CONHSO_2R^2$.

10 49. A compound according to claim 48, wherein R^2 is optionally substituted C_1 - C_6 alkyl, preferably methyl.

50. A compound according to claim 48, wherein R^2 is optionally substituted C_3 - C_7 cycloalkyl, preferably cyclopropyl.

15

51. A compound according to claim 48 wherein R^2 is optionally substituted C_0 - C_6 alkylaryl, preferably optionally substituted phenyl.

52. A compound according to claims 1 to 35, wherein A is $COOR^1$.

20

53. A compound according to claim 52, wherein R^1 is H or C_1 - C_6 alkyl

54. A compound according to claim 51 wherein R^1 is hydrogen, methyl, ethyl, or tert-butyl.

25

55. A compound according to any preceding claim, wherein W is $-OC(=O)NH-$, $-OC(=O)-$, $-NH-$, $-NR^6-$, $-NHS(O)_2-$ or $-NHC(=O)-$.

56. A compound according to claim 55 wherein W is $-OC(=O)NH-$ or $-NH-$

30

Int. Patent No. 2003/01-31

2003-01-31

P. 1

M183

141

57 A compound according to claim 55 or 56 wherein R^8 is optionally substituted C_0 - C_3 -alkylcarbocyclyl or C_0 - C_3 -alkylheterocyclyl.

58 A compound according to claims 1 to 54 wherein W is -S- or preferably -O-.

59 A compound according to claim 58 wherein R^8 is C_0 - C_3 alkylaryl, or C_0 - C_3 alkylheteroaryl either of which is optionally mono, di, or tri substituted with R^9 , wherein;

R^9 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , OH, halo, trifluoromethyl, amino or amido optionally mono- or di-substituted with C_1 - C_6 alkyl, C_0 - C_3 alkylaryl, C_0 - C_3 alkylheteroaryl, carboxyl, aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, C_1 - C_3 alkyl amide), sulfonyl(C_1 - C_3 alkyl, NO_2 , OH, halo, trifluoromethyl, carboxyl, or heteroaryl).

60 A compound according to claim 59 wherein R^9 is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino, di-(C_1 - C_3 alkyl)amino, C_1 - C_3 alkylamide, aryl or heteroaryl, the aryl or heteroaryl being optionally substituted with R^{10} ; wherein

R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino, mono- or di- C_1 - C_3 alkylamino, amido, C_1 - C_3 alkylamide, halo, trifluoromethyl, or heteroaryl.

61 A compound according to claim 60, wherein, R^{10} is C_1 - C_6 alkyl, C_1 - C_6 alkoxy, amino optionally mono- or di substituted with C_1 - C_3 alkyl, amido, C_1 - C_3 -alkylamide, halo, or heteroaryl.

62. A compound according to any preceding claim wherein R^{10} is methyl, ethyl, isopropyl, tert-butyl, methoxy, chloro, amino optionally mono- or di substituted with C_1 - C_3 alkyl, amido, C_1 - C_3 alkylamide, or C_1 - C_3 alkyl thiazole.


M183

142

63 A compound according to claims 59 to 62, wherein R^8 is 1-naphthylmethyl, 2-naphthylmethyl, benzyl, 1-naphthyl, 2-naphthyl, or quinolinyl unsubstituted, mono, or disubstituted with R^9 as defined.

5 64 A compound according to claim 63 wherein R^8 is 1-naphthylmethyl, or quinolinyl unsubstituted, mono, or disubstituted with R^9 as defined.

65 A compound according to claim 63 wherein R^8 is:



10

wherein R^{9a} is C_1 - C_6 alkyl; C_1 - C_6 alkoxy; thio C_1 - C_3 alkyl; amino optionally substituted with C_1 - C_6 alkyl; C_0 - C_3 alkylaryl; or C_0 - C_3 alkylheteroaryl, C_0 - C_3 alkylheterocyclyl, said aryl, heteroaryl or heterocycle being optionally substituted with R^{10} wherein




15 R^{10} is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 alkoxy, amino optionally mono- or disubstituted with C_1 - C_6 alkyl, amido, C_1 - C_3 alkyl amide, heteroaryl or heterocyclyl; and

R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl) amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

20

66 A compound according to claim 63, wherein R^{9a} is aryl or heteroaryl, all optionally substituted with R^{10} as defined.

67 A compound according to 66, wherein R^{9a} is selected from the group
25 consisted of :



Int. Patent Reg.

2004-01-30

Patent No.


M183

143

wherein R^{10} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl.

5 68. A compound according to claim 65, wherein R^{9a} is phenyl


69. A compound according to claim 68, wherein R^8 is:



10

wherein R^{10a} is H, C_1 - C_6 alkyl; C_1 - C_6 alkoxy; or halo; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, carboxyl.

15 69. A compound according to claim 65, wherein R^8 is:



20

wherein R^{10a} is H, C_1 - C_6 alkyl, or C_0 - C_3 alkyl- C_3 - C_6 cycloalkyl, amino optionally mono- or di-substituted with C_1 - C_6 alkyl, amido, (C_1 - C_3 alkyl)amide, heteroaryl or heterocyclyl; and R^{9b} is C_1 - C_6 alkyl, C_1 - C_6 -alkoxy, amino, di(C_1 - C_3 alkyl)amino, (C_1 - C_3 alkyl)amide, NO_2 , OH, halo, trifluoromethyl, or carboxyl.

Patent Application

7-12-01-30

11-11-01-11

M183

144

70. A compound according to any claim 65-70, wherein R^{9b} is C_1 - C_6 -alkoxy, preferably methoxy.

71. A compound according to any preceding claim, wherein Rx is methyl or preferably H.

72. A compound according to any preceding claim, wherein R^{11} is C_1 - C_6 alkyl, C_0 - C_3 alkyl(C_3 - C_7 cycloalkyl), C_0 - C_3 alkylaryl or C_0 - C_3 alkylheteroaryl, any of which is optionally substituted with hydroxy, halo, amino, C_1 - C_6 alkoxy, C_1 - C_6 thioalkyl, $COOR^{14}$, carboxyl, (C_1 - C_6 alkoxy)carbonyl, aryl, heteroaryl or heterocyclyl;

73. A compound according to claim 72, wherein the substituent is hydroxy or $COOR^{14}$.

74. A compound according to claim 73, wherein R^{11} is tert-butyl, iso-butyl, cyclohexyl, phenylethyl, 2,2-dimethyl-propyl, cyclohexylmethyl, phenylmethyl, 2-pyridylmethyl, 4-hydroxy-phenylmethyl, or carboxylpropyl.

75. A compound according to claim 74, wherein R^{11} is tert-butyl, iso-butyl, or cyclohexyl.

76. A compound according to claim 1 or 8, wherein Ru is methyl or preferably H.

77. A compound according to any preceding claim, wherein R^{15} is optionally substituted C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_0 - C_3 alkyl(C_3 - C_7 cycloalkyl).

78. A compound according to claim 77, wherein R^{15} is cyclohexyl, cyclohexylmethyl, tert-butyl iso-propyl, or iso-butyl.

79. A compound according to claim 1 or 8, wherein m is zero and T is absent.

Ekt. Patent-Office

73.4-01-13

1994-01-13

M183

145

80. A compound according to any preceding claim, wherein G is -NRy-.
81. A compound according to claim 80, wherein Ry is methyl or preferably H.
- 5 82. A compound according to any of claims 1 to 79, wherein G is O.
83. A compound according to any preceding claim, wherein R¹⁶ is C₁-C₈alkyl, C₀-C₃alkylheterocyclyl, C₀-C₃alkylcarbocyclyl, any of which is optionally substituted with hydroxy, halo, amino, or C₁-C₆alkoxy.
- 10 84. A compound according to claim 83, wherein R¹⁶ is methyl.
85. A compound according to claim 83, wherein R¹⁶ is 2-indanol, indanyl, 2-hydroxy-1-phenyl-ethyl, 2-thiophenemethyl, cyclohexylmethyl, 2,3-methylenedioxybenzyl, cyclohexyl, benzyl, 2-pyridylmethyl, cyclobutyl, iso-butyl, n-propyl, or 4-methoxyphenylethyl.
- 15 86. A compound according to claim 83, wherein R¹⁶ is 2-indanol, indan, 2-hydroxy-1-phenyl-ethyl, 2-thiophenemethyl, 2,3-methylenedioxybenzyl, or cyclohexylmethyl.
- 20 87. A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable carrier therefore.
- 25 88. A pharmaceutical composition according to claim 87, further comprising an additional HCV antiviral, selected from nucleoside analogue polymerase inhibitors, protease inhibitors, ribavirin and interferon.
- 30 89. Use of a compound as defined in any of claims 1-86 in the manufacture of a medicament for the prophylaxis or treatment of flavivirus infections, including HCV.

Patent Application

2004-01-30

Patent Application

M183

146

Abstract of the Disclosure

5 Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds comprise a novel linkage between a carbocyclic or heterocyclic P2 unit and those portions of the inhibitor more distal to the cleavage site, which linkage which reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

01223 847894

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE05/000097

International filing date: 28 January 2005 (28.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0400199-6
Filing date: 30 January 2004 (30.01.2004)

Date of receipt at the International Bureau: 02 May 2005 (02.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.